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There are two distinctive types of vascular calcification: atherosclerotic intimal 
calcification (AIC) and elastin specific medial arterial calcification (MAC). AIC occurs 
in the context of atherosclerosis, associated with lipids, macrophages, and vascular 
smooth muscle cells; whereas, MAC can exist independently of atherosclerosis and is 
associated with elastin and vascular smooth muscle cells. The work presented here 
focuses on the mechanisms and reversal of MAC. MAC, termed as Monckeberg’s 
sclerosis, is a type of vascular calcification disease mostly occurs as linear deposits along 
elastic lamellae. Vascular calcification, including medial calcification, is a strong 
predictor of cardiovascular morbidity and mortality. Currently the only options to treat 
vascular calcifications are surgical methods like directional atherectomy and placement 
of stent grafts. These surgical methods are quite invasive and expensive, and currently 
there is no available alternative to surgical therapy for reversal of vascular calcification. 
One possible approach is EDTA chelation therapy. EDTA chelation therapy most often 
involves the injection of disodium ethylene diamine tetraacetic acid (EDTA), a chemical 
that binds, or chelate ionic calcium, trace elements and other divalent cations so as to 
reverse calcification. However, chelation therapy is not yet accepted in US and not 
approved by FDA as there is no clinical proof that it works and improves cardiovascular 
function. Besides, it has severe side effects such as renal toxicity, hypercalcemia, and 
bone loss.  
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Overall goal of our research is to understand the mechanisms of elastin specific 
MAC, to evaluate efficacy of chelating agents to reverse elastin specific MAC, and to 
develop a targeted delivery system to reverse elastin specific MAC and circumvent side 
effects.  
First, we investigated the mechanisms of elastin specific MAC, specifically cause-
and-effect relationship between the elastin-specific MAC and osteoblast-like 
differentiation of vascular smooth muscle cells (VSMCs). It has been accepted for 
decades that the pathology of vascular calcification resembles physiological bone 
mineralization. However, the cause-and-effect relationship between calcification and 
osteoblast-like differentiation of VSMCs is still unclear. We, for the first time, showed 
that in response to the calcified matrix, for both hydroxyapatite crystals and calcified 
aortic elastin, VSMCs lost their smooth muscle lineage markers and underwent 
chondroblast/osteoblast-like differentiation. Interestingly, this phenotypic transition was 
reversible and VSMCs restored their original linage upon reversal of calcification. 
Secondly, we evaluated the efficacy of chelating agents to reverse elastin specific 
MAC. We tested if chelating agents, such as disodium ethylene diamine tetraacetic acid 
(EDTA), diethylene triamine pentaacetic acid (DTPA) and sodium thiosulfate (STS) can 
remove calcium from hydroxyapatite (HA) and calcified tissues without damaging the 
tissue architecture. Our results indicated that both EDTA and DTPA could effectively 
remove calcium from hydroxyapatite and calcified tissues, while STS was not effective. 
The tissue architecture was not altered during chelation.  
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Thirdly, we investigated the therapeutic effects of systemic EDTA chelation 
therapy for reversal of calcification and its possible side effects in vivo. We used CaCl2 
mediated abdominal aorta injury in rats to mimic local aortic calcification similar to what 
is observed in clinical cases. We demonstrated that systemic EDTA chelation therapy did 
not reverse local aortic calcification. Moreover, systemic EDTA chelation therapy caused 
adverse events for serum and urine calcium, specifically hypocalcemia and 
hypercalciuria, but did not cause bone loss. 
Finally, we developed a targeted delivery system to reverse elastin specific MAC 
and to avoid side effects associated with systemic EDTA chelation therapy. We have 
recently shown that the nanoparticles (NPs) coated with elastin-antibody can be targeted 
to vascular calcification sites. This paved the way to design an elastin antibody coated 
and EDTA loaded albumin NPs to reverse elastin-specific medial calcification and avoid 
side effects. Our in vitro and in vivo results demonstrated that elastin antibody coated and 
EDTA loaded albumin NPs had good therapeutic effect to reverse elastin specific MAC 
and did not have side effects typically seen in systemic EDTA chelation therapy such as 
hypocalcemia and bone loss.  
In conclusion, our work led to enhanced understanding the possible mechanisms 
of osteogenesis in vascular calcification and possible alternative therapy to reverse elastin 
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CHAPTER 1: INTRODUCTION   
Cardiovascular disease (CVD) refers to several types of conditions that affect the 
heart and blood vessels. CVD is the leading cause of death in the world, responsible for 
30% of all deaths globally, and 1 in 3 (over 800,000) deaths in the US [1]. Pathological 
vascular calcification has been observed in many CVD and is recognized as a major risk 
factor for various cardiovascular events including heart failure, pulmonary hypertension 
(PTH), and death in chronic kidney disease (CKD) patients. Based on the location, 
vascular calcification can be classified atherosclerotic intimal calcification (AIC), medial 
arterial calcification (MAC) or Mönckeberg’s medial calcific sclerosis, aortic valve 
calcification (AVC), and calcific uremic arteriolopathy(CUA) or calciphylaxis [2]. AIC 
occurs in the context of atherosclerosis, associated with lipids, macrophages, and vascular 
smooth muscle cells; whereas, MAC can exist independently of atherosclerosis and is 
associated with elastic lamellae and vascular smooth muscle cells [3]. The work 
presented here focuses on the mechanisms and reversal of MAC.  
Currently the only option to treat vascular calcifications are surgical methods like 
directional atherectomy to remove mineral physically and placement of stent grafts to 
keep the artery open [4, 5]. These surgical methods are quite invasive and detrimental, 
and there is no available alternative pharmacological treatment for reversal of vascular 
calcification [6, 7]. One possible approach is EDTA chelation therapy. EDTA chelation 
therapy most often involves the injection of disodium ethylene diamine tetraacetic acid 
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(EDTA), a chemical that binds, or chelate ionic calcium, trace elements and other 
divalent cations so as to reverse calcification. There are, however, contradictory opinions 
for its success in improving cardiovascular health in patients.  
Overall goal of our research is to understand mechanisms of elastin specific 
MAC, to evaluate efficacy of chelating agents to reverse elastin specific MAC and their 
possible side effects, and to develop a targeted delivery system to reverse elastin specific 
MAC that can circumvent side effects.  
Over the last decade it has been well established that vascular calcification is not a 
passive deposition of mineral but an active process that resembles physiologic skeletal 
mineralization in that it shows the presence of many bone proteins and 
osteo/chondrogenic cells. It has been reported that the vascular calcification process is 
mineral-ion dependent and can be caused by either osteogenic transdifferentiation of 
VSMCs or reduced levels of mineralization inhibitors. However, it is unclear if 
calcification occurs first and that triggers osteoblast-like differentiation of vascular 
smooth muscle cells (VSMCs) or vice versa. It is still unclear if there exists a 
chronological occurrence between the osteoblast-like differentiation of VSMCs and 
passive deposition of hydroxyapatite on elastin, or if both processes occur simultaneously 
causing the eventual calcification of arteries. We, for the first time, showed that in 
response to the calcified matrix, for both hydroxyapatite crystals and calcified aortic 
elastin, VMCs lost their smooth muscle lineage markers and underwent 
chondroblast/osteoblast-like differentiation. Interestingly, this phenotypic transition was 
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reversible and VSMCs restored their original linage upon reversal of calcification. Our 
data supports the hypothesis that mineral deposition occurs first before osteogenic 
transformation of VSMCs 
EDTA chelation therapy has been touted as an effective treatment to reverse 
vascular calcification; however, it has been controversial with opposing views [8-10]. At 
present no systemic scientific studies prove that it could reverse cardiovascular 
calcification or improve cardiovascular function [9]. Moreover, most chelating studies are 
performed for atherosclerotic intimal calcification and no studies looked at whether such 
therapy would work to reverse medical arterial calcification (MAC). First, we showed 
that common chelating agents, such as disodium ethylene diamine tetraacetic acid 
(EDTA), diethylene triamine pentaacetic acid (DTPA) and sodium thiosulfate (STS) can 
remove calcium from hydroxyapatite (HA) and calcified tissues without damaging the 
tissue architecture in vitro. EDTA and DTPA were more effective than STS. This paved a 
way to test if such chelation can be used to reverse MAC in vivo. 
Most of the EDTA chelation therapies include EDTA subcutaneous infusion, or 
systemic application of EDTA solution at very high dose (around 40 ~ 50 mg/kg) [11-
17]. Many side effects have been found with such a high systemic dose of EDTA 
chelation therapy including: renal toxicity [18-23] , hypocalcemia [14, 24, 25], and bone 
loss [14, 26]. But results are quite controversial for side effects. On the basis of these 
reports for EDTA chelation therapy and our own in vitro results showing its effectiveness 
in reversing elastin-specific MAC, we performed an animal study to investigate whether 
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or not systemic EDTA chelation therapy could reverse local medial aortic calcification 
(MAC). A CaCl2 mediated abdominal aortic injury model was used to induce local aortic 
calcification in abdominal aortic region in rats [27, 28]. We demonstrated that systemic 
EDTA chelation therapy did not reverse local aortic calcification. Not only it did not 
reverse MAC, but it also caused adverse events for serum and urine calcium, specifically 
hypocalcemia and hypercalciuria. Thus, our data showed that systemic infusion of EDTA 
may not be a right option for reversal of MAC. 
In contrast to systemic EDTA chelation therapy, nanoparticle-based targeted 
EDTA delivery to the calcified aorta could lower dosage required due to improved 
bioavailability and sustained release at the site [29]. Thus, we tested if we can load 
EDTA in albumin based nanoparticles and target them to the aortic calcification sites in 
vivo. We show that the elastin antibody coated nanoparticles can be targeted to vascular 
calcification sites [30]. Our in vitro  and in vivo studies demonstrated that elastin 
antibody coated and EDTA loaded albumin NPs  reversed elastin specific MAC and did 
not cause side effects such as hypocalcemia and bone loss typically seen in systemic 
EDTA chelation therapy. 
Organization of dissertation 
1) In Chapter 2, we present comprehensive overview of:  




 Vascular disease: atherosclerosis, aortic aneurysms and medial arterial 
calcification (MAC).  
 Vascular calcification: mechanisms. Types and characteristics, animal 
models for investigating vascular calcification, current or prospective 
therapies for treating vascular calcification.  
 Chelation therapy: types and applications of chelation therapy, in vitro and 
animal studies of chelation therapy.  
 EDTA chelation therapy: case studies and clinical trials, side effects with 
traditional systemic EDTA chelation therapy, current opinions of EDTA 
chelation therapy for cardiovascular disease and targeted EDTA chelation 
therapy.  
 Targeted EDTA chelation therapy: local drug delivery in the vasculature, 
albumin nanoparticles as drug carriers for different application and targeted 
EDTA chelation therapy using EDTA loaded albumin nanoparticles 
2) Chapter 3 describes the project goals, scope, and rationale.  
3) In Chapter 4, we investigate mechanisms of elastin specific MAC, specifically 
cause-and-effect relationship between the elastin-specific MAC and osteoblast-
like differentiation of vascular smooth muscle cells (VSMCs). 
4) In Chapter 5, we evaluate efficacy of chelating agents to reverse elastin specific 
MAC. We show that chelating agents, such as disodium ethylene diamine 
tetraacetic acid (EDTA), diethylene triamine pentaacetic acid (DTPA) and sodium 
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thiosulfate (STS) can remove calcium from hydroxyapatite (HA) and calcified 
tissues without damaging the tissue architecture. 
5) In Chapter 6, we investigate systemic EDTA chelation therapy’s therapeutic 
effects in reversal of MAC and possible side effects in rat model of MAC. 
6) Finally in Chapter 7, we developed a targeted delivery system to reverse elastin 
specific MAC and circumvent side effects associated with systemic EDTA 
chelation therapy. This study proved the concept that elastin antibody coated and 
EDTA loaded albumin NPs might be a promising nanoparticle protein 









CHAPTER 2: LITERATURE REVIEW   
2.1 Vascular architecture 
2.1.1 Normal anatomy of blood vessel 
The cardiovascular system consists of the heart, blood vessels, and the 
approximately five liters of blood for humans. The heart is a muscular pumping organ 
that circulates blood to the organs. There are two primary circuits in the human body: the 
pulmonary circuit and the systemic Circuit. Pulmonary circuit consists of vessels that 
carry blood from the heart to the lungs and back to the heart. Systemic circuit composed 
of vessels that lead from the heart to all body parts (except the lungs) and back to the 
heart. 
Blood vessels are the body’s highways that allow blood to flow quickly and 
efficiently from the heart to every region of the body and back again. The walls of 
arteries and veins have three layers or tunics (Figure 2.1): 1) an outer layer (tunica 
adventitia) of connective tissue with collagen fibers and fibroblast cells; 2) a middle layer 
(tunica media), is mainly composed of smooth muscle cells and elastic fibers; 3) an inner 
layer (tunica intima), is mainly composed of a monolayer of endothelial cells and a 




Figure 2.1. Structure of blood vessel [31]. 
 
2.1.2 Structure of aortic elastin 
Elastin is the predominant structural protein of the arteries comprising of ~ 50% 
of the arterial extracellular matrix (ECM) [32]. Elastin is primarily synthesized during 




Figure 2.2. Structure of aortic elastin. A: aorta stained by Verhoeff Van Gieson staining 
10x magnification [33]; B: Depiction of elastic recoil [34]; C: Schematic representation 
of elastin and microfibrils [35]; D: Structural features of elastin showing the repetitive 
alternating sequence (square brackets) of β-hydrophobic domains and α-crosslinking 
areas [36]; E: TEM of cross section of elastin and fibrillin fibers deposited by vascular 
cells in culture [37]; F: TEM of longitudinal section of elastin. Elastin is stained in black 




Structure of elastin with different scale is shown in Figure 2.2. Verhoeff Van 
Gieson histological staining shows elastin in aorta as black wavy structures in cross-
section. Elastic lamina in the artery is structured as sheets similar to lasagna.  (Figure 
2.2A).  Elastin is endowed with high resilience capable to undergoing cyclic stretching 
(Figure 2.2B).  Elastic fibers are composed of 90% elastin core and 10 % microfibrils 
(Figure 2.2C). Elastin is a biopolymer with tropoelastin as its single repeating 
monomeric unit. The typical amino acid composition consists of non-polar amino acids 
with few polar side chain residues. Elastin contains alternating hydrophobic segments and 
alanine and lysine rich segments (Figure 2.2D) [36]. Under transmission electron 
microscope, elastin appears either in cross-section as amorphous clumps exhibiting low 
electron density measuring 100-800 nm at the core (Figure 2.2E) [37] or as 
longitudinally-aligned, laterally-associating bundles of elastin (Figure 2.2F) [38]. 
2.2 Vascular diseases related to calcification 
2.2.1 Atherosclerosis 
Atherosclerosis is a disease of the arteries in which cholesterol deposited in the 
wall of an artery, resulting in inflammation and narrowing of the arterial lumen channel 
that may eventually impair blood flow. Atherosclerosis is characterized as combination of 
tear in artery wall, cholesterol deposits, macrophage cell, macrophage foam cells, fat 





Figure 2.3. Cut section of an artery showing atherosclerosis [40].  
The pathogenesis of atherosclerosis remains incompletely understood. 
Accumulation of oxidized lipoproteins (oxLDL) within the vascular wall drives a related 
immune response very early during the disease course. Such an immune response is self-
amplified and eventually escapes from physiologic control mechanisms [41]. 
Inflammation plays a large role in atherosclerosis. The process of inflammation regulates 
the production of many chemokines and acute phase proteins. One of those acute phase 
proteins is C-reactive proteins (CRP) [42]. CRP is a phylogenetically highly conserved 
plasma protein, with homologs in vertebrates and many invertebrates, that participates in 
the systemic response to inflammation. Recently, an association between minor CRP 
elevation and future major cardiovascular events has been recognized [42].  
Since atherosclerosis is an inflammatory disease, most treatments include 
strategies to reduce inflammatory changes include interfere with the production of 
reactive oxygen species or, more desirably, with protein kinase C and nuclear factor 
kappa B (NF-kB) pathways [43]. From aspects of lifestyle and diet, a balanced diet 
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should be low in saturated fatty acids and enriched in polyunsaturated fatty acids –n-3 
fatty acids in particular [44]. And more uptake of antioxidants (such as vitamins E and C) 
[45], and polyphenols present in green tea and in red wine [46] would also be helpful. 
Some available pharmaceutics include: 1) anti-inflammatory drugs such as 
glucocorticoids and non-steroidal anti-inflammatory drugs [47], and aspirin [48]; 2) MG-
CoA reductase inhibitors (statins). Statins competitively inhibit HMG-CoA reductase, the 
rate-limiting enzyme in cholesterol synthesis. Statins also have non-lipid-decreasing 
effects include partial agonism of PPARα and PPARγ [49]. PPARs are nuclear receptors 
that, after ligand-induced activation, form a heterodimer with a ligand-activated retinoic 
acid receptor.  
Surgical methods currently used include: bypass graft surgery [50], stented or 
non-stented balloon angiography [51]. However, neither of these methods reverses 
calcification.  
2.2.2 Aortic aneurysms 
Aortic aneurysm is a local dilatation of the aorta with respect to the original 
arterial size or the adjacent area of the artery (Figure 2.4). As a convention, arterial 
diameter greater than 1.5 times the normal size or greater than 3 cm in diameter, is 
considered aneurysmal, although the definition may vary somewhat by age and body 
surface area [52]. 
The gross characterization of aortic aneurysms include locally dilated aorta, 
atheromatous plaque deposition and mural thrombosis, whereas typical histological 
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characterization include trans-mural inflammation, increased pro-inflammatory and 
immune markers, extensive local proteolytic activity, apoptosis, local oxidative-stresses 
and neovascularization. 
 
Figure 2.4. Normal aorta and aorta with large abdominal aneurysm [53].  
 
Currently advanced imaging techniques are used to detect and monitor aneurysms 
include: ultrasonography, computed tomography (CT), and magnetic resonance imaging 
(MRI). Ultrasonography is currently the safest, easiest and most economic examination 
for the diagnosis of aneurysms. CT accurately demonstrates the size and extent of 
aneurysms and also detects thrombus (crescent sign) effectively. MRI demonstrates 
features without the need for a contrasting agent. MRI is completely non-invasive. 
Currently there are two different methods to treat aneurysms in patients- an open 
repair or an endovascular approach. There are no well-defined pharmacological therapies 
for the treatment of aneurysms. Some available therapies have been tested including: 
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statins [54], Beta androgenic blockers [55], tetracyclines [56], anti-platelet therapy [57],  
anti-oxidant therapy- Vitamin E [58], and anti-inflammatory agents [59].  
 
2.3 Vascular calcification 
Cardiovascular disease (CVD) refers to several types of conditions that affect the 
heart and blood vessels. CVD is the leading cause of death in the world, responsible for 
30% of all deaths globally, and 1 in 3 (over 800,000) deaths in the US[1]. Pathological 
vascular calcification has been observed in many CVD and is recognized as a major risk 
factor for various cardiovascular events including heart failure, pulmonary hypertension, 
and increased blood pressure [60]. Based on the location, vascular calcification can be 
classified as intimal calcification, medial calcification, valvular calcification, and 
calciphylaxis [2]. Many animal models have been developed to study mechanisms of 
vascular calcification, however; there is only little literature available about preventing or 
reversing vascular calcification. We are mostly concerned here with medial arterial 
calcification (MAC) in the present work. 
2.3.1 Medial arterial calcification (MAC) 
Calcification of the media or medial artery calcification (MAC), also known as 
Monckeberg’s sclerosis is a pathological ossification of the medial part of arteries 
(Figure 2.5). Intimal calcification occurs in the context of atherosclerosis, associated with  
lipid,  macrophages  and  vascular  smooth  muscle  cells, whereas MAC can exist 
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independently of atherosclerosis  and  is  associated  with  elastin  and  vascular smooth 
muscle cells [3]. 
 
Figure 2.5. H&E of a patient with MAC. The arrow depicts calcium deposits within the 
media of a peripheral artery [61].  
 
MAC is frequently observed in patients with diabetes and is associated with 
increased risk of nephropathy, retinopathy, lower limb amputation, and coronary artery 
disease and all-cause mortality [62].  
2.3.2 Mechanisms of vascular calcification 
Pathologic calcification of cardiovascular structures, or vascular calcification, is 
associated with a number of diseases including end-stage renal disease (ESRD) and 
cardiovascular disease (CVD) [63]. 
Five different mechanisms for initiating vascular calcification are shown in 
Figure 2.6 [63].  First, lack of or loss of inhibitors of mineralization, such as matrix Gla 
protein (MGP), pyrophsophate in blood vessels normally expressed, have been shown 
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cause spontaneous vascular calcification [64, 65]. Second, osteogenic mechanisms may 
also play a role in vascular calcification. Many bone proteins such as osteopontin [66], 
osteocalcin [67], and BMP-2 [68] have been identified in calcified vascular lesions. 
Third, the link between osteoporosis and vascular calcification is identified and loss of 
bone in osteoporosis has been correlated with higher calcium content in the arteries 
(REF). Bone turnover causing circulating nucleational complexes has been proposed to 
explain the link between vascular calcification and osteoporosis in postmenopausal 
women [69]. Fourth, cell death produce phospholipid rich membranous debris and 
apoptotic bodies that may serve to nucleate apatite which induce vascular calcification 
[70]. Finally, via thermodynamic mechanisms (also referred to as “passive” mechanisms), 
elevated Ca and P, promote apatite nucleation and crystal growth and would also 
exacerbate vascular calcification initiated by any of the other mechanisms described 
above. These mechanisms are not mutually exclusive and some or all can occur 




Figure 2.6. Schematic illustrating four, non–mutually exclusive theories for vascular 
calcification [63]. 1) Loss of inhibition like matrix Gla protein (MGP), osteopontin 
(OPN), fetuin, pyrophsophate, and others; 2) Induction of bone formation due to high 
level of Pi, lipids, inflammatory cytokines, and others; 3) Circulating nucleational 
complexes; 4) Cell death.  
 
Current understanding of cause-and-effect relationship between 
osteo/chondrocytic differentiation of VSMCs and vascular calcification is shown in 
Figure 2.7 [71]. Normally, mesenchymal stem cells differentiate to adipocytes, 
osteoblasts, chondrocytes, and vascular smooth muscle cells (VSMCs). In the setting of 
chronic kidney disease, diabetes, aging, inflammation, and multiple other toxins, these 
VSMC can dedifferentiate or transform into osteo/chondrocytic-like cells by upregulation 
of transcription factors such as runt-related transcription factor 2 (RUNX-2) RUNX-2 
and muscle segment homeobox 2 (MSX2). These cells lay down collagen and 
noncollagenous proteins in the intima or media and incorporate calcium and phosphorus 
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into matrix vesicles to initiate mineralization and further mineralize into hydroxyapatite. 
What triggers this dedifferentiation of VSMCs is currently unknown. 
Our research is testing the hypothesis that vascular calcification might precede 
osteo/chondrocytic differentiation of VSMCs. Detailed experimental rationale is 
discussed in Chapter 3.  
 
Figure 2.7. Osteo/chondrocytic differentiation of VSMC and vascular calcification [71]. 
Abbreviations: CKD-Chronic kidney disease; PPi-pyrophosphate; MGP-matrix Gla 
protein; OP-osteopontin.  
 
2.3.3 Types and characteristics of vascular calcification  
Based on histoanatomy or location, vascular calcification can be mainly classified 
as four types (Table 2.1, Figure 2.8): atherosclerotic intimal calcification (AIC), medial 
19 
 
arterial calcification (MAC) or Mönckeberg’s medial calcific sclerosis, Aortic valve 
calcification (AVC), and calcific uremic arteriolopathy (CUA) or calciphylaxis.  
AIC forms at the intimal layer of the blood vessel, and is mostly associated with 
conditions of atherosclerosis, hyperlipidemia, and hypertension. ACI is characterized by 
eccentric lumen-deformation, vessel remodeling, elastinolysis and increased oxidized 
low-density lipoprotein (LDL) [68, 72-74].  
MAC forms at the tunica media. MAC is mostly associated with type 2 diabetes 
mellitus, end-stage renal disease (ESRD), hyperphosphatemia and Lower-extremity 
amputations. MAC has circumferential calcium deposition in the arterial tunica media 
along with the elastic lamina, adventitial inflammation, fibro-fatty expansion [75-79].  
AVC forms at the aortic side of the leaflets and is usually associated with 
hyperlipidemia, congenital bicuspid valve and rheumatic heart disease. AIC has fibro-
fatty expansion and inflammation of the lamina fibrosa, displaced and/or split elastic 
lamina and nodular amorphous calcium phosphate accumulation via epitaxial deposition 
[12, 80-82].  
CUA refers to calcification formed in micro-vessels and is mainly associated with 
end-stage renal disease (ESRD), and warfarin treatment.  CUA is exhibited in arteriolar 
(~ 0.6 mm diameter) medial calcification in dermal, pulmonary and mesenteric vessels. 
CUA has fibroproliferative occlusion, secondary skin and dermal fat necrosis, 
periarteriolar inflammation and bone morphogenetic protein 4 (BMP4) expression and 




Table 2.1. Types and characteristics of vascular calcification (Modified from  
Demer(2008)[87], Towler(2008)[88]) 
Type Location Associated 
conditions 
Histopathology 
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BMP4:  bone morphogenetic protein 4; MGP:  matrix Gla protein; ESRD: end-stage renal disease;  LDL: 






Figure 2.8. Representative images for types of vascular calcification. Top: photos or 
radiograph. Scale bar: 1 cm. bottom: H&E staining images. Magnification: 100X, Scale 
bar: 100 µm. A: Healthy non-calcified aorta as control; B: Severe atherosclerotic intimal 
calcification; C: Medial arterial calcification; Top:Pelvic and lower extremity radiograph 
shows extensive calcification of the femoral arteries; Bottom: Microphotography of 
arterial wall with calcified (violet colour) atherosclerotic plaque; D: Aortic valve 
calcification; E: Calcific uremic arteriolopathy; Calciphylaxis on the abdomen of a 
patient with end stage renal disease. Markings are in cm. Images information and 
resources: A (49 years old male patients) and B (Severe stherosclerotic patients, 75 years 
old male patients) were from cadavers provided by Dr. Michael E. Ward at Greenville 
Hospital System (Greenville, SC).  
C:http://en.wikipedia.org/wiki/Monckeberg's_arteriosclerosis;  D and E bottom: From 
pathologist - Lang Lei at The Second Affiliated Hospital to Nanchang University (Jiang 
Xi, P. R. China); E top: http://en.wikipedia.org/wiki/Calciphylaxis. 
 
2.3.4 Animal models for investigating vascular calcification 
Many animal models are developed to study vascular calcification. Table 2.2 
summarizes these animal models based on specific treatment protocols, species studied, 
and location of calcification. Treatments studied include calcium chloride (CaCl2) injury 
of abdominal aorta [27, 28, 30, 89-91], local perfusion of pancreatic elastase [92-94], 
balloon angioplasty[95],  systemic delivery of warfarin plus vitamin K [30, 96, 97], 
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Vitamin D [78, 98-100], nicotine plus vitamin D [101-104], indoxyl sulphate [105], and 
many types of gene knockout models [64, 106-108].  
 The calcium chloride (CaCl2) injury model has been used for rat, mice, and rabbit 
[27, 28, 30, 89-91]. Local damage to the abdominal aorta (or other regions like carotid 
artery or thoracic aorta) is caused by direct application of CaCl2 resulting in chemical 
damage of the tissue. This type of localized medial calcification is pathologically similar 
to clinical cases and minimal injury to the arterial wall.  In this model, adult rat aorta is 
exposed and inflammation is induced by a single, periarterial application of calcium 
chloride. This acute insult to the artery induces an accelerated and extensive calcification 
accompanied by intense inflammation and severe elastin degradation [109].     
The warfarin plus vitamin K model for rat typically uses 20 mg/kg/day of 
warfarin in drinking water and 15 mg/kg/day of Vitamin K by subcutaneous injection 
every other day for a total period of three weeks [30, 96, 97]. This treatment will cause 
systemic calcification in the aorta, major arteries and heart valves for rats. Warfarin 
inhibits activation of MGP (an important inhibitor of calcification), and vitamin K 
restores normal coagulation time to offset the anticoagulant side effects of warfarin.  
The vitamin D model for rat typically uses daily intraperitoneal injections of 
vitamin D (1µg/kg) or supra-physiological vitamin D doses in diet (7.5 mg/kg) [78, 98-
100]. This treatment also causes systemic calcification in the aorta and major arteries. 
The vitamin D model was used to mimic vascular calcification disease related to 
osteoporosis and hyperparathyroidism secondary to chronic kidney disease. Toxicity of 
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vitamin D is associated with hyperabsorption of calcium and phosphorus [100]. Vitamin 
D exerts a stimulatory effect on vascular calcification through direct inhibition of the 
expression of parathyroid hormone–related peptide (PTHrP) in VSMCs as an endogenous 















Table 2.2. Animal models of vascular calcification. 
Protocol  Species Mechanisms   Location Characteristics References 
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The nicotine plus vitamin D model for rat uses combination of vitamin D with 
nicotine (25 mg/kg, 5 ml/kg) given by oral administration [101-104]. This treatment 
causes systemic calcification in the aorta and major arteries. Nicotine is added in 
conjunction to the vitamin D to amplify the calcification processes. The nicotine plus 
vitamin D model mimics calcification disease associated with advancing age and is 
accompanied by systolic hypertension and left ventricular (LV) concentric hypertrophy.  
The indoxyl sulphate (IS) model for rat uses 200 mg/kg of indoxyl sulphate in 
drinking water [105]. The IS model showed increase thickness of the aorta. IS promotes 
aortic wall thickening and aortic calcification with colocalization of osteoblast - specific 
proteins [105].  Administration of IS to 5/6 nephrectomized rats caused glomerular 
sclerosis in the remnant kidney with a decline in renal function [111]. Furthermore, IS 
stimulated transcription of genes related to renal fibrosis [112].  
The elastase model has been studied in swine and rabbit [92-94]. By intraluminal 
infusion of elastaste after surgical exposure of aorta, an important number of necrotic 
lesions were observed, and they were associated with the development of calcium 
deposits by 3 weeks [92]. Elastase degrades elastin in elastic lamina of arteries, which in 
turn induces local calcification for abdominal aorta. Many surgical modified techniques 
have been investigated to get reproducible elastase-induced aneurysms related 
calcification, such as direct exposure of the origin of the right common carotid artery 
(RCCA) with placement of a temporary aneurysm clip instead of an occlusion balloon for 
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isolation of the artery, and more extensive dissection of the RCCA, down to its origin 
from the brachiocephalic artery [94]. 
The balloon angioplasty model for rabbit uses mechanical damage to induce local 
calcification of  abdominal aorta [95]. The aortic injury was rapidly followed by calcified 
deposits that appeared in the media as soon as 2 days after injury and then accumulated in 
zipper-like structures. This rapid aortic calcification model is good to study mechanisms 
involved in the initiation step of the aortic calcification process but mainly related to 
restenosis [45].  
Many types of gene knockout models for mice have been studied including 
Fibroblast growth factor 23(FGF23) deficient, Klotho deficient, matrix GLA protein 
(MGP) knockout, OPG (Osteoprotegerin) knockout and fetuin A knockout  model[64, 
106-108]. Knocking out specific genes related to regulation of vascular calcification will 
cause systemic calcification in arteries and will show the specific role of proteins in the 
calcification process. Kuro-o et al. in 1997 showed that defect in klotho gene expression 
in the mouse results in a syndrome that resembles human ageing, including a short 
lifespan, arteriosclerosis, skin atrophy etc. The klotho gene encodes a membrane protein 
that shares sequence similarity with theb-glucosidase enzyme [106].  Luo et al. in 1997 
showed that mice that lack MGP develop to term but die within two months as a result of 
arterial calcification which leads to blood vessel rupture and concluded that MGP is the 
first inhibitor of calcification of arteries and cartilage to be characterized in vivo [64].  
Schäfer et al. in 2003 identified the serum protein α2–Heremans-Schmid glycoprotein 
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(Ahsg, also known as fetuin-A) as an important inhibitor of ectopic calcification acting 
on the systemic level. Ahsg-deficient mice were phenotypically normal, but develop 
severe calcification of various organs on a mineral and vitamin D–rich diet [107]. 
Razzaque et al. in 2006 foung that FGF23 deficient mice exhibited numerous 
biochemical and morphological features consistent with premature aging-like phenotypes, 
along with severe atherosclerosis, widespread soft tissue calcifications [108].  
2.3.5 Current or prospective therapies for treating vascular calcification 
Current or prospective therapies for treating vascular calcification are summarized 
in Table 2.3 (Modified from Kapustin (2009) [6],  Wu (2013) [7]).  These treatments are 
often existing therapies for related conditions and could be classified as three categories 
based on different targets and mechanisms of action: chronic kidney disease and 
osteoporosis therapies, cardiovascular disease therapies, and experimental therapies.  
Therapies for treating vascular calcification associated with chronic kidney 
disease (CKD) and osteoporosis include: 1) treatments using bisphosphonates, sevelamer, 
calcimimetics and thyroidectomy so as to target mineral imbalance, and 2) sodium 
thiosulfate (STS) as a vasodilator, antioxidant, and calcium chelator [113-118]. The 
treatments with bisphosphonates, sevelamer, calcimimetics and thyroidectomy were 
proposed to maintain Ca and P serum levels, inhibit initialization and growth of calcium 
apatite crystals and prevent osteo/chondrogenic transition of vascular smooth muscle cell 
(VSMC). However, these treatments had complications and limitations such as crosstalk 
with bone metabolism and require strict dialysis protocols; [116, 117, 119-122]. STS 
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treatment could improve local circulation, reduce inflammation and calcification. STS is 
an established treatment for calciphylaxis. However, STS also has possible side effects 
such as hypocalcemia and bone loss [119].  
Most common therapies for treating vascular calcification associated with 
cardiovascular diseases are statins. Statins are a group of drugs that help to lower serum 
cholesterol by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase in the liver, to help prevent the formation of atherosclerotic lesions. Statins 
have been used to lower serum cholesterol and reduce arterial calcification [123-125]. 
Statin treatments prevent inflammation and increase VSMC survival and viability. 
Callister et al. in 1998 demonstrated that treatment with HMG-CoA reductase inhibitors, 
or statins  can reduce the calcium-volume score and volume  of  calcified  plaque  in  the  
coronary arteries [123]. A retrospective study of 174 patients with mild to moderate 
calcific aortic stenosis was conducted by Novaro et al. in 2001 [124]. Results showed that 
statin-treated patients had reduced aortic stenosis progression compared with those not 
treated with a statin [124]. Although statins could prevent atherosclerosis, it is ineffective 
for diabetic CKD [125].  Besides, statin treatments had side effects with the immune 
system and tissue remodeling [126, 127]. Statins were found to suppress the induction of 
Major histocompatibility complex class II (MHC-II) molecules, which affect the immune 




Table 2.3.Current or prospective therapies for treating vascular calcification(Modified 
from Kapustin(2009)[6],  Wu(2013)[7]).  
Treatment Mechanisms of action Complication and limitation References 





Target mineral imbalance;  
Maintain Ca and P serum levels;  
Inhibition of initialization and 
growth of the calcium apatite 
crystal;  
Side effects with bone metabolism;  








Sodium thiosulfate A vasodilator, antioxidant, and 
calcium chelator;  
Improves local circulation, 
reduces inflammation and 
calcification 
Established treatment for 
calciphylaxis;  
Possible side effects such as 








Vitamin K Increases activation of circulating 
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Only worked for patients have vitamin 






Cardiovascular disease therapies 
Statins Prevent inflammation;  
Increase VSMC survival and 
viability 
Side effects with immune system and 
tissue remodeling;  
Could prevent atherosclerosis but  










Carbonic anhydrase II  Induction of calcium deposit 
resorption 
Side effects with bone metabolism Rajachar(2009)[132] 
Osteoclast-mediated 
demineralization 
Main mineral-resorbing cells in 
the body;  
Resorb abnormal minerals in 
vascular calcification 
Cells only migrated to the adventitial 
layer of the artery; 
Successful delivery of the osteoclasts is 
still a big challenge  
Simpson(2007)[133] 
EDTA Directly remove calcium from 
calcified tissue 
Binds serum calcium to reduce 
calcification;  
Chelate toxic heavy metals;  
Normalize calcium metabolism 
by reactivation of enzymes 
inhibited by toxic heavy metals;  
Anti-nanobacteria;  
Remove Fe and Cu to protect cell 
membrane 
Passible side effects including renal 
toxicity, hypocalcemia, bone loss and 













Treatments in italic type: clinical trials and are currently used; Treatments as listed not by italic type:  hypothetical and experimental.  
 
MGP: Matrix gla protein; VSMC: vascular smooth muscle cell 
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Finally, many experimental therapies were tested in animal models including: 1) 
Carbonic anhydrase II [132]; 2) Osteoclast-mediated demineralization [133]; and 3) 
EDTA chelation therapy [135-137] [13, 14, 138-140] [17]. Carbonic anhydrase II had 
shown an induction of calcium deposit resorption but it had side effects on bone 
metabolism [132]. Osteoclasts are the only mineral-resorbing cells in the body and 
osteoclasts delivery was tried as a method to resorb abnormal minerals in vascular 
calcification. However, the Osteoclast-mediated demineralization method showed that 
cells only migrated to the adventitial layer of the artery and successful delivery of the 
osteoclasts still remains a challenge [133].  
2.4 Chelation therapy 
Chelation therapy most often involves the injection of EDTA, a chemical that 
binds, or chelates ionic calcium, trace elements, and other divalent cations [141]. At 
present, whether or not chelation therapy reverses vascular calcification is quite 
controversial [9]. There are many proposed mechanisms for EDTA chelation therapy to 
reverse calcification. EDTA can directly remove calcium from calcified tissue [28, 134]. 
EDTA can bind serum calcium to reduce calcium levels and that way can prevent mineral 
augmentation. It can also chelate toxic heavy metals and normalize calcium metabolism 
by reactivation of enzymes inhibited by toxic heavy metals [135-138]. EDTA also been 
shown as an anti-nanobacteria and can remove Fe and Cu to protect the cell membrane 
[13, 139, 140]. However, systemic side effects including renal toxicity [18-23] , 
hypocalcemia [14, 24, 25], bone loss [14, 26] prevent it from being an accepted form of 
treatment for vascular calcification. If one can reduce systemic side effects, EDTA 
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chelation therapy might still be a promising treatment for diseases of vascular 
calcification. Site-specific targeted drug delivery has advantages such as lower toxicity, 
higher therapeutic effect, thus one can envision such therapies for resorbing mineral from 
arteries. 
2.4.1 Types and applications of chelation therapy 
Many types of chelators have been studied for medical applications including: 
EDTA [17, 24, 142-144], calcium disodium EDTA (calcium disodium versante, CaNa2-
EDTA) [145-147], STS [120, 121, 148-151], diethylene triamine pentaacetic acid (DTPA) 
[152, 153], dimercaprol (British anti-Lewisite; BAL) [145, 154],  Dimercaptosuccinic 
acid (DMSA) [145, 155], dimercapto-propane sulfonate (DMPS) [156, 157], 
penicillamine [145, 158], deferoxamine and deferasirox [159, 160]. Current types and 









Table 2.4. Types and applications of chelation therapy. 
Type of chelator Medical applications  References 
EDTA Hypercalcemia; 
Prevent calcification of fixed tissue;  







 Calcium disodium EDTA  
(calcium disodium versenate; 
CaNa2-EDTA) 
mercury and lead poisoning Trevor(2007)[145] 
Saxena(2004)[146] 
Leckie(1958)[147] 
Sodium thiosulfate(STS) Antioxidant;  
Cyanide toxicity;  
Skin diseases like acne and pityriasis 
versicolor;  
Carboplatin and cisplatin-induced oto- and 
nephrotoxicity; 
Calcific uremic arteriolopathy(CUA) a.k.a 
“calciphylaxis”;  
Decrease vascular calcification in ESRD;  
Delay progress of CAC in hemodialysis 









DTPA MRI contrasting agents; 
Treatment of radioactive materials such as 
plutonium, americium, and other actinides 
Caravan(1999)[152] 
Brown(2012)[153] 
Dimercaprol                                 
(British anti-Lewisite; BAL) 
Lewisite poisoning (for which it was 
developed as an antidote); 
Arsenic, mercury, lead poisoning 
Goldman(1989)[154] 
Trevor(2007)[145] 
Dimercaptosuccinic acid  
(DMSA) 
Arsenic, mercury, lead poisoning Archbold(2004)[155] 
Trevor(2007)[145] 
Dimercapto-propane sulfonate  
(DMPS) 
severe acute arsenic, mercury poisoning Aposhian(1990)[156] 
Gonzalez-
Ramirez(1998)[157] 
Penicillamine Mainly in copper toxicity of Wilson's 
disease; 
Occasionally adjunctive therapy in: gold 




Deferoxamine and Deferasirox 
 




CAC: coronary artery calcification; DTPA: diethylene triamine pentaacetic acid; ESRD:  End-stage renal 




EDTA has been used in hypercalcemia, prevention of calcification for fixed tissue, 
and as a treatment for cardiovascular diseases including atherosclerosis [17, 24, 142-144]. 
Tables 2.5 shows EDTA’s binding constants to metal ions (modified from Halstead 
[103]), Rozema [104]). Higher binding constant indicates more potential of binding to the 
metal ion. Clearly, EDTA binds strongly with iron, mercury and lead. 
Table 2.5. EDTA’s  binding constants to metal ions(modified from Halstead (1979[161]), 
Rozema(1997)[162]) 
Metal cation Fe+++ Hg++ Cu++ Pb++ Ni++ Zn++ Cd++ Co++ Al+++ Fe++ Mn++ Ca++ Mg++ 
Log K 25.1 21.8 18.8 18.5 18.0 16.5 16.5 16.3 16.1 14.3 13.7 10.7 8.7 
 
Calcium disodium EDTA (calcium disodium versenate, CaNa2-EDTA) [145-147] 
has been used as treatment in mercury and lead poisoning and has been approved by US 
Food and Drug Administration (FDA). STS has been used as an antioxidant, treatment 
for cyanide toxicity, skin diseases like acne and pityriasis versicolor, carboplatin and 
cisplatin-induced oto- and nephrotoxicity, calcific uremic arteriopathy(CUA) a.k.a 
“calciphylaxis”. STS treatment has been shown to decrease vascular calcification in 
ESRD and delay progress of CAC in hemodialysis patients [120, 121, 148-151].  
DTPA has been used as magnetic resonance imaging (MRI) contrasting agents, 
treatment of radioactive materials such as plutonium, americium, and other actinides [152, 
153]. Dimercaprol (British anti-Lewisite; BAL) has been used for Lewisite poisoning (for 
which it was developed as an antidote) and arsenic, mercury, lead poisoning [87, 96]. 
DMPS also has been used for severe acute arsenic, mercury poisoning [98, 99]. 
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Penicillamine is mainly used in copper toxicity of Wilson's disease and occasionally 
adjunctive therapy in: gold toxicity, arsenic poisoning, and lead poisoning rheumatoid 
arthritis [87, 100]. Deferoxamine and deferasirox is mainly used in acute iron poisoning 
and iron overload [101, 102].  
2.4.2 In vitro and animal studies of chelation therapy for vascular 
calcification 
Few studies have been reported for chelation therapy using EDTA [134] [11, 13, 
21, 28, 144, 163-165] and STS [119, 166] to prevent or reverse calcification (Table 2.6).  
It has been shown in vitro that EDTA could remove calcium from human 
calcified tissue. A modified form of EDTA, NH4-EDTA, provided a quantitative method 
of decalcifying tissue [134]. EDTA also has been used as a pre-treatment for 
bioprosthetic materials such as collagen-elastin matrix (CEM) and bovine pericardium 
specimens and significantly decreased the calcification of these tissues in a rat subdermal 
model [163] [144, 164]. One study of the mechanism of renal vacuologenesis induced by 
EDTA systemic infusion (jugular vein injection, 1000 mg/kg, disodium Ca-EDTA) 
showed EDTA-induced vacuologenesis is a reflection of the induction of pinocytosis by 
the chelate [21]. 
EDTA treatment by direct infusion (50 mg/kg, 15 mg/minutes, total 20 infusions) 
showed significantly less calcium in the aorta of the EDTA infused animals in an 
atherosclerotic rabbit model (cholesterol diet and Vitamin D3 injection) [11]. However, 
O'Brien et al. shown that EDTA treatment (40 mg/kg, daily intravenous injection, 4 
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weeks) caused a 74% increase in triglyceride levels and no benefit on arterial lesions in 
an  atherosclerotic, obese, diabetic rat model [165]. Cavallotti et al. showed that EDTA 
treatment (40 mg/kg or 120 g/3 kg rabbit, daily intravenous injection, 10 days) showed a 
marked decrease of the calcification in a rabbit calcification model [13].  We recently 
compared chelating efficacy  EDTA, DTPA and STS (1–10 mg/mL) to remove calcium 
from hydroxyapatite (HA), calcified elastin and aortic tissue and showed that EDTA and 
DTPA could effectively remove calcium from HA and calcified tissues, while STS was 
not effective [28]. We further showed that EDTA-loaded PLGA nanoparticle pellets (30 
mg) when placed periadventitially on calcified abdominal aorta could also reverse local 











Table 2.6. In vitro and animal studies for chelation therapy 
Chelating 
agent 
Study design Results  References 
EDTA  NH4-EDTA and EDTA were used to remove 
calcium from human calcified tissue 
Provided a quantitative 
method of decalcifying tissue 
Bolick(1961)[134] 
SD rats, n=5 in each group; 1000 mg/kg of 
disodium Ca-EDTA; jugular vein injection;  
Renal toxicity Schwartz(1970)[21] 
Rat subdermal model; Collagen-elastin matrix 
(CEM) were implant  after pretreatment with 
various conditions of ethanol and EDTA  
Significantly decreased the 
calcification rate of CEM 
Singla(2003)[163] 
Rat subdermal model; Pericardium specimens were 
treated with PBS containing 100 µg/ml EDTA  
EDTA was useful in the 
attenuation of calcification 
Sucu(2006)[144] 
Rat subdermal model; Freshly excised bovine 
pericardium fixed in PBS solution containing 11% 
EDTA for a period of 48 h (30 ml/g tissue) 
 
Calcium content of EDTA-
treated pericardium was 
significantly lower 
Sucu(2004)[164] 
Atherosclerotic rabbit model by cholesterol diet and 
Vitamin D3 injection; 
EDTA:  50 mg/kg, 15 mg/minutes, total 20 
infusions 
 
Significantly less calcium in 
the aortas of the EDTA 
infused animals 
Kaman(1990)[11] 
Atherosclerotic, obese, diabetic rat model;  
EDTA: 40 mg/kg, daily intravenous injection, 4 
weeks 
No benefit on arterial lesions; 
But produced in a 74% 
increase in triglyceride levels 
O'Brien(2000)[165] 
Rabbit calcification model by a single dose of 8 mg 
of dihydro-tachysterol(synthetic vitamin D analog); 
EDTA: 40 mg/kg(120 g/3 kg rabbit), daily 
intravenous injection, 10 days 
Marked  decrease of the 
calcification 
Cavallotti(2004)[13] 
EDTA, DTPA and STS(1–10 mg/mL) were used to 
remove calcium from hydroxyapatite calcified 
tissue; 
EDTA-loaded PLGA nanoparticle pellets (30 mg) 
were placed periadventitially on calcified abdominal 
aorta 
EDTA and DTPA could 
effectively remove Ca from 
HA and calcified tissues, 





Uremic rat model by adenine-induced nephropathy;  
STS:  0.4 g/kg intraperitoneally 3 times a week; 
Prevent vascular calcifications 
in 
uremic rats; 
Side effects such as bone loss 
and transiently lowered 
ionized calcium in blood 
plasma 
Pasch(2008)[119] 
Aortic calcification model and hydroxyapatite 
formation in vitro;  
STS: 1-2 mM;  
Aimed to determine effect of thiosulfate on vascular 
calcification and hydroxyapatite formation 
 
Thiosulfate inhibited vascular 
calcification through a direct 





One recent study  by O’Neill et al. using STS aimed to determine the effect of 
thiosulfate on vascular calcification and hydroxyapatite formation using an aortic 
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calcification model and hydroxyapatite formation in vitro [166]. Their results showed that 
thiosulfate prevented calcification of injured or devitalized aortas but not uninjured aortas.  
Another animal study using systemic STS (0.4 g/kg intraperitoneally 3 times a week) 
showed that STS treatment could prevent vascular calcifications in a uremic rat model by 
adenine-induced nephropathy [119]. However, the STS treatment had side effects such as 
bone loss and transiently lowered ionized calcium in blood plasma.  
2.5 EDTA chelation therapy 
2.5.1 Case studies and clinical trials of EDTA chelation therapy 
Many case studies and clinical trials have been conducted for EDTA chelation 
therapy (Summarized in Table 2.7). Results of all these studies are quite controversial. 
On the positive side there are several studies that show improvement with chelation 
therapy. Clarke et al.  in 1956 [142]  reported a case study of EDTA chelation therapy (5 
g  EDTA, intravenous infusion) with 20 patients with coronary heart disease showing 19 
patients with improved symptoms post treatment with EDTA. They continued their 
research with another bigger case study with 700 patients afflicted by  coronary heart 
disease and showed that 87% of the patients had improved symptoms post treatment with 
EDTA [167]. Olszewer et al. in 1990 [137] did a pilot double blinded study with EDTA 
chelation therapy (1.5 g EDTA, 20 intravenous infusion) with 10 patients (all male, aged 
41 to 53 years) diagnosed with peripheral vascular disease. Results showed that EDTA 
chelation therapy had substantial improvements for the walking test and master exercise 
test. Rudolph et al.  in 1991 [168]  reported a case study with 30 patients diagnosed with 
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atherosclerotic vascular disease. EDTA chelation therapy (3 g EDTA, 30 intravenous 
infusions, and 10 months) was shown to decrease intra-arterial obstruction and reduce in 
stenosis post treatment with EDTA. Hancke et al. in 1993 [169] reported a case study 
with 470 patients and showed that after EDTA chelation therapy (50 mg/kg, 30 
intravenous infusions, 3-4 months) more than 80% of the patients had objective evidence 
for improvement post treatment with EDTA. Maniscalco et al.  in 2004 [139] reported a 
case study with 100 patients who had stable coronary artery disease (CAD) using ComET 
therapy, which  is composed of (1) nutraceutical powder, (2) tetracycline HCl, and (3) 
EDTA 1.5 g taken in a rectal suppository base. After ComET therapy, coronary artery 
calcium (CAC) scores decreased. Shoskes et al. in 2005 [170] reported a case study with 
16 male patients with recalcitrant chronic prostatitis/chronic pelvic pain syndrome(CPPS) 
showing significant improvement of symptoms in the majority of men after ComET 
therapy. Cacchio et al. in 2009 [171] reported a case study with 80 patients with 
radiographically verified calcific tendinitis of the shoulder and after single-needle 
mesotherapy (1 ml of 15%disodium EDTA) calcifications were greatly decreased.  
However, there were four published randomized trials of EDTA chelation therapy 
therapy that are not completely consistent with the aforementioned case studies. The first 
randomized trial was done by Guldager et al.  in 1993 [14] with a total of 54 patients (15 
women and 39 men, aged 41 to 81 years) with  intermittent claudication. Patients 
underwent EDTA chelation therapy (3 g EDTA, 20 intravenous infusion, 5-9 weeks). 
However, results in this study showed no differences in groups in any clinically relevant 
parameter and the EDTA chelation therapy was accompanied by bone loss. A study by 
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Van et al. in 1994 [15] with 32 patients with intermittent claudication and also showed 
that EDTA chelation therapy (3 g  EDTA, intravenous infusion) had no significant 
beneficial effects in patients with intermittent claudication but had some improvement in 
resting ankle-brachial index. Knudtson et al. reported in 2002 [16] a case with 84 patients 
who were at least 21 years old with coronary artery disease (CAD). This study showed 
that EDTA chelation therapy (40 mg/kg EDTA, intravenous infusion) had no evidence to 
support a beneficial effect. A recently study conducted by Lamas et al.  in 2013 and 
funded by NIH [17] with 1708 patients with myocardial infraction showed that EDTA 
chelation therapy (50 mg/kg EDTA,  intravenous infusion , one time a weeks, 40 weeks) 
would modestly reduce the risk of adverse cardiovascular outcomes but the data did not 










Table 2.7. Case studies and clinical trials of EDTA chelation therapy.  
Reference Sample size Study design Results 
Clarke(1956)[142] 20 patients; 
with coronary heart disease 
5 g  EDTA, intravenous infusion 19 improved, 1 died 
Clarke(1960)[167] 700 patients; 
with coronary heart disease 
NA 87%  improved 
Olszewer(1990) [137] 10 patients(all male, aged 41 
to 53 years); 
pilot double blinded study; 
with peripheral vascular 
disease;  
 
1.5 g EDTA, 20 intravenous infusion 
 
Substantial improvements for 
walking test, master exercise 
test 
Rudolph(1991) [168] 30 patients; 
with atherosclerotic vascular 
disease 




Reduction in stenosis 
Guldager(1993) [14] Total 54 patients(15 women 
and 39 men, aged 41 to 81 
years);  
randomized controlled trial;  
with  intermittent 
claudication 
3 g EDTA, 20 intravenous infusion, 5-
9 weeks 
Accompanied  by bone loss 
Hancke(1993) [169] 470 patients 50 mg/kg EDTA, 30 intravenous 
infusions, 3-4 months 
more than 80% had objective 
evidence for improvement 
Van(1994)[15] 32 patients; 
randomized controlled trial;  
with intermittent claudication 
3 g  EDTA, intravenous infusion No significant beneficial effects 
in patients with intermittent 
claudication; 
Some improvement in resting 
ankle-brachial index 
Knudtson(2002) [16] 84 patients(at least 21 years 
old);  
randomized controlled  trial;  
with CAD 
 
40 mg/kg EDTA, intravenous 
infusion; 
No evidence to support a 
beneficial effect ; Positive 
treadmill test for ischemia 
Maniscalco(2004)[139] 100 patients; 
with stable CAD and positive 
CAC scores 
ComET therapy was composed of (1) 
Nutraceutical Powder (2) Tetracycline 
HCl;(3) EDTA 1.5 g taken in a rectal 
suppository base  
 
CAC scores decreased during 
ComET therapy trial 
Shoskes(2005) [170] 16 male patients; 
with recalcitrant chronic 
prostatitis/chronic pelvic pain 
syndrome(CPPS) 
ComET therapy Significant improvement in the 
symptoms of recalcitrant CPPS 
in the majority of men 
Cacchio(2009) [171] 80 patients; 
with radiographically 
verified calcific tendinitis of 
the shoulder 
1 ml of 15% EDTA, single-needle 
mesotherapy 
 
Calcifications greatly decreased 
Lamas(2013)[17] 1708 patients; 
Randomized controlled trial; 
myocardial infraction 
50 mg/kg EDTA,  intravenous 
infusion , one time a weeks, 40 weeks 
Modestly reduced the risk of 
adverse cardiovascular 
outcomes; Did not highlight 
calcium score data 
 




2.5.2 Side effects with traditional systemic EDTA chelation therapy 
Many side effects have been found with traditional systemic EDTA chelation 
therapy (Table 2.8), which include but are not limited to: renal toxicity [18-23] , 
hypocalcemia [14, 24, 25], bone loss [14, 26] and burning at injection site or along course 
of vein [25]. 
The most important potential adverse event with EDTA chelation therapy is renal 
toxicity [18-23]. Holland et al.  in 1953 [18] reported that two instances of renal tubular 
vacuolization following administration of sodium-EDTA. Schwartz et al.  in 1966 [19] 
showed that vacuolization also occurred and part of the chelate enters the cells via 
pinocytosis post EDTA treatment. Doolan et al. in 1967 [20] also showed tubular 
vacuolization produced in the rat by intraperitoneal injection of EDTA daily for 10 days;. 
Schwartz et al.  in  1970 [21] showed renal tubular cell vacuolization in the outer renal 
cortex after EDTA chelation therapy (1000 mg/kg of disodium Ca-EDTA; Jugular vein 
injection). Oliver et al.  in 1984 [23] reported that patients have renal failure accompanied 
with underlying renal disease after EDTA chelation therapy. However, McDonough et al. 
in 1982 [22] did  a study with 383 patients diagnosed with occlusive arterial disease and 
showed that EDTA infusion (3 g EDTA; 10 intravenous infusion; 5 days between 
infusions) is not nephrotoxic.  
The second possible adverse event is hypocalcemia [14, 24, 25]. Spencer et al.  in 
1956 [24] showed transient hypocalcemia after EDTA chelation therapy. Meltzer et al. in 
1961[25] showed that with 81 patients, 20 occurrences of mild hypocalcemia presented 
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after EDTA chelation therapy (2000 infusions given on alternate days over 2 years). 
Guldager et al. in 1993 [14] conducted a randomized controlled trial with 15 women and 
39 men (aged 41 to 81 years, 20 intravenous infusion, 5-9 weeks)  and showed a decrease 
in serum calcium after EDTA chelation therapy.  
Some other side effects include bone loss [14, 26].  Results for bone loss are non-
consistent. Rudolph et al. in 1988 [26] conducted a case study with 61 patients and 
showed that EDTA chelation therapy (3 g EDTA, 20 intravenous infusion, 5-9 weeks) 
had no effect on bone density and may even enhance bone growth in patients with 
osteoporosis. On the contrary, Guldager et al. in 1993 [14]  did a randomized controlled 
trial with total 54 patients (15 women and 39 men, aged 41 to 81 years) with intermittent 
claudication and showed that EDTA chelation therapy (3 g EDTA, 20 intravenous 









Table 2.8. Side effects of EDTA chelation therapy.  
Side effect Sample size Treatment 
protocol 
Results References 
Renal toxicity  5; human NA Two instances of renal 
tubular vacuolization 
following administration of 




NA NA Vacuolization occurred;  
part of the chelate enters the 
cell via pinocytosis 
Schwartz(1966) 
[19] 
NA; rats NA Tubular vacuolization 
produced in the rat by 
intraperitoneal injection of  
EDTA daily for 10 days; 
Doolan(1967) [20] 
SD rats, n=5 






vacuologenesis is a 
reflection of the induction of 





3 g EDTA, 10 
intravenous 
infusion, 5 days 
between infusions 
 




NA NA Renal failure accompanied 
with underlying renal 
disease 
Oliver(1984)[23] 
Hypocalcemia NA NA Transient Hypocalcemia Spencer(1956)[24] 
81 patients 2000 infusions 
given on alternate 
days over 2 years  




patients;   




Decreased in serum calcium Guldager(1993) 
[14] 




No effect to  bone density; 
Mayt enhance bone growth 












Increased bone resorption; 
Accompanied by bone loss 
Guldager(1993) 
[14] 




2.5.3 Current opinions of EDTA chelation therapy for cardiovascular disease 
Current opinions of EDTA chelation therapy for cardiovascular disease are still 
quite disputed (Table 2.9). There are many positive opinions from proponents [17, 141, 
168, 172] but there are many negative opinions from opponents [173-176]. Proponents 
stated that “EDTA chelation can significantly decrease atheromatous plaque” [168],  
“modestly reduced the risk of adverse cardiovascular outcomes” [17]. On the contrary, 
opponents stated that “It was not useful for CAD or PVD”  [173], “Chelation therapy is 
not recommended for the treatment of chronic angina or atherosclerotic cardiovascular 
disease and may be harmful because of its potential to cause hypocalcaemia” [174]. Most 
proponents highlight therapeutics effects of EDTA chelation therapy in aspects of 
cardiovascular outcomes but whether or not it reverses calcification is not clear. 
EDTA treatment to treat hypercalcemia is FDA approved but EDTA drugs for 
purpose of chelation is not approved by FDA.  FDA has not received statistically 
significant clinical data sufficient to support either the safety or efficacy of EDTA drugs 








Table 2.9. Current opinions of EDTA chelation therapy for cardiovascular disease.  
References Organization Statements 
Negative opinions from opponents 
Soffer(1964) 
[173] 
Editor-in-Chief of both 
Chest and Archives of 
Internal Medicine 
“It was not useful for CAD or PVD.” 
Fraker(2007) 
[174] 
Cardiologist and professor 
of clinical medicine at The 
Ohio State University 
Medical Center 
“Chelation therapy (intravenous infusions of 
ethylenediamine tetra-acetic acid or EDTA) is not 
recommended for the treatment of chronic angina or 
atherosclerotic cardiovascular disease and may be 




Editor of International 
Journal of Clinical Practice 
“Chelation therapy is TACT-less, one wonders why it 
is still widely used, given the lack of evidence of 
benefit and potential to do harm (financial gain seems 
the most likely reason).” 
Atwood(2008) 
[176] 
Assistant Clinical Professor 
at the Tufts University 
School of Medicine 
“We conclude that the TACT is unethical, dangerous, 
pointless, and wasteful. It should be abandoned.” 
“Chelation for atherosclerosis was condemned by the 
Medical Letter, the American Heart Association 
(AHA), and the American College of Physicians, the 
American ....” 
Positive opinions from proponents 
Rudolph(1991) 
[168] 
Associate Professor and 
Chairman in Biochemistry 
Department of Texas 
College of Osteopathic 
Medicine  
“EDTA chelation can significantly decrease 




President, American College 
for Advancement in 
Medicine, 1991-1992. 
Editor-in-Chief, Journal for 
Advancement in Medicine, 
1986 to 1989. 
 
"This therapy has been proven effective over and over 
again in clinical practice."  
 
"More than one million patients have received more 
than twenty million infusions with no serious or lasting 
adverse effects." 
Lamas(2006,. 
2013) [17, 141] 
Chief, Division of 
Cardiology at Mount Sinai 
Medical Center, Columbia 
University;  
 
“EDTA chelation therapy meets evidence-based 
medicine.” 
 
“Among stable patients with a history of Myocardial 
infarction (MI), use of an intravenous chelation 
regimen with disodium EDTA, compared with placebo, 
modestly reduced the risk of adverse cardiovascular 
outcomes.” 
 
CAD: coronary artery disease; MI: myocardial infarction; PVD: peripheral vascular disease; TACT: Trial 




2.6 Targeted EDTA chelation therapy 
2.6.1 Local drug delivery in the vasculature 
MAC occurs heterogeneously along vascular tree. Thus local drug delivery would 
a good option for treating MAC. Ideally local drug delivery would: 1) maximize drug’s 
therapeutic effects and also 2) minimize undesired systemic side effects.  
Three possible approaches to delivers drug locally to vasculature can be classified 
as: 1) intra-luminal delivery; 2) peri-adventitial delivery; and 3) Novel sustained release 
vehicles as showed in Figure 2.9, Figure 2.10, and Figure 2.11.  
Some current available intra-luminal delivery devices include: double balloon 
catheter (Figure 2.9A) and periadventitial delivery using needle injection catheter 
(Figure 2.9B). Jo̸rgensen et al. in 1989 did a study with 6 consecutive patients 
undergoing percutaneous transluminal angioplasty (PTA) for superficial femoral artery 
occlusion, with a 7-French double-balloon catheter. Recombined human tissue-type 
plasminogen activator (rt-PA) and heparin were then infused into the enclosed space for 
30 minutes, followed by intravenous heparin for 24 hours. Results showed that at 10 and 
30 days all 6 patients had evidence of recanalisation and remission of symptoms [177]. 
Needle injection catheter used fine needles that penetrate the media to deliver drugs. 
Although it is invasive, a study done by Ikeno et al. in 2004 with 17 swine by delivering 
Oregon green-labeled paclitaxel (OGP) and tacrolimus with this method showed limited 




Figure 2.9. Intra-luminal delivery devices. A: Double balloon catheter [144]; B: 
Periadventitial delivery using needle injection catheter [178].  
 
Several animal studies showed successful peri-adventitial delivery of therapeutics 
in local vasculature. Peri-adventital delivery methods include: Drug eluting polymer wrap 
(Figure 2.10A), and polyvinyl alcohol (PVA) foam sutured to the artery (Figure 2.10B). 
Villa et al. in 1994 did a rat study using a silicone polymers wrapped around the common 
carotid arteries for 3 weeks, and results showed that periadventitial local delivery of 
dexamethasone markedly inhibits neointimal proliferation after balloon vascular injury 
[179]. Researches also have used PVA foams loaded with drugs for peri-adventitial 
delivery.  Sho et al. in 2004 used a mini-osmotic pump loaded with doxycycline into 
PVA foam in order to provide a continuous infusion via periaortic delivery system 
(PDS) and showed that PDS (1.5 mg/kg/day) and subcutaneous (60 mg/kg/day) delivery 
methods caused comparable reductions in abdominal aortic aneurysm (AAA) diameter 
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during the period of 14 days. PDS rats gained more weight during the postoperative 
period, possibly as a result of reduced serum drug levels and systemic toxicity [56].  
 
Figure 2.10. Peri-adventital delivery methods.  A: Drug eluting polymer wrap [179]; B: 
PVA foam sutured to the artery [56].  
 
Above mentioned delivery methods, intra-luminal and peri-adventitial delivery of 
drugs to the site of pathology are all one time single application. However, sustained 
release of drugs might be an attractive option to optimize drug’s therapeutic effects. 
Some examples are discussed below. 
Ogata et al. in 2010 developed a doxycycline loaded controlled release 
biodegradable fiber (DCRBF) for local administration in AAA tissue (Figure 2.11A, B 
and C).These doxycycline incorporated poly-lactic acid fibers showed a controlled in-
vitro drug release of 28 days and in-vivo release of  up to 84 days  [180].  
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Franck et al. in 1998 successfully created hydrocortisone loaded microspheres and 
delivered them via perforated balloon catheters into rabbit arteries after balloon 
angioplasty [181]. Westedt et al. also formulated nanoparticles that were infused coupled 
with porous balloon catheter (Figure 2.11D) [182].   
 
Figure 2.11. Novel sustained release vehicles. A: gross appearance of DCBRF; B and 
C:TEM images of DCBRF[180]. D: TEM showing the nanoparticles eluting out of the 
porous balloon [182].  
 
 
All above mentioned local delivery methods require surgical manipulation which 
would be quite invasive for patients. Also for several vascular calcification diseases, the 
diseased aorta is spread heterogeneously along vascular tree. Thus an ideal delivery 
method should be able to be applied systemically and targeted to various sites of 
calcification. One possible way is using targeted albumin nanoparticles as discussed 
below.    
50 
 
2.6.2 Albumin nanoparticles as drug carriers for different application 
Albumin, a versatile protein carrier for drug delivery, is nontoxic, non-
immunogenic, biocompatible and biodegradable [183]. Therefore, it is ideal material to 
fabricate nanoparticles for drug delivery.  
Types of albumin used as drug carrier in nanoparticles include: Ovalbumin, 
Bovine serum albumin (BSA) and Human serum albumin (HSA). Bovine serum albumin, 
with a molecular weight of 69 KDa and an isoelectric point of 4.7 in water (at 25 °C), is 
widely used for drug delivery because of its medical importance, abundance, low cost, 
ease of purification, unusual ligand-binding properties, and its wide acceptance in the 
pharmaceutical industry [184].  BSA could be replaced by HSA in order to circumvent a 
possible immunologic response in vivo. HSA has preferential uptake in tumor and 
inflamed tissue and its ready availability, biodegradability and lack of toxicity make it an 
ideal candidate for drug delivery [185].  
Methods to prepare albumin nanoparticles include: desolvation [186], 
emulsification [187], thermal gelation [188] and recently nano spray drying [189], nab-
technology [190] and self-assembly [191]. In desolvation process, nanoparticles are 
obtained by a continuous dropwise addition of ethanol to an aqueous solution of albumin 
(pH 5.5) under continuous stirring until the solution becomes turbid. During the addition 
of ethanol into the solution, albumin is phase separated due to its diminished water-
solubility. Coacervates are hardened by crosslinking with glutaraldehyde where the 
amino moieties in lysine residues and arginine moieties in guanidine side chains of 
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albumin are solidified by a condensation reaction with the aldehyde-group of 
glutaraldehyde [192].  
Many in vivo studies have shown BSA to be a suitable carrier to target gamma-
interferon (IFN-γ) to macrophages and thus potentiating their therapeutic activity [193]. 
In a platelet aggregometric study, Das et al. clearly showed that the amount of aspirin 
diffused from aspirin-loaded BSA nanoparticles at the end of 48 h was sufficient to 
prevent platelet aggregation [194].  
Many surface-modified albumin nanoparticles using antibody have been 
investigated for better targeting. It has been shown that many malignancies like colorectal, 
head, neck, non-small cell lung ovarian, breast and prostate cancers, as well as glioma, 
show an overexpression of the epidermal growth factor receptor (EGFR) on their surfaces. 
Thus, cetuximab, a humanized IgG1 monoclonal antibody (mAb)  targets EGFR and was 
approved for the treatment of colorectal cancer by FDA in 2004 [195]. Therefore, 
cetuximab-modified HSA nanoparticles are a promising carrier system for drug transport. 
A specific accumulation targeting the EGFR could be shown in EGFR-expressing colon 
carcinoma cells  [195]. Besides, DI17E6, a monoclonal antibody directed against αv-
integrins, was covalently coupled to HSA nanoparticles loaded with doxorubicin [196]. 
The thiolated antibody was coupled with sulfhydryl-reactive nanoparticle suspension to 
achieve a covalent linkage between antibody and the nanoparticle system. The target-
specific nanoparticles specifically targeted αvβ3 integrin positive melanoma cells 
showing increased cytotoxic activity compared to the free drug [196]. Since many 
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antibody coated albumin nanoparticles have been approve by FDA and are in clinical use, 
our strategy to use anti-elastin antibody coated albumin nanoparticles would be also have 
great clinical relevance.  
2.6.3 Targeted EDTA chelation therapy using EDTA loaded albumin 
nanoparticles 
Previous attempts at systemic chelation therapy with EDTA to reverse 
calcification required high dosage and had many side effects such as hypocalcemia, renal 
toxicity and bone loss [14, 18, 119]. We propose that targeted EDTA chelation therapy 
might be a promising way to address issues accompanied with systemic chelation therapy.  
Nanoparticle-based targeted drug delivery could lower dosage of EDTA required 
and have many other advantages such as improved bioavailability and sustained release 
of drugs [29]. We propose that nanoparticle protein engineering therapy using targeted 
EDTA loaded albumin NPs with elastin antibody offers potential solutions to reverse 
vascular calcification and also circumvent possible side effects from systemic chelation 
therapy by reducing the high dosage that systemic infusion requires.  More specific data 





CHAPTER 3: PROJECT RATIONALE  
3.1 Project objective and aims 
Based on the literature reviewed earlier, the main objectives of this project are:  
a) Understand mechanisms of elastin specific medial arterial calcification 
(MAC), specifically cause-and-effect relationship between the elastin-
specific MAC and osteoblast-like differentiation of vascular smooth 
muscle cells (VSMCs). 
b) Evaluate the efficacy of several chelating agents to reverse elastin specific 
MAC. 
c) Evaluate the therapeutic effects of systemic EDTA chelation therapy in the 
aspect of reversal of calcification and possible side effects. 
d) Develop a targeted delivery system based on EDTA loaded nanoparticles 
to reverse elastin specific MAC at low doses and to circumvent systemic 
side effects. 
3.2 Specific aims and rationale 
Specific Aim 1: 
Determine cause-and-effect relationship between the elastin-specific MAC and 
osteoblast-like differentiation of vascular smooth muscle cells (VSMCs). 
Rationale: Osteoblast-like differentiation of vascular smooth muscle cells 
(VSMCs) has been found in vascular calcification sites in animal studies as well as in 
54 
 
clinical retrospective studies; however, whether this osteogenesis plays a major role in 
the initiation of vascular calcification is unclear. We hypothesize that the initial 
deposition of hydroxyapatite-like mineral in MAC occurs on degraded elastin first and 
that causes osteogenic transformation of VSMCs. Thus, we wanted to test if rat aortic 
smooth muscle cells (RASMCs) cultured on hydroxyapatite crystals and calcified aortic 
elastin would transform to osteoblast like cells. Another interesting question is upon 
removal of calcified conditions, whether or not differentiated cells would have the ability 
to revert back to SMC-like cell behavior. This is important as we can then envision 
demineralizing strategies to remove mineral from arteries and bring homeostasis to the 
arterial structures. 
Specific Aim 2: 
Evaluate the efficacy of chelating agents to reverse elastin specific MAC. 
Rationale: Chelation therapy has been touted as an effective treatment to reverse 
vascular calcification; however, it has been controversial with opposing views [8-10]. 
Most of the previous work is focused on atherosclerotic intimal calcification and 
unfortunately, the efficacy of various chelating agents in reversing elastin specific 
calcification from the peripheral vascular tissue is not studied very well either in vitro or 
in animal experiments. We want to assess the chelating ability of EDTA, DTPA, and STS 
on removal of calcium from hydroxyapatite (HA) powder, calcified aortic elastin, and 
calcified human aorta in vitro. We further want to assess whether or not that local 
periadventitial delivery of EDTA loaded nanoparticles could reverse elastin specific 
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calcification in the aorta. This research will allow us to select the best chelating agent for 
reversal of MAC in vivo. 
Specific Aim 3: 
Evaluate therapeutic effects of systemic EDTA chelation therapy for reversal of 
elastin specific MAC and its possible systemic side effects. 
Rationale: At present whether or not EDTA chelation therapy reverses vascular 
calcification is still quite disputed [9]. Currently, most of the EDTA chelation therapies 
studied were using EDTA by subcutaneous infusion, or systemic application of EDTA 
solution at very high dose (around 40 ~ 50 mg/kg) [11-17]. Many side effects have been 
found with such a high systemic dose of EDTA chelation therapy including: renal 
toxicity [18-23] , hypocalcemia [14, 24, 25], and bone loss [14, 26]. But results are quite 
varied for side effects. We want to investigate whether or not systemic EDTA chelation 
therapy could reverse local aortic calcification in an animal model of MAC and test 
possible side effects to serum Ca, urine Ca, and bone loss. This would provide an 
important pre-clinical animal study investigating EDTA’s therapeutic as well as potential 
side effects in the aspect of reversal of MAC.  
Specific Aim 4: 
Develop a targeted delivery system for EDTA to reverse elastin specific MAC 
and to avoid side effects associated with systemic therapy.  
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Rationale: Systemic chelation therapy using EDTA or sodium thiosulfate to 
reverse calcification requires high dosage and has side effects such as hypocalcemia, 
bone loss, and renal toxicity [14, 18, 119]. If we can target EDTA to the local vascular 
calcification sites, we could lower the dosage of EDTA and can also improve efficacy 
and reduce side effects [29]. We have recently shown that the elastin antibody coated 
nanoparticles (NPs) can be targeted to vascular calcification sites [30]. Thus, in this study 
we want to test if albumin NPs may be a good drug carrier to load EDTA. By surface 
coating of anti-elastin antibody, these elastin antibodies coated and EDTA loaded 
albumin NPs could be a promising nanoparticle protein engineering therapy to reverse 
elastin-specific medial calcification and reduce side effects associated with systemic 
EDTA chelation therapy. 
3.3 Clinical significance  
Cardiovascular diseases (CVD) are the leading cause of death worldwide. 
Pathological vascular calcification has been observed in many CVD and is recognized as 
a major risk factor for mortality and morbidity in patients with diabetes and chronic 
kidney disease. The mechanisms of medial arterial calcification (MAC) are not 
understood well and currently there is no available alternative to surgical repair for 
reversal of vascular calcification [6, 7]. One possible approach is EDTA chelation 
therapy that has been tested in animals and in clinical trials. However, clinical trials did 
not prove statistically significant improvement in cardiovascular function and thus such 
therapies are not approved by FDA. Moreover, such chelation therapies have shown 
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many side effects such: renal toxicity [18-23] , hypocalcemia [14, 24, 25], and bone loss 
[14, 26]. 
In this research we wanted to shed light on the mechanisms of elastin specific 
MAC, specifically cause-and-effect relationship between the elastin-specific MAC and 
osteoblast-like differentiation of vascular smooth muscle cells (VSMCs). This research 
would pave the way for mechanistic based therapies for vascular calcification.  
Secondly, although EDTA chelation therapy has been tried for atherosclerotic 
calcification, no research has looked at its effectiveness in reversing elastin-specific 
MAC. If successful, such therapies would help millions of patients with end stage renal 
disease and diabetes where MAC is prevalent. The literature also suggests that chelation 
therapies are not approved by FDA for vascular calcification due to its systemic side 
effects. No research is performed so far to see if EDTA chelation can be targeted to 
vascular calcification sites by some sort of drug delivery approaches. Our research 
presented in this thesis could pave the way to target chelation therapies vascular 





CHAPTER 4: MECHANISMS OF ELASTIN SPECIFIC MEDIAL ARTERIAL 
CALCIFICATION  
(This work has been published in  
Experimental Cell Research 2014; 323:198-208) 
4.1 Introduction  
There are two distinctive types of vascular calcification: intimal atherosclerotic 
plaque calcification and medial elastin-specific arterial calcification (MAC). Intimal 
calcification occurs in the context of atherosclerosis, associated with lipids, macrophages, 
and vascular smooth muscle cells; whereas, medial calcification can exist independently 
of atherosclerosis and is associated with elastin and vascular smooth muscle cells[3]. In 
this study we mainly focused on the mechanisms of MAC. It has been accepted for 
decades that the pathology of vascular calcification resembles physiological bone 
mineralization in that it shows the presence of bone proteins and osteo-chondrogenic cells 
[197, 198]. However, mere presence of osteogenic cells and bone protein expression in 
the calcified arterial tissue does not warrant the role of osteogenesis in the initiation of 
elastin calcification. The scientific knowledge gap still exists about the cause-and-effect 
relationship between the elastin-specific medial calcification and osteoblast-like 
differentiation of vascular smooth muscle cells (VSMCs). It is still unclear if there exists 
a chronological occurrence between the osteoblast-like differentiation of VSMCs and 
passive deposition of hydroxyapatite on elastin, or if both processes occur simultaneously 
causing the eventual calcification of arteries.     
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Based on our previous in vivo data [199, 200], we hypothesize that the initial 
mineral deposition on elastin precedes the osteoblast-like differentiation of VSMCs, 
which is a pathological response to elastin degradation and early arterial calcification. To 
test this hypothesis, we exposed rat aortic smooth muscle cells (RASMCs) to calcified 
conditions, by culturing them on hydroxyapatite and calcified elastin. We show when 
exposed to a calcific environment, healthy RASMCs transform to osteoblast-like cells; 
removal of calcific environment restores the native phenotype of SMCs.  
4.2 Materials and methods 
Cell culture and treatment  
Primary rat aortic smooth muscle cells (RASMCs) were isolated from rat aorta 
according to published protocol[201]. Passage numbers 5 to 8 were used for all 
experiments. Cells were cultured in 60 mm tissue culture petri dish (2×10
6
 cells/well) in 
Dulbecco's Modified Eagle Medium (Cellgro-Mediatech, Manassas, VA), containing 
10% fetal bovine serum (Cellgro-Mediatech, Manassas, VA), 100 units/ml penicillin and 
100 units/ml streptomycin (Cellgro-Mediatech, Manassas, VA) in a humidifier incubator 
(Innova® CO-170) at 37 ℃, with 5% CO2. Media was replenished every 3 days. 
Hydroxyapatite powder (average size <200 um) was purchased from Aldrich Chemical 
Company (Milwaukee, WI). One mg of hydroxyapatite was coated onto 60 mm tissue 
culture Petri dish. Here the coating process was achieved by first placing a 
hydroxyapatite suspension in sterile phosphate-buffered saline (PBS) on a Petri dish and 
then drying it overnight under sterile cell culture hood. For control group, the RASMCs 
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were cultured in a Petri dish without hydroxyapatite coating. To better mimic the 
calcified pathological situation, RASMCs were also cultured in a Petri dish with a coating 
of calcified porcine aortic elastin fibers (10 mg per well) while a coating with non-
calcified elastin served as a control. The calcified porcine aortic elastin fibers were 
prepared in vitro based on a modified protocol[202] and the average size for both the 
pure and calcified elastin fiber were less than 200 µm (passed through 200 µm sieve). 
Briefly purified elastin was suspended in a calcifying solution (Tris-HCl buffer PH7.4; 
KCl 55 mmol/l; KH2PO4 35 mmol/l; CaCl2 35 mmol/l) for 7 days with shaking at 37℃. 
Poorly crystalline hydroxyapatite was deposited on elastic fibers. The calcium deposition 
was characterized by alizarin red stain and scanning electron microscope (SEM, Hitachi's 
SU6600) with energy dispersive X-ray spectrometer (EDX) and quantified by atomic 
absorption spectroscopy (Perkin-Elmer Model 3030, Norwalk, CT). Cells were grown on 
top of calcified matrix for 1 day and 7 days. To study the RASMCs’ fate after removing 
calcified conditions, the cells were first cultured for 7 days on calcified matrix 
(specifically both hydroxyapatite and calcified elastin) followed by isolation and 
placement on a 60 mm tissue culture Petri dish without calcified matrix for an additional 
7 days, or 14 days total as referred to below (n=12 per group total, 3 for RNA isolation, 3 
for protein isolation, 3 for cell immunofluorescence and another 3 for staining for 




At each time point, cell monolayers were scraped and homogenized (n=3 per 
group) using a homogenizer (PowerGen Model 125 Homogenizer, Fisher Scientific, 
Atlanta, GA). The total RNA from the cells was isolated using the RNeasy Mini Kit 
(Qiagen, MD). The concentration of the extracted RNA was quantified by UV 
spectroscopy using Take3 Micro-Volume Plates from BioTek (Winooski, VT). One 
microgram of RNA was reverse transcribed to cDNA by High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA) using a Mastercycler gradient 
(Eppendorf Scientific, Inc., Westbury, NY). The cDNA samples were further amplified 
on a Rotor gene 3000 thermal cycler (Corbett Research, Mortlake, NSW, Australia) for 
real - time polymerase chain reaction (PCR). The primers sequences for β-2microglobulin 
(β2-MG)[200], alpha smooth muscle actin (SMA)[203], myosin heavy chain 
(MHC)[204], aggrecan[205], collagen type II alpha 1(Col2a1)[206], alkaline phosphatase 
(ALP)[200], Runt-related transcription factor 2 (RUNX-2)[200] and osteocalcin[200] are 
listed in Table 4.1. Gene expression in each sample was normalized to the expression of 
β2-MG as housekeeping gene and compared with control samples (for the hydroxyapatite 
study group, the control was the cells grown on standard culture plates while for the 
calcified elastin group, the control was the cells grown on non-calcified elastin coated 
culture plates) using the 2
-ΔΔC
T method[207] as follows: 
ΔΔC
T= (CT target gene-CT β-2 





Table 4.1. PCR primers used in the RT-PCR study. 
Name References  Forward primer Reverse primer 
β2 MG Lee et al[200]. CGTGATCTTTCTGGTGCTTGTC ACGTAGCAGTTGAGGAAGTTGG 
SMA Simionescu et al[203] ACTGGGACGACATGGAAAAG CATACATGGCAGGGACATTG 
MHC Low et al[204]. AAGCAGCTCAAGAGGCAG AAGGAACAAATGAAGCCTCGTT 
Aggrecan Agung et al[205].  TAGAGAAGAAGAGGGGTTAGG AGCAGTAGGAGCCAGGGTTAT 
 
Clo2a1 Zhang et al[206].  TCCTAAGGGTGCCAATGGTGA AGGACCAACTTTGCCTTGAGGAC 
 
OCN Lee et al[200]. TATGGCACCACCGTTTAGGG CTGTGCCGTCCATACTTTCG 
 
ALP Lee et al[200]. TCCCAAAGGCTTCTTCTTGC ATGGCCTCATCCATCTCCAC 
RUNX2 Lee et al[200]. CAACCACAGAACCACAAGTGC CACTGACTCGGTTGGTCTCG 
 
Immunofluorescence 
The cells were fixed in 4% paraformaldehyde (Affymetrix, Cleveland, OH) for 15 
minutes at room temperature, treated with 1% bovine serum albumin (Sigma, St. Louis, 
MO)/0.2% Triton X-100 (MP Biomedicals, Solon, OH)/PBS for 1 hour at room 
temperature to block non-specific binding. The primary antibodies used include: mouse 
monoclonal Anti- SMA at 1:200 dilutions (Sigma, St. Louis, MO), mouse monoclonal 
[1C10] to smooth muscle Myosin heavy chain I at 1:200 dilution (Abcam, Cambridge, 
MA) and mouse anti-collagen type I at 5 µg/ml (Developmental Studies Hybridoma 
Bank, Iowa City, IA). After overnight incubation at 4 °C, cells were stained for 2 hours at 
room temperature in the dark with AlexaFlour 594 donkey anti-mouse IgG secondary 
antibody (Molecular Probes, Eugene, OR) diluted to 10 µg/ml. All well plates were 
mounted in VECTASHIELD HardSet Mounting Medium (VECTOR LABORATORIES, 
INC, Burlingame, CA) with DAPI (4', 6-diamidino-2-phenylindole dihydrochloride) blue 





Cell monolayers were washed once with PBS and isolated in a mammalian 
extraction buffer. To prepare the buffer, 1 tablet of protease inhibitor cocktail (Roche 
Diagnostics, Indianapolis, IN) was added to 10ml of SoluLyse-M™ Mammalian Protein 
Extraction Reagent (Genlantis, San diego, CA). SoluLyse-M™ reagent (500 µl) was 
added into the 60 mm tissue culture petri dishes. Cells were incubated for 10 minutes at 
25 ℃ with gentle rotation and then homogenized and centrifuged at 14,000 X g for 5 
minutes. The supernatant was collected (preserved in -20℃ freezer) and assayed for 
different proteins of interest. The total cellular protein was quantified by Pierce® BCA 
protein assay kit (Thermo scientific, Rockford, IL).  
Western blotting 
Ten micrograms of protein from each sample and molecular weight standards 
(Precision Plus Protein™ Kaleidoscope Standards, Bio Rad Life Science, Hercules, CA), 
were loaded in duplicate on 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis gels. After electrophoresis, the proteins were electro-transferred to 
Immobilon-P membranes (Millipore Corporation, Bedford, MA). Membranes were 
blocked in 2% nonfat dry milk (LabScientific, Inc., New Jersey) for 1 hour at room 
temperature and then probed with primary antibody overnight at 4°C. Primary antibodies 
used include: mouse monoclonal Anti- SMA at 1:1000 dilution (Sigma, St. Louis, MO), 
mouse monoclonal [1C10] to smooth muscle Myosin heavy chain I at 1:1000 dilution 
(Abcam, Cambridge, MA) and rabbit monoclonal [EP2978Y] to beta 2 Microglobulin 
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(Abcam, Cambridge, MA). The proteins were detected by enhanced chemiluminescence 
according to the manufacturer’s recommendations (Roche, Indianapolis, IN) and 
analyzed by densitometry using Image J software. The optical densities of the bands were 
reported as relative density units (RDU) comparing to the control groups. Beta 2 
Microglobulin antibodies were used as the loading control and the target protein’s band 
densities were first normalized by beta 2 Microglobulin.  
ALP assay – colorimetric quantification and cell stain 
Cell lysates were analyzed for alkaline phosphatase (ALP) using p-nitrophenyl 
phosphate (PNPP) as a substrate and diethanolamine buffer. Two PNPP tablets (Thermo 
scientific, Rockford, IL) were dissolved in 10 ml diethanolamine substrate buffer (Pierce, 
Rockford, IL). PNPP solution (200 µl) and protein samples (40 µl) were added into each 
well of the 96-well plate. The plate was incubated at room temperature for 30 minutes or 
until sufficient color developed. The reaction was stopped by adding 50 µl of 2N NaOH 
to each well. The absorbance was measured at 405 nm. Alkaline phosphatase was 
calculated using a p-nitrophenol (MP Biomedicals Inc, Solon, Ohio) standard curve and 
was normalized to the total protein content. Additionally, cells in culture were stained to 
corroborate the expression of ALP by the cells. Cells were stained with premixed 
BCIP/NBT solution (Sigma Aldrich, St. Louis, MO). The premixed BCIP/NBT solution 
contains 0.48 mM NBT (nitro blue tetrazolium), 0.56 mM BCIP (5-bromo-4-chloro-3-
indolyl phosphate), 10 mM Tris HCl, 59.3 mM MgCl2, and pH ~9.2.  Cells were 
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incubated in the staining solution in the dark for 1 hour at room temperature and then 
washed.  
Osteocalcin Assay- Enzyme-linked immunosorbent assay (ELISA) 
The total cellular protein samples were analyzed for osteocalcin using a Rat 
Osteocalcin ELISA Kit (Biomedical Technologies Inc., Stoughton, MA) following the 
manufacturer’s instructions. 25 µl of total protein sample, rat osteocalcin serial 
standards(1.0, 2.5, 5.0, 10 and 20 ng/ml) and rat serum controls were pipetted into 
osteocalcin antibody coated well plate strips followed by 100 µl of osteocalcin 
antiserum(second antibody, goat polyclonal) at 37 °C for 2.5 hours. Donkey anti-goat 
IgG peroxidase conjugate was used as secondary antibody and 3, 3′, 5, 5′-
Tetramethylbenzidine (TMB) was used as the peroxidase substrate. Levels of osteocalcin 
were calculated by rat osteocalcin standard curve and then normalized to total protein 
concentration.  
Statistical Analysis 
Results are expressed as means ± standard error of the mean (SEM). Statistical 
analyses of the data were performed using single-factor analysis of variance. Differences 
between means were determined using the least significant difference with an α value of 
0.05. Asterisks in figures denote statistical significance (P < 0.05) for each group 
compared with controls. 
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4.3 Results  
Characterization of calcified elastin 
Calcified elastin was prepared in vitro and the calcium level in the calcified 
elastin fiber was detected as 15 ± 2 µg/mg using atomic absorption spectroscopy. The 
calcium deposition was evenly distributed over the porcine elastin fiber as seen by 
alizarin red stain, which stains calcium red while no staining was seen in the control pure 
elastin (Figure 4.1A). The morphology of calcified elastin, as studied by scanning 
electron microscopy, showed globular calcific deposits. These were confirmed as calcium 




Figure 4.1. Characterization for calcified elastin. A: Alizarin red staining for pure elastin 
(PE, left) and calcified elastin (CE, right). Calcium was stained red. Scale bar: 50µm. B: 
Scanning electron microscope (SEM) image for pure elastin (PE, left) and calcified 
elastin (CE, right). C: Energy-dispersive X-ray spectroscopy (EDX) pseudo colored 
image for Ca and P element distribution (Ca purple and P red). Mineral deposition is 





RASMCs lose smooth muscle lineage markers under calcified conditions 
We analyzed gene and protein level expression of two typical smooth muscle 
lineage markers:  alpha smooth muscle actin (SMA)[208] and myosin heavy chain 
(MHC)[209] in two different simulated calcified conditions: (1) pure hydroxyapatite; (2) 
calcified elastin. These markers were studied at two time points (day 1 and day 7) to see 
the changes compared to the control groups. Cellular localization based on 
immunofluorescence stain of SMA showed that both hydroxyapatite and calcified elastin 
groups had similar SMA expression at day 1 as controls; however, at day 7 they exhibited 
very low expression of SMA protein (Figure 4.2A). Similarly, immunofluorescence stain 
for MHC also showed little change at day 1 but a significant decrease was observed at 






Figure 4.2. Expression of SMA and MHC in RASMCs cultured on hydroxyapatite and 
calcified elastin at day 1 and day 7. A and B: Immunofluorescence stains of SMA and 
MHC respectively (red fluorescence). Nuclei were stained blue by DAPI. Scale bar: 
100µm. Abbreviations: HA-hydroxyapatite; PE: pure elastin; CE: calcified elastin. D1: 
day 1; D7: day 7.  C and D: SMA and MHC gene expression respectively as measured by 
RT-PCR. E: protein expression measured by western blot followed by densitometry as 
relative density units (RDU) and expressed as relative percentage ratio comparing to 
control groups (For HA treatment group the control was normal media while for CE 
treatment group the control was PE). The band density was first normalized by loading 
control protein- β2 MG. Results are presented as mean ± SEM (* p<0.05). 
 
Furthermore, both hydroxyapatite and calcified elastin treated groups showed 
decrease in the gene expression (quantified by RT-PCR) and protein expression (detected 
by western blot) of SMA and MHC at day 7. Compared to respective control groups, 
SMA gene expression decreased by 48 ± 18% in hydroxyapatite groups and 53 ± 5% in 
calcified elastin groups (Figure 4.2C). Similarly, MHC gene expression decreased by 64 
± 19% in hydroxyapatite groups and 60 ± 13% in calcified elastin groups (Figure 4.2D). 
Western blotting results confirmed the down-regulation of translation of both SMC 
markers. Compared to respective control groups, the SMA protein expression decreased 
by 56 ± 2 % in hydroxyapatite groups and 48 ± 2% in calcified elastin groups (Figure 
4.2E). The MHC protein expression decreased by 52 ± 6% in hydroxyapatite groups and 
53 ± 2% in calcified elastin groups (Figure 4.2E). 
RASMCs develop an osteogenic/chondrogenic phenotype under calcified conditions 
We then analyzed expression of three typical osteogenic markers: Runt-related 
transcription factor 2 (RUNX2) [210, 211], Alkaline phosphatase (ALP) and osteocalcin 
(OCN)[208, 209, 212, 213]  and two typical chondrogenic markers: aggrecan and 
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collagen type II alpha 1(Col2a1) to see whether RASMCs develop an 
osteogenic/chondrogenic phenotype with the stimuli of hydroxyapatite and calcified 
elastin. At day 1, we found significant upregulation of RUNX2 gene under mineralized 
conditions, which is the earliest transcription factor involved in osteogenesis. No other 
osteogenic markers were changed at day 1 as compared to controls (Figure 4.3A). 
Compared to respective control groups, RUNX2 gene expression increased by 87 ± 43% 
in hydroxyapatite groups and 116 ± 19% calcified elastin groups at day 7. Similarly, at 
day 7, ALP gene expression increased by 41 ± 20% in hydroxyapatite groups and 188 ± 
21% in calcified elastin groups while OCN gene expression increased by 111 ± 30% in 






Figure 4.3. Expression of osteogenic/chondrogenic markers in RASMCs cultured on 
hydroxyapatite and calcified elastin elastin at day 1 and day 7. A: gene expression of 
RUNX2, ALP and OCN. B: Histochemical staining of ALP activity in cells in four 
groups (C-control, HA-hydroxyapatite, PE-pure elastin, CE-calcified elastin). Scale bar: 
50µm. C: ALP protein quantification. D: OCN protein quantification. OCN was 
determined by ELISA assay and expressed as ng osteocalcin /mg protein. The relative 
protein expression for both ALP and OCN has been calculated compared to respective 
control groups.  E: Gene expression of chondrogenic markers – aggrecan. F: Gene 
expression of chondrogenic markers – Col2a1. G: Immunofluorescence stains for 
collagen type I (red fluorescence). Nuclei were stained blue by DAPI. Scale bar: 100µm. 
Results are presented as mean ± SEM (* p<0.05). 
 
Histochemical staining for ALP revealed intense purple coloration in both 
hydroxyapatite and calcified elastin groups indicating greater ALP activity compared to 
control groups (Figure 4.3B). Additionally, quantification of cellular ALP activity 
showed an increase by 207 ± 35 % in hydroxyapatite groups and 72 ± 9 % in calcified 
elastin groups at day 7 (Figure 4.3C). Osteocalcin protein expression increased by 97 ± 
13 % in hydroxyapatite groups and 23 ± 12 % in calcified elastin groups respectively at 
day 7 (Figure 4.3D). The ALP and OCN protein expression in calcified elastin groups 
was much less elevated might because of relative lower concentration of hydroxyapatite 
in elastin group, specifically one mg of of HA in hydroxyapatite versus only ~150 µg in 
elastin group (10 mg of calcified elastin with mineral deposition of 15 ± 2 µg Ca /mg 
tissue) (Figure 4.3C, 4.3D).  It is also possible that HA crystal structure in two groups is 
different and that can cause variation in relative expression.  
For the chondrogenic markers, at day 7, compared to respective control groups, 
Aggrecan gene expression increased by 125 ± 76% in hydroxyapatite groups and 179 ± 
84% in calcified elastin groups (Figure 4.3E); Col2a1 gene expression increased by 613 
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± 108% in hydroxyapatite groups and 370 ± 141% in calcified elastin groups (Figure 
4.3F).  
RASMCs show up-regulation of Collagen Type I  under calcified conditions 
Immunofluorescent detection of collagen type I showed an intense signal both for 
hydroxyapatite and calcified elastin treated group at day 7 (Figure 4.3 G). The increase 
of collagen type I expression under calcified conditions, indicated more synthetic 
phenotype of RASMCs under mineralized conditions.  
RASMCs restore their original phenotype after removal of calcified matrix 
In an independent set of experiments, RASMCs were cultured on calcified matrix 
for 7 days and then were cultured for another 7 days without the calcified matrix to study 
cellular behavior after removing calcified matrix. After 14 days (7 days post reversal) 
both hydroxyapatite and calcified elastin treated group showed dramatic restoration of 
VSMCs markers (comparable to control groups: for the hydroxyapatite study group, the 
control was the cells grown on standard culture plates while for the calcified elastin 
group; the control was the cells grown on non-calcified elastin coated culture plates at 
day 14) as detected by immunofluorescence (Figure 4.4A, 4.4B) and RT-PCR and 
western blotting (Figure 4.4C, 4.4D). All the earlier mentioned osteogenic/chondrogenic 
markers including RUNX2, ALP, OCN, aggrecan and col2a1 decreased gene expression 
at day 14 and restored close to normal level (Figure 4.5A, 4.5B). The protein expression 
of ALP and OCN also decreased comparing to day 7 although still remained elevated 
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comparing to the normal control levels (Figure 4.5C). Histochemical staining for ALP 
restored to normal level comparing to the controls (Figure 4.5D). Collagen type 1 
expression also restored close to normal level (Figure 4.5E). These results indicate that 
the phenotypic transition from smooth muscle cells to osteoblast-like cells is reversible 








Figure 4.4. Expression of SMA and MHC in RASMCs after removal of calcified matrix. 
Cells were cultured on calcified matrix for 7 days, then removed and cultured in normal 
cell culture plate for additional 7 days (total 14 days of culture) A: Immunofluorescence 
stains of SMA (red fluorescence). B: Immunofluorescence stains of MHC (red 
fluorescence). Nuclei were stained blue by DAPI. Scale bar: 100µm. Abbreviations: C-
control, HA-hydroxyapatite; PE: pure elastin; CE: calcified elastin. D14: day 14.  C: 
SMA and MHC gene expression measured by RT-PCR. D: protein expression measured 
by western blot followed by densitometry as relative density units (RDU) and expressed 
as relative percentage ratio comparing to control groups (For HA treatment group the 
control was normal media while for CE treatment group the control was PE). The band 
density was first normalized by loading control protein- β2 MG. Results are presented as 





Figure 4.5. Expression of osteogenic/chondrogenic markers in RASMCs after removal of 
calcified matrix. Cells were cultured on calcified matrix for 7 days, then removed and 
cultured in normal cell culture plate for additional 7 days (total 14 days of culture) A: 
gene expression of RUNX2, ALP and OCN. B: gene expression of aggrecan and Col2a1. 
C: protein quantification of ALP and OCN. D: Histochemical staining of ALP activity in 
cells at in four groups(C, HA, PE, CE). Original magnification, 400X. Scale bar: 50µm. 
E: Immunofluorescence stains for collagen type I (red fluorescence). Nuclei were stained 
blue by DAPI. Scale bar: 100µm. Results are presented as mean ± SEM (* p<0.05). 
 
4.4 Discussion 
Our data shows that, in response to the calcified matrix, for both hydroxyapatite 
crystals and calcified aortic porcine elastin, RASMCs lose their smooth muscle lineage 
markers, specifically alpha smooth muscle actin (SMA) and myosin heavy chain (MHC). 
In addition, RASMCs undergo chondroblast/osteoblast-like differentiation confirmed by 
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an increase in expression of typical bone-markers such as Runt-related transcription 
factor 2 (RUNX2), alkaline phosphatase (ALP), osteocalcin (OCN), aggrecan, and 
collagen type II alpha 1(Col2a1). RASMCs also turn synthetic as indicated by increased 
expression of collagen type I. Interestingly, this phenotypic transition was reversible and 
RASMCs restored their original linage upon reversal of calcification. 
Putative relationship between osteoblast-like transformation of VSMCs and 
vascular calcification is still under debate and the cause-and-effect relationship between 
these two processes is unclear. It has been reported that the vascular calcification process 
can be caused by osteoblast-like differentiation of VSMCs[214]. Chronic kidney disease 
(CKD) related vascular calcification has often been associated with increase serum Ca 
and P levels[71]. Elevated phosphate conditions could cause osteogenic/chondrogenic 
differentiation of VSMC [208, 215]. In rat models of renal failure, animals with severe 
calcification showed the presence of chondrocyte-like cells. Mature cartilage tissue and 
major chondrogenic factors were found in the calcified vessels[216]. Osteoblast-like 
differentiation of VSMCs was also reported in the aortas of transgenic mice, ubiquitously 
expressing Msx2 (encodes an osteoblast-specific transcription factor), that were fed with 
a high-fat diet. High-fat diets led to vascular calcification in these transgenic mice but not 
in their non-transgenic littermates[217]. In type-2 diabetes related medial calcification, 
BMP-2/Mxs2/Wnt signaling has been established[218]. Studies in patients with type 2 
diabetes showed that medial calcification is a cell-mediated process characterized by a 
phenotypic change of VSMCs to osteoblast-like cells[219]. Based on these studies, it is 
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thought that chondrogenic/osteogenic transformation of VSMCs is the earliest step in 
vascular calcification.  
Alternatively, there are many studies support that medial elastin-specific 
calcification can occur due to degraded elastin without osteoblastic differentiation of 
VSMCs. In early 1970s, Urry has shown that elastin has a specific calcium binding site 
serving as the neutral nucleation site for calcium [220]. We previously showed that pure 
aortic elastin when implanted subdermally in rats undergoes calcification with bone-
protein expression occurring only in the later stages of mineral propagation[200]. In 
circulatory rat model, we confirmed that matrix metalloproteinases (MMPs) mediated 
degradation of elastin, leads to elastic-lamina calcification in absence of cell-associated 
calcification [199]. Price et al. have shown that in the presence of serum factors, arterial 
elastin calcifies in vitro in absence of  cells[221]. Furthermore, VSMCs have shown 
osteoblast-like behavior in vitro when exposed to elastin peptides along with TGF-beta, 
therefore suggesting a causative role of elastin degradation in  VSMCs mediated 
calcification [212]. Recently Murshed et al found in a MGP-deficient (Mgp−/−) mice 
model, chondro/osteogenic markers are not up-regulated in the arteries prior to the 
initiation of calcification[222]. One recent study found that calcium phosphate deposition 
was a passive phenomenon and it was responsible for the osteogenic changes for the 
VSMCs[223]. All these studies indicate that initial vascular calcification may be formed 
without osteoblastic differentiation of VSMCs.  
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Our study was designed to investigate the effect of calcified matrix on RASMCs’ 
phenotypic change. We hypothesize that the initial mineral deposition on elastin precedes 
the osteoblast-like differentiation which is a pathological response to elastin degradation 
and early arterial calcification. Our results showed that RASMCs lose their smooth 
muscle lineage markers like SMA and MHC (Figure 4.2) and undergo 
chondrogenic/osteogenic transformation (Figure 4.3) under calcified conditions. It is 
unclear as to how calcified matrix triggers this response in RASMCs and further study is 
needed to test this. Calcium and phosphorus levels in the media were similar in controls 
and calcified matrix groups (data not shown), thus osteoblast-like transformation seen on 
our studies was not due to higher amounts of free ions as shown by others[71, 208, 215]. 
We speculate that RASMCs synthesize small quantities of bone proteins (they come from 
same mesenchymal origin of osteoblasts). These proteins in healthy state do not 
accumulate in the vessel media; however, calcified elastin matrix can bind to these 
synthesized proteins[224, 225] and increase local concentration causing RASMCs to turn 
to osteoblast-like cells. Interestingly, our work, for the first time shows that upon removal 
of calcified conditions, cells have the ability to revert back to SMC-like cell behavior. 
When calcified matrix was removed from culture conditions, SMA and MHC expression 
increased to normal levels, whereas osteogenic/chondrogenic markers decreased to 
normal levels (Figure 4.4, Figure 4.5). This is important as we can then envision 
demineralizing strategies to remove mineral from arteries and bring homeostasis to the 
arterial structures.  
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To summarize, there are possibilities of two distinctly different, yet 
interconnected mechanisms to demonstrate the cause-and-effect relationship between 
chondro/osteoblast-like differentiation of VSMCs and medial elastin-specific 
calcification as shown in Figure 4.6. Model A: chondro/osteoblast-like differentiation of 
VSMCs precedes medial elastin-specific calcification. Many factors could induce 
VSMCs into osteoblast-like cells, such as elevated level of phosphate, lipids, 
inflammatory cytokines and others[226]. Those differentiated osteoblast-like VSMCs 
synthesize bone proteins such as osteocalcin, alkaline phosphatase to initiate mineral 
deposition. This may be true in patients with chronic kidney disease and type-2 diabetes 
where increase incidences of vascular medial calcification has been found[71, 219]. 
Model B: Medial elastin-specific calcification precedes chondro/osteogenic 
differentiation of VSMCs. In ageing patients or in patients with diseases like aortic 
aneurysm and arteriosclerosis, increased matrix metalloproteiases activity can lead to 
accelerated elastic fiber degradation. This degradation would expose calcium binding 
sites in elastin and allow initial mineral deposition[220]. This early mineral deposits may 
anchor calcium binding proteins such as osteocalcin. This local increase in bone proteins 
may lead to transformation of SMCs to osteoblast-like cells.  It is also possible that these 
two processes occur simultaneously and add mutually. Our current data mostly supported 
Model B, that is, the first calcium deposition on elastin appear prior to the osteoblast-like 
differentiation of RASMCs. Interestingly based on our data of reversal of osteogenic 
markers, we hypothesize that demineralization of calcified arteries will return 
homeostasis in arteries. In fact, recently we have shown that local delivery of chelating 
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agent such as ethylene diamine tetraacetic acid (EDTA) led to regression of arterial 
calcification in rats[227].  
 
Figure 4.6. Model of putative links between medial elastin-specific calcification and 
chondro/osteoblast-like differentiation of VSMCs in the artery. A: chondro/osteoblast-
like differentiation of VSMCs precedes medial elastin-specific calcification. Elevated 
levels of phosphate, lipids, inflammatory cytokines and many other factors could induce 
chondro/osteoblast-like differentiation of VSMCs. B: Medial elastin-specific calcification 
precedes chondro/osteoblast-like differentiation of VSMCs. The elastin degradation 
happens due to inflammatory conditions and matrix metalloproteinases. This in turn 
exposes calcium binding sites on elastin causing first calcific deposits. This early 
calcification leads to osteoblast-like differentiation in VSMCs that can further augment 
calcification process.  
 
Limitations of Current Study 
There are some limitations to our studies. First, we used reagent grade synthetic 
hydroxyapatite to mimic the ectopic deposition of mineral in vascular calcification, which 
might not be ideal to represent the real pathologic condition of vascular calcification, 
which shows poorly crystalline hydroxyapatite crystals and other calcium phosphate 
minerals. We also used porcine aortic elastin that was allowed to calcify in vitro. It 
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indeed showed poorly crystalline hydroxyapatite deposits along the elastin fibers. Finally, 
we did the studies only for two time points: day 1, and day 7. It is still unknown if longer 
exposure of RASMCs to calcified conditions would prevent reversal to normal 
phenotype.  More physiologic or animal studies are needed to further test the hypothesis 
that medial elastin-specific calcification occurs first followed by cellular changes to 
osteoblast like cells to augment mineral deposits.  
4.5 Conclusion 
In conclusion, our results demonstrate that hydroxyapatite and calcified elastin 
induce chondrogenic and osteoblast-like differentiation of rat aortic smooth muscle cells, 
and these studies support that elastin degradation and calcification may occur prior to 

















Figure 4.8. Graphical Abstract. At Day 0 rat aortic smooth muscle cells (RASMCs) were 
seeded on petri dishes which have different substrate: two control groups, one was 
normal media without substrate for hydroxyapatite (HA) study group, and another one 
was pure elastin (PE) substrate for calcified elastin (CE). By Day 7 we found RASMCS 
seeded on calcified matrix (Both HA and CE groups) had osteoblastic differentiation; at 
Day 7 upon removal of calcified matrix, which was done by trypsinizing RASMCs first 
and then re-seeding RASMCs on new petri dishes without any substrate but only normal 






CHAPTER 5: EFFICACY OF CHELATING AGENTS TO REVERSE ELASTIN 
SPECIFIC MEDIAL ARTERIAL CALCIFICATION  
(This work has been published in  
Calcified Tissue International 93, no. 5 (2013): 426-435.) 
5.1 Introduction  
Pathological calcification is defined as ectopic deposition of poorly crystalline 
hydroxyapatite in soft tissues as observed in blood vessels and cardiac valves [228], The 
two areas of calcification seen in arterial tissues include intimal calcification, detected in 
atherosclerotic plaque present in the intima, and medial artery calcification of elastic 
layers (MAC), detected in patients with diabetes, renal failure, and old age [6]; which is 
independent of atherosclerosis. Medial calcification, termed as Monckeberg’s sclerosis, 
mostly occurs along the elastic fibers of the media. Its presence correlates well with risk 
of cardiovascular events and leg amputation in diabetic patients [229]. Currently no 
clinical therapy is available to prevent or reverse this type of vascular calcification. Some 
possible targets to block and regress calcification include local and circulating inhibitors 
of calcification as well as factors that may ameliorate vascular smooth muscle cell 
apoptosis [6]. Many of these approaches were focused on atherosclerotic calcification. 
Almost no research has targeted reversing of elastin specific medial calcification[6]. 
Chelation therapy most often involves the injection of disodium ethylene diamine 
tetraacetic acid (EDTA), a chemical that binds, or chelate ionic calcium, trace elements 
and other divalent cations [141]. Chelation therapy has been touted as an effective 
87 
 
treatment to reverse vascular calcification; however, it has been controversial with 
opposing views [8-10]. At present no systemic scientific studies prove that it could 
reverse cardiovascular calcification [9]. The Trial to Assess Chelation Therapy (TACT) 
funded by the National Center for Complementary and Alternative Medicine began in 
2003 to determine the safety and effectiveness of EDTA chelation therapy in individuals 
with coronary artery disease has been finished by 2013. First published results showed 
that intravenous chelation regimen with EDTA reduced the risk of adverse cardiovascular 
outcomes but data was not sufficiently convincing to support the routine use of chelation 
therapy for treatment of patients who have had an myocardial infarction [230]. 
Unfortunately, the efficacy of various chelating agents in reversing elastin specific 
calcification from the peripheral vascular tissue is not studied very well either in vitro or 
in animal experiments. Here we tested the hypothesis that common chelating agents, such 
as disodium ethylene diamine tetraacetic acid (EDTA), diethylene triamine pentaacetic 
acid (DTPA) and sodium thiosulfate (STS) can remove calcium from hydroxyapatite 
(HA) and calcified tissues without damaging the tissue architecture.  
5.2 Materials and methods 
Chemicals 
Hydroxyapatite, disodium ethylene diamine tetraacetic acid (EDTA), diethylene 
triamine pentaacetic acid (DTPA) and sodium thiosulfate (STS), dichloromethane, were 
all reagent grades and were purchased from Sigma-Aldrich Chemicals (St. Louis, MO). 
Polyvinyl alcohol or PVA (Molecular Weight, M.W. = 15kDa) was purchased from MP 
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Biomedicals Inc. (Solon, OH). Poly (L-lactic-co-glycolic acid) or PLGA 
(lactide:glycolide = 50:50, M.W.= 60~80kDa)  was a gift from Ortec, Inc. (Piedmont, 
SC). Stock solutions of EDTA, DTPA and STS with concentration of 1, 5, 10 mg/mL 
were prepared and stored at room temperature.  Five mg/mL EDTA had pH of 4.8 while 
5 mg/mL DTPA in 0.1 M NaOH had a pH of 12.2. 
Tissues Preparation 
In order to study chelation effect on elastin specific calcification, we wanted to 
avoid effect of cells and other extracellular matrix components. Thus, we obtained pure 
aortic elastin from porcine aorta with standard methods of purification[231]. We used 
porcine aorta because of easy access and large quantities of elastin could be obtained. 
Elastin homology is maintained in all species. In previous study, we showed that when 
pure aortic elastin is implanted subcutaneously in rats, it undergoes calcification[200]. 
Thus, this calcified elastin could be used to study demineralization of elastin specific 
calcification by chelating agents. 
Calcified porcine aortic elastin (20 days explanted sample, 160~180 µg Ca/mg 
tissue) was prepared by subdermal implantation of pure porcine aortic elastin in rats as 
described previously [200]. Briefly, in juvenile male Sprague-Dawley rats (21 days old, 
35 to 40 g; Harlan, Indianapolis, IN) a small incision was made on the back, and two 
subdermal pouches were formed by blunt dissection. Each rat received two 30- to 40-mg 
purified elastin implants (one per pouch), which were rehydrated in sterile saline 1 to 2 
hours before implantation. The rats were sacrificed by CO2 asphyxiation after 20 days 
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implantation and the implants were retrieved and stored at -80°C.  Calcified human aorta 
(100~300 µg Ca/mg tissue) was from cadavers (age 49-75, both male and female with 
moderate or severe atherosclerosis) received from Greenville Hospital System 
(Greenville, SC) following standard dissection technique. All samples were from the 
abdominal aorta, just below the renal arteries. 
Demineralization of Hydroxyapatite 
To study optimal concentration chelating agents for best chelating efficacy, three 
serial concentrations (1, 5 and 10 mg/ml) of chelating agents (STS, EDTA and DTPA) 
were prepared. 10 mg of hydroxyapatite (HA) each was soaked in 1 ml chelating 
solutions while the control was soaked in distilled and deionized water (DD water). For 
the kinetic study of demineralization, Five mg of hydroxyapatite powder was suspended 
in 30 mL solution of chelating agents (STS, EDTA, DTPA respectively, 5 mg/mL, n=3), 
while the control group included DD water. At frequent intervals (2, 4, 6, 8, 24 hours), 1 
mL of supernatant was withdrawn for Ca assay. Calcium content was measured by 
atomic absorption spectroscopy (Perkin-Elmer Model 3030, Norwalk, CT) as described 
previously [232].  Briefly, each sample (15–40 mg) was hydrolyzed in 1 ml of 6 N HCl in 
a test tube at 70°C overnight and then the solution was completely evaporated at 70°C 
with a continuous flow of nitrogen in the tube. The residue in the test tube was dissolved 
in 1 ml of 0.01 N HCl. The hydrolyzed sample were diluted and analyzed by atomic 
absorption spectroscopy with calcium standards. 
Demineralization of Calcified Tissues 
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Calcified porcine aortic elastin and separately calcified human aorta (10 mg each) 
were treated with 30 mL chelating solutions (5 mg/mL of STS, EDTA, and DTPA, n=3). 
The control group was treated with DD water both for calcified porcine aortic elastin and 
calcified human aorta. At certain intervals (2, 4, 6, 8, 24 hours for porcine elastin and 8, 
12, 24, 36, 48 hours for human aorta), 1 mL of solution was withdrawn for calcium assay. 
Calcium content was measured by atomic absorption spectroscopy (Perkin-Elmer Model 
3030, Norwalk, CT).  
Alizarin Red Stain for Calcium 
Calcified elastin samples were treated with chelating agents as described 
previously and were then embedded in paraffin blocks, sectioned, and stained for 
qualitative analysis of calcium with Dahl’s alizarin red stain. Since the calcified porcine 
aortic elastin sample had more even distribution of calcification, we did the chelation 
treatment to the bulk calcified elastin first and then made sections and stained the calcium 
by Dahl’s alizarin red stain. For human aorta sample, since the distribution of 
calcification was non uniform, we first sectioned samples and located calcification site 
and then did the chelation treatment as described. Calcified human aorta were fixed in 
10% neutral buffered formalin at room temperature for 24 h, processed with an automatic 
tissue processor (Tissue TEK VIP, Miles Inc., Mishawaka, IN) and 6 µm paraffin 
sections (n=12 sections per sample) were soaked in chelating solutions (5 mg/mL of STS, 
EDTA, and DTPA, n=3) respectively for 4 hours. The control group was treated with DD 
water (n=3). And then the slides were stained for 3 minutes at room temperature with 1% 
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Alizarin red solution, and rinsed with distilled water. Sections were counterstained with 
1% light green solution for 10 seconds and rinsed with distilled water and mounted.  
Preparation of EDTA-loaded PLGA nanoparticles 
EDTA-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles were prepared 
by double emulsion method [233]. PLGA (200 mg) was dissolved in 2 mL 
dichloromethane. EDTA (100 mg) was dissolved in 1 mL deionized water. For the 
control group, no EDTA was used. Water-in-oil (W1/O) emulsion was prepared with an 
Omni Ruptor 4000 ultrasonic homogenizer by 20 watts for 5 minutes. This prepared 
primary emulsion was subsequently added to 10 mL of 1 % (w/v) PVA solution and the 
second emulsion was prepared with homogenizer (20 watts, 5 minutes) to obtain water-
in-oil-in-water (W1/O/W2) emulsion. The nanoparticles were isolated by solvent 
evaporation with stirring overnight at room temperature.  After threes wash of deionized 
water, the nanoparticles were lyophilized and stored at 4 ℃.  
Measurement of loading efficiency and release profile of EDTA in PLGA 
nanoparticles 
5 mg EDTA-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles were 
dissolved in 1 mL of dichloromethane and 5 mL distilled water was added and solutions 
were vortexed for 30 minutes. After centrifugation at 13,000 rpm for 5 minutes the 
supernatant were collected and the concentration of EDTA was spectrophotometrically 
measured at 257 nm [234]. The loading efficiency is calculated by equation: EDTA 
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loading efficiency = The amout of EDTA in nanoparticles/weight of nanoparticle *100%. 
Five (5) mg EDTA-loaded PLGA nanoparticles were enclosed in dialysis units (Slide-A-
Lyzer® MINI Dialysis Units. Thermo Scientific, Rockford, IL) and incubated in 30 ml 
PBS at 37 ℃ with mild agitation. At determined time intervals 1 ml sample was 
withdrawn for quantification of EDTA release.  
Local EDTA treatment in CaCl2 injury model of vascular calcification  
Calcium chloride (CaCl2) injury model was used to create local arterial 
calcification (abdominal aortic region) in rats [235].  10 male Sprague-Dawley (SD) rats 
(5-6 weeks old) were placed under general anesthesia (2% to 3% isoflurane), and the 
infrarenal abdominal aorta was exposed and treated periadventitially with 0.20 mol/L 
CaCl2 by placing CaCl2-soaked sterile cotton gauze on the aorta for 15 minutes. The area 
was flushed with warm saline and wound site was closed with sutures. Animals were 
allowed to recover and placed on normal diet. One week after first surgery, the abdominal 
aorta was re-exposed in order to provide a treatment directly to the aorta. EDTA loaded 
poly (lactic-co-glycolic acid) (PLGA) nanoparticle pellet (30 mg, with 5% EDTA 
loading, n=5), and pure PLGA particle pellet (No EDTA entrapped, n=5) were placed 
periadventitially. The rats were allowed to recover. After 1 week, rats were euthanized 
and tissues (aorta) and blood were harvested and frozen in liquid nitrogen for plasma 
calcium and phosphorus quantification.  Calcium and Phosphorus level were measured by 




Results are expressed as means ± SEM (standard error of the mean). Statistical 
analyses of the data were performed using single-factor analysis of variance. Differences 
between means were determined using the least significant difference with an α value of 
0.05. Asterisks in Figures denote statistical significance (P < 0.05). 
5.3 Results  
Chelation of calcium from hydroxyapatite (HA) 
Three series of concentration (1, 5, 10 mg/ml) of chelating agent solutions (STS, 
EDTA and DTPA) were prepared in order to optimize the concentration needed for 
efficient demineralization. HA powders (10 mg in each group) were suspended with 
aqueous chelating agent solutions and the percentage HA solubilization was calculated 
(Figure 5.1A). EDTA & DTPA were stronger chelating agent than STS, and could 
remove more calcium from HA (Figure 5.1A). The chelating capacity was dependent on 
concentrations of chelating agents with 10 mg/mL showing highest activity. 1 mg STS or 
EDTA or DTPA chelate 1.3 mg HA, that is, 1 mole of STS, EDTA, DTPA chelate 0.41, 




Figure 5.1. Demineralization of Hydroxyapatite. A: Effect of concentration of chelating 
agents on dissolving calcium from hydroxyapatite powder. B: Kinetics of 





The concentration of 5 mg/mL of chelating agents were used for further studies 
[236]. The kinetics of demineralization of hydroxyapatite is shown in Figure 5.1B. Most 
of the chelation and removal of calcium occurred in first 2 hours and continued slowly up 
to 24 hours for EDTA and DTPA. The chelating ability was: EDTA>DTPA>STS. Since 
EDTA and DTPA solution as prepared had pH 4.8 and pH 12.2 respectively, we 
examined the effect of pH on the demineralization of HA. HA was suspended in pH 
buffers (pH 4.8 buffer: 59.0 mL 0.2M Sodium acetate and 41.0 mL 0.2M acetic acid; pH 
12.2 buffer: 50 mL 0.2 M KCl and 20.4mL 0.2 M NaOH ). Calcium was not released 
from HA in the pH range of 4.8 to 12.2 thus suggesting pH did not play a role in calcium 
chelation. We also neutralized pH to 7.4 for all chelating solutions and still found similar 
results of chelation (data not shown). 
Chelation of calcium from calcified elastin 
Calcified aortic elastin (3~5 mg, implanted subdermally in rats to calcify and then 
isolated) were immersed in 1 mL solution of STS, EDTA, and DTPA with concentrations 
of 5 and 1 mg/mL for 24 hours under vigorous shaking while the control group was 
immersed in DD water (n=3 each group). Remnant calcium levels in the treated elastin 
fiber were measured by atomic absorption spectroscopy. All chelating agents (STS, 
EDTA and DTPA) could remove calcium from the calcified porcine elastin, with the 
chelating ability sequence: EDTA ≥DTPA>STS (Figure 5.2A). This is consistent to the 
previous HA results. For the EDTA treatment we calculated the percentage of calcium 
loss by using the equation: the percentage of calcium loss = (the total calcium in calcified 
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elastin - the remnant calcium in calcified elastin)/ the total calcium in calcified 
elastin*100.  Treatment with 1 mg/mL chelating agent for EDTA resulted in about 53 % 
removal of calcium (Figure 5.2A), while higher EDTA concentration (5 mg/mL) was 
effective in removing 75% of calcium (Figure 5.2A). Such increase in calcium 
dissolution was not found in DTPA and STS groups after increasing chelating agent 
concentrations (Figure 5.2A). 
The kinetics of demineralization of calcified elastin for chelating agents with the 
concentration of 5 mg/mL is shown in Figure 5.2B (n=3 in each group). Both EDTA and 
DTPA were effective in removal of calcium from calcified porcine elastin while STS was 
not effective, which corroborated with the result of hydroxyapatite. However; kinetics of 
calcium removal from calcified elastin was much slower than HA. Longer incubation 
times lead to continuous removal of calcium so that within 24 hours EDTA could remove 
almost all calcium from calcified elastin (Figure 5.2B). Dahl’s alizarin red stain at 24 
hours of treatment further confirmed that EDTA treatment could remove all calcium 





Figure 5.2. Demineralization of calcified elastin. A: Optimal concentration of chelating 
agents needed to remove Ca from calcified elastin. B: Kinetics of demineralization of 
calcified porcine elastin. All data are presented as means ±SEM, n=3 per group. c: Dahl’s 
alizarin red stain for porcine elastin after chelation treatments. Alizarin red stains calcium 




Chelation of calcium from calcified human aorta 
The kinetics of extraction of calcium from calcified human aorta after treating 
with chelating agents for 48 hours, showed that EDTA and DTPA were most effective in 
removing calcium while STS was not effectively similar to what was observed in HA and 
elastin studies presented above (Figure 5.3A). The kinetics of calcium dissolution was 
slower probably due to denser nature of aortic tissue. To study tissue architecture after 
chelation, 6 µm sections of human aorta were treated with chelating solutions for 4 hours. 
Dahl’s alizarin red stain (Figure 5.3B) for the human aorta sections showed that EDTA 
and DTPA removed the calcium while STS treatment was not effective.  The tissue 
sections maintained their typical arterial integral structure. Chelation treatment did not 
cause delamination or removal of certain parts of artery for all chelating agents treated 




Figure 5.3. Demineralization of calcified human aorta. A:Kinetics of demineralizaion of 
calcified human aorta. All data are presented as means ±SEM, n=3 per group. B: Dahl’s 
alizarin red stain for human aorta sections after treatment with chelating agents showing 




Reversal of arterial calcification in vivo by EDTA 
As EDTA was found to be most successful in removing calcium in vitro, we 
tested its efficacy in removing calcium from calcified aorta in vivo. We prepared PLGA 
nanoparticles loaded with EDTA so that prolonged (24 hour) controlled release of EDTA 
could be achieved when the nanoparticles are placed close to the calcified aorta.  Our in 
vitro release profile showed that EDTA could be released from PLGA nanoparticles 
within 3 days (Figure 5.4). Next, we tested if local delivery of EDTA could remove 
calcium from calcified rat aorta in vivo. We have shown previously that when abdominal 
aorta of rats were exposed to chemical injury with calcium chloride, it lead to elastin 
specific medial arterial calcification with time [199]. We used 7 day time point after 
injury for EDTA therapy as substantial calcification is seen in this model at that time 
[15]. After 7 days, EDTA loaded PLGA nanoparticle pellets (30 mg with 5% EDTA 
loading, thus dosage was 0.01 g EDTA/kg) were placed on the aorta. We observed that 
the PLGA particles were spontaneously absorbed onto the wet abdominal aorta. Seven 
days after initial EDTA treatment rats were sacrificed to test if local EDTA therapy 
would reverse elastin calcification. In vivo studies were continued for 7 days to make sure 
all of the EDTA could be released and available to remove calcium. Both calcium and 
phosphorous level were significantly lower in the EDTA treated group as compared the 
control group with blank nanoparticles (Figure 5.5A). Histology analysis also showed 
that the aortic calcification was greatly reversed in the EDTA treated group (Figure 
5.5B). The calcium and phosphorus level of the blood plasma in both groups were also 
quantified and there was no statistical significant difference between the EDTA treated 
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group and pure PLGA control group (Figure 5.5C). Clearly suggesting that local delivery 




Figure 5.4. EDTA release profile from PLGA nanoparticles. All data are 




Figure 5.5. Reversal of arterial calcification in vivo by EDTA. A: Calcium and 
phosphorus level of the harvested abdominal aorta after treatment of PLGA particles. 
Study group: EDTA-loaded PLGA. Control group: PLGA alone. Asterisks in Figures 
denote statistical significance (P < 0.05) comparing to control group without EDTA 
entrapped. B: Alizarin Red stains for the harvested aorta treated by EDTA-loaded PLGA 
particles and control PLGA particles. C: Calcium and phosphorus level of the rats’ 
plasma after treatment of PLGA particles. There is no statistical significant difference 
(P>0.05) comparing to control group without EDTA entrapped. All data are presented as 




5.4 Discussion  
This is the first study to compare three types of chelating agents (STS, EDTA, and 
DTPA) used for chelation therapy and their chelating efficiency to remove calcium from 
the hydroxyapatite, calcified aortic porcine elastin and calcified human aorta. We found 
an optimal concentration (1~10 mg/mL) of chelating agents works very well to remove 
calcium. Our results indicate that both EDTA and DTPA could effectively remove 
calcium from hydroxyapatite and calcified tissues, while STS was not effective. The 
tissue architecture was not altered during chelation. Furthermore, our in vivo study 
demonstrates the proof of the concept for the first time that local delivery of chelating 
agents such as EDTA could be used to reverse medial aortic calcification which is found 
in arteriosclerosis. 
Chelating agents’ effectiveness in removing plaques has been advertised and used 
in certain countries, however, the treatment is not FDA approved in US because lack of 
substantial conclusive data. The actual published data is very scarce in both animals and 
human patients and no comparative in vitro or animal studies have been performed to 
demonstrate the calcium chelating ability of different types of chelating agents (STS, 
DTPA and EDTA). Pasch et al [119] found  that STS could probably chelate calcium by 
forming soluble calcium thiosulfate complex. They found that it prevents vascular 
calcification in uremic rats. But systemic treatment of STS also lowered the bone strength 
in animals probably due to STS chelation of bone HA. They proved direct calcium 
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chelation by STS through a decline of serum ionized calcium concentrations when 
exposed to STS in vivo and in vitro. Adirekkiat et al[120]  demonstrated that STS could 
remove calcium from precipitated minerals and delayed the progression of coronary 
artery calcification(CAC) in hemodialysis patients. Patients with a CAC score≥300 were 
included to receive intravenous sodium thiosulfate infusion twice weekly post-
hemodialysis for 4 months. They found that CAC score did not change significantly in 
the STS treatment but increased substantially in the control group.  Our present study 
shows that the chelating ability of EDTA and DTPA was superior to STS to remove 
calcium from hydroxyapatite like mineral from calcified elastic tissue.  
Disodium EDTA is an amino acid used to sequester divalent and trivalent metal 
and mineral ions (e.g., lead, mercury, arsenic, aluminum, cobalt, calcium etc.). EDTA 
binds to metals via 4 carboxylate and 2 amine groups [237]. Diethylene triamine 
pentaacetic acid (DTPA) is consisting of a diethylenetriamine backbone with five 
carboxymethyl groups. The molecule can be viewed as an expanded version of EDTA 
and it is used similarly for metal chelation. Cavallotti et al [238] found that intravenous 
injection of EDTA substantially reduced the extent of calcium deposits in the aortic wall. 
The general decalcifying mechanism of EDTA may derive from its affinity for divalent 
ions, especially calcium. Maniscalco et al [239] demonstrated that calcification in 
coronary artery disease could be reversed by EDTA–tetracycline long-term therapy. 
Their hypothesis was that calcification is caused by nanobacteria (NB). In that study, 
EDTA was given as a rectal suppository base every evening, which was shown to result 
in high blood EDTA levels sustained for a long time. They proposed that NB were 
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sensitive in vitro to tetracycline and its action is increased by EDTA dissolving NB 
apatitic protective coat. Thus, they concluded that combination of these drugs might offer 
a novel treatment for calcific atherosclerotic disease. EDTA has also been proven to  
reduce the risk of calcific tendinitis of the shoulder [237] if used as a chelating agent. In 
that study EDTA was administered through single needle mesotherapy and 15 minutes of 
pulsed-mode 1 MHz-ultrasound. Calcifications disappeared completely in 62.5% of the 
patients in the study group and partially in 22.5%; calcifications partially disappeared in 
only 15% of the patients in the control group, and none displayed a complete 
disappearance. 
Despite these clinical studies and other EDTA chelation therapies that have gone 
to clinical trials since 2003[240], little basic research is done to study chelation of 
hydroxyapatite like mineral in vitro and in animal studies. This might be one of the 
reasons why lots of negative opinions directed toward the chelation therapy for removal 
of calcium from atherosclerotic plaques. Dr. Jackson[8], the editor of International 
Journal of Clinical Practice, stated that “Chelation therapy is TACT-less, one wonders 
why it is still widely used, given the lack of evidence of benefit and potential to do harm 
(financial gain seems the most likely reason)”. Atwood et al[9] concluded that “…TACT 
is unethical, dangerous, pointless, and wasteful. It should be abandoned.” Fraker et al[10] 
concluded that “Chelation therapy (intravenous infusions of ethylenediamine tetra-acetic 
acid or EDTA) is not recommended for the treatment of chronic angina or atherosclerotic 
cardiovascular disease and may be harmful because of its potential to cause 
hypocalcaemia.” First randomized clinical trial results published this year for EDTA 
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chelation therapy for coronary artery disease showed some improvements but the data 
was not statistically significant to warrant use of chelation therapy for all patients with 
myocardial infarction [8]. In all clinical studies, chelation therapy was tested to remove 
calcium from atherosclerotic plaque and improve heart function. Atherosclerotic plaque 
calcium deposits are due to necrotic tissue core and removal of calcium from plaque may 
not remove cholesterol laden fatty deposits, thus may not be very effective in reducing 
heart burden. Some have suggested that calcification make plaques more stable and 
removal of calcium may make them vulnerable to rupture and that may have led to 
negative connotations.  Our present study with chelating agents is necessary and 
significant because such therapy was never tested suitably to remove calcium from 
medial arterial calcification that occurs in absence of atherosclerotic plaques in patients 
with diabetes, end stage renal disease, and old age. In those cases calcification is 
observed along the medial elastic layers that make arteries stiff. We envision using 
chelation therapy for such type of calcification. 
Our current results show that both EDTA and DTPA could effectively remove 
calcium from calcified aortic elastin and calcified human aorta, while STS is not so 
effective. We have demonstrated that vascular elastin specific calcification could be 
reversed by chelating agents in vitro. Our in vivo study in the CaCl2 injury model, for the 
first time, shows proof of the concept that chelating agent loaded PLGA nanoparticles 
could reverse medial elastin-specific aortic calcification. One criticism of chelation 
therapy is its effects on serum calcium and bone HA. One previous study of systemic 
administration of STS in rats showed that such systemic chelation treatment led to the 
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decrease of serum calcium, phosphate and also compromised bone integrity. STS 
treatment group required significantly lower load to fracture the femurs as compared to 
controls[236].  Another study in humans also showed that systemic administration of 
chelation agent caused decrease in serum calcium and serum phosphate levels and caused 
bone loss by increasing endogenous parathyroid hormone secretion[14]. We consider 
chelation therapy could be useful in patients with diabetes and old age to remove elastin 
specific calcification if chelating agents such as EDTA are protected in polymeric 
capsules (such as nanoparticles) and delivered at the site or targeted to vascular 
calcification. Such treatment would prevent serum calcium chelation and undesired effect 
on bone density. Our result in rats study showed such local EDTA treatment with PLGA 
nanoparticles, completely reversed calcification without damaging vascular structure. 
This is for the first time anyone has shown effectiveness of local therapy in reversal of 
calcification. Such local EDTA treatment also did not change serum calcium and 
phosphorus levels; thus could be used without systemic effects. This is because local 
delivery method used in this study had much lower dose of chelating agents, specifically 
0.01 g EDTA/kg rats comparing to those systemic administration of 0.4 g STS/kg 
rats[236] and 0.04 g EDTA/kg human[230].Our long term goal is to develop site-specific 
delivery of the chelating agents with targeted nanoparticles to reverse vascular 





Limitations of Our Study 
There are some limitations of our current study. Firstly, for in vivo chelation study 
we did not measure plasma level of other biochemically important metal ions such as 
chromium, zinc, cobalt, and copper and toxic metals, such as cadmium and lead, which 
might be affected by the chelation treatment [241]. We used local delivery of small 
concentrations of EDTA and thus systemic concentrations of chelating agent would be 
negligible and may not affect other metal ions. Secondly, our animal study results might 
not be directly applicable to patients with chronic kidney disease or patients on dialysis. 
In our animal study, the rats had normal kidney function while those patients with 
arteriosclerosis typically have non-regulated plasma level of calcium, phosphorus and 
other ions[242]. Finally, we did not look at the bone integrity which might affected by the 
EDTA treatment. Again, because we used local therapy of EDTA at very low 
concentrations (4 fold lower than used in clinical trials, per kg basis) instead of systemic 
delivery, we hypothesize that it will not affect bone integrity.  
5.5 Conclusion 
In conclusion, we did a comparative in vitro study for three types of chelating 
agents (STS, EDTA and DTPA) and showed that EDTA and DTPA could effectively 
remove calcium from calcified aortic elastin and calcified human aorta. We, for the first 
time, show that local EDTA treatment with PLGA nanoparticles could reverse 
calcification without causing vascular damage and change in the normal plasma level of 





Figure 5.6. Types of chlating agents and chemical structure.  
 
 
Figure 5.7. Surgery protocol and photos.  
 
Reversal of aortic calcification in vivo by EDTA 
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CHAPTER 6: SYSTEMIC EDTA CHELATION THERAPY FAILED TO 
REVERSE MAC AND HAD SIDE EFFECTS 
6.1 Introduction 
Vascular calcification is an independent risk factor for cardiovascular morbidity 
and mortality. Vascular calcification occurs at two different sites- intima and media. 
Intimal calcification is generally associated with atherosclerotic plaques and 
inflammation and can occlude the lumen while medial calcification (MAC) occurs in the 
elastin lamina of medium and large arteries in patients with chronic kidney disease (CKD) 
or diabetes causing increase in arterial stiffness. Surgical methods like directional 
atherectomy and stent grafts are used to treat atherosclerosis and intimal calcification and 
to open occluded arteries [4, 5]. However, there are no treatments available for medial 
elastin-specific calcification.  
EDTA (disodium, ethylenediamine tetraacetic acid) chelation therapy has been 
tried for reversing intimal vascular calcification with some success [17, 168, 172]. EDTA 
binds or chelates ionic calcium (Ca), trace metals, and other divalent cations [141]. Many 
possible mechanisms are proposed for EDTA chelation therapy to reverse calcification. 
These mechanisms include: directly removing calcium deposits from calcified arteries 
[134], binding serum calcium to reduce calcification, chelating heavy metals, and 
normalizing Ca metabolism by reactivation of enzymes inhibited by toxic heavy metals 
[135-138]. However, at present effectiveness of EDTA chelation therapy is still disputed 
[9]. Most of the EDTA treatments were performed by subcutaneous infusion, or systemic 
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application of EDTA solution at very high dose (around 40 ~ 50 mg/kg) [11-17]. Many 
side effects have been found with such a high systemic dose of EDTA chelation therapy 
including: renal toxicity [18-23] , hypocalcemia [14, 24, 25], and bone loss [14, 26]; 
however, side effects are variable.  
No animal studies are performed as yet to test if systemic EDTA therapy can 
reverse elastin specific medial calcification (MAC). We created vascular medial elastin 
specific calcification by abdominal application of calcium chloride to the abdominal aorta 
of rats and tested if systemic EDTA therapy can reverse this type of calcification [27, 28]. 
We also analyzed possible side effects to serum Ca, urine Ca, bone loss, and kidney 
toxicity. 
6.2 Materials and methods 
CaCl2 injury model and EDTA administration 
An illustration of the experimental design is shown in Figure 6.1. All procedures 
and treatments in animal studies were approved by the Institutional Animal Care and Use 




Figure 6.1. Experimental protocol for CaCl2 injury model and EDTA treatment of rats. 
CaCl2 injury model (represent as symbol of arrow) was bone by a single periadventitial 
0.5 M CaCl2 injury to abdominal aorta (15 minutes treatment) at starting time point of 
experiment (Day 0, week 0). There were two treatment groups: 1) saline as control group 
(n=5, 5 rats), tail vein injections with saline 2 times a week for another 2 weeks. 2) 
EDTA as study group (n=5, 5 rats), tail vein injections with EDTA (50 mg/kg) 2 times a 
week for another 2 weeks. Rats were placed in metabolic cages for urine collection for 24 
hours (Day 21); after that all rats were given another injection (Day 22) of saline or 
EDTA (depending on individual treatment groups) and then urine samples were taken at 
time points of 1, 2, 3 and 4 hours post injection; finally rats were euthanized and organs 
were harvested (represent as symbol of six-point stars).  
 
CaCl2 injury model was used to mimic local aortic calcification at the abdominal 
aortic region following previous protocol [27, 28]. Briefly, ten male Sprague-Dawley (SD) 
rats (6 to 8 weeks old) were anesthetized by 2-3% isoflurane.  A ventral laparotomy 
exposed the peritoneal cavity. A 15 mm section of the infrarenal abdominal aorta was 
exposed and injury was created by placing 0.5 M CaCl2 soaked sterile cotton gauze on 
top of the aorta for 15 minutes. After CaCl2 application, the gauze was removed and the 
area was briefly flushed with warm saline. Incisions were then closed with continuous 
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sutures (Abdominal and subcutaneous) and surgical staples. Then rats were allowed to 
recover and maintained in standard chow conditions for one week.  
One week after CaCl2 injury, rats were randomly separated into two groups: 1) 
control saline group and 2) EDTA group (n=5/group). Either saline or EDTA (50 mg/kg 
EDTA in saline) was delivered intravenously 2 times a week, for 2 weeks by tail vein 
injections The dosage for EDTA was chosen based on other animal studies and  clinical 
trials for EDTA therapy [11-17].  
On the final day of treatments (Day 21), all rats were placed in metabolic cages 
(fasting for a day - removal of food only, water supply not removed) for urine collection.  
The day immediately following fasting (Day 22), all rats were given another injection of 
saline or EDTA (depending on individual treatment groups) and then urine samples were 
taken at time points of 1, 2, 3, and 4 hours post injection and kept in – 80 ℃ for further 
analysis. Immediately after urine collection all rats were euthanized by CO2 asphyxiation 
and all organs including the aorta (from the heart to the iliac bifurcation), blood, femoral 
bone, kidney, heart, liver and spleen were harvested. Heparin (10 units/ml blood) was 
used as anti-coagulant for blood samples and serum was isolated and stored at – 80 ℃ for 
further assay. Aorta, kidney, heart, liver and spleen were fixed in 10% buffered formalin 
for further analysis. 
Evaluation of aortic calcification 
Aortic calcifications were evaluated by stereomicroscope micro-computed 
tomography (micro-CT) scanner, histology, and atomic absorption spectrometry (AAS). 
114 
 
Aortas from all 10 rats were cleaned of all adherent tissues by blunt forceps after 
formalin fixation. Plastic tube (PE, 1 mm outside diameter) was inserted into the cleaned 
aortas for easier handling during imaging.  
Whole aortas were imaged by stereomicroscope (Leica M80 stereo microscope, 
Leica Microsystems Inc. Buffalo Grove, IL) both before and after alizarin red staining 
[96, 243, 244]. Briefly, whole aortas were soaked in freshly made 2% alizarin red 
solution (pH 4.1-4.3, pH) for 10 minutes and washed by distilled and deionized water for 
another 5 minutes.  Then aortas were then imaged by stereomicroscope.  
Micro-CT imaging for harvested aortas was based on modified protocol [237, 
239]. Micro-CT was done by using Siemens Inveon microPET/CT scanner (Preclinical 
Solutions, Siemens Healthcare Molecular Imaging, USA).  Briefly, a 360-degree axial 
scan was collected at a peak tube potential of 80kVp and tube current of 500uA. Data 
were reconstructed to 100 μm pixel size using a Feldkamp cone beam algorithm. Virtual 
2D cross-sections and 3D maximum intensity projection views were created using 
MeVisLab software (MeVisLab, Mevis, Bremen, Germany). Exported movies from 
MeVisLab were further edited by video-editing software- Corel VideoStudio Pro 
X7(Corel Inc, Mountain View, CA). (Available as online video supplement 1).  
Following the non-invasive imaging by stereomicroscope and micro-CT scanner 
mentioned above, aortas were processed for histology with alizarin red staining for 
visualization of calcium. Briefly, aortas were fixed in 10% buffered formalin, processed 
with an automatic tissue processor (Tissue TEK VIP; Miles, Mishawaka, IN) and then 
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sectioned into 6 μm paraffin sections for Alizarin red staining. Slides were stained in 
freshly made 2% alizarin red solution (pH 4.1-4.3) for 3 minutes, washed by distilled and 
deionized water and then counterstained with 1% light green solution for 10 sec and 
mounted for optical microscope examination.  
Remaining parts of abdominal aortas were used for Ca quantification by AAS. [28, 
232]. Briefly, 2 ~ 10 mg of abdominal aortas were hydrolyzed in 1mL of 6N Ultrex HCl 
(Baker Company, Phillipsburg, NJ) and then re-suspended in 0.01N Ultrex HCl. 
Hydrolyzed samples were diluted and analyzed  with AAS for calcium.  
Calcium in serum and urine  
Serum and urine samples were diluted before Ca quantification by AAS. Same 
protocols were used as mentioned above for AAS.  
Bone Analysis by Micro-CT and three points bending 
The rat femoral bones were dissected and fixed in 10% buffered formalin from 
both groups (saline group and EDTA group, n=5 each). The integrity of femoral bone 
was evaluated by Micro-CT and by functional stiffness and fracture studies. Stiffness and 
maximum load were tested based on three points bending mechanical test. Micro-CT for 
rat femoral bones was performed by the same protocol as aortas mentioned earlier. 
Representative scanning data for the whole 2D view slices from each group (saline group 
and EDTA group) is available as an online supplement video 2. 
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Three points bending test was performed using Bose test machine (Electroforce 
3200, Bose, MN, USA) equipped with a 450N load cell. Rat femoral bones were placed 
in the machine (available as online supplement video 3 to show the fixture and fracture 
locations). The stiffness was tested by measuring bone displacement (in mm) at a given 
force (N). Later, bones were exposed to higher force until fracture occurred from which 
the maximum enduring load (N) was determined.  
Statistical analysis 
Results are expressed as means ± standard deviation (SD). Statistical analyses of 
the data were conducted using single-factor analysis of variance. Differences between 
means were determined using the least significant difference with an α value of 0.05. 
Asterisks in Figures represent statistical significance (P < 0.05). 
6.3 Results 
Systemic EDTA chelation therapy did not reverse aortic calcification 
Periarterial application of calcium chloride led to medial elastin specific 
calcification in the abdominal aorta. Whole rat aorta when stained with alizarin red 
showed intense red staining for calcification where injury was created. Histology of 
cross-sections of aorta confirmed elastin specific medial calcification (Figure 6.2A). Two 
weeks of systemic EDTA chelation therapy did not reverse aortic calcification (Figure 
6.2) as assessed by stereomicroscopy of whole aorta, histology, and calcium 
quantification methods (AAS). Results showed no visible difference in calcification level 
between saline study group and EDTA study group (Figure 6.2A).  Ca quantification in 
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aortas by AAS also did not show statistical differences (P = 0.6491, n = 5) between 
EDTA treated group and saline group confirming that 2 weeks of EDTA treatment was 





Figure 6.2. Evaluation of aortic calcifications by stereomicroscope, histology and AAS.A: 
Photos for aortas took by stereomicroscope both before and after staining with alizarin 
red and also one representative images of histological section after alizarin red staining 
(n=5). B: Ca quantification in aortas by AAS. Micro-CT data were available as online 
video supplementary materials.  
 
Micro-CT results for aorta corroborated histology and no visible differences 
between saline study group and EDTA study group were found (online video supplement 
1).  
Systemic EDTA chelation therapy led to hypocalcemia and hypercalciuria 
Systemic EDTA chelation therapy caused side effects that influenced the Ca 
amounts in serum and urine (Figure 6.3).  Ca amount in the rats’ serum for EDTA study 
group were significantly lower than the saline control group (Figure 6.3A, P = 0.0045, n 
= 5).  On the contrary,   Ca amount in rats’ urine at the end (Day 22) after two weeks 
EDTA treatment were significantly higher than saline control group (Figure 6.3B, P = 
0.0001, n = 5).  After EDTA application, urinary total Ca excretion increased 




Figure 6.3. Ca quantification in serum and urine by AAS. A: Ca amounts in serum. B: Ca 
amounts in urine at the end day (Day 22). C: Changes in urinary Ca concentrations post 
saline and EDTA application.  
 
Systemic EDTA chelation therapy did not cause bone loss 
Since hypercalciuria (excessive urinary calcium excretion) induced by EDTA 
application can potentially cause bone loss, we did morphology and functional test for 
rats’ femoral bones both for EDTA treated and untreated groups. Micro-CT for rat 
femoral bones selectively at 15 mm below the trochanter major showed no visible 
difference, such as reduced mineralization or cystic transformation, between EDTA-
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treated and untreated groups (Figure 6.4A). 2D imaging of virtual-slices (Total about 500 
slices, 100 μm resolution) of rats’ femoral bones also indicated no visible differences for 
all virtual-slices (online supplement video 2). Functional studies on bone integrity by 
three points bending test revealed no significant changes to stiffness (measured as bone 
displacement at a given force, N/mm) of rat femoral bones for EDTA treated group 
compared to untreated group (Figure 6.4B, P = 0.8309, n = 3). Interestingly, EDTA 
treated groups even had slightly higher maximum load compared to untreated group 




Figure 6.4. Bone integrity of EDTA-treated (study group) and untreated rats. A: Rats’ 
femoral bone morphology by Micro-CT. No visible difference were seen such as reduced 
mineralization or cystic transformation for EDTA-treated and untreated groups. B: 
Stiffness of rats’ femoral bones analyzed from three point bending test. C: Maximum 
(Max) load of rats’ femoral bones analyzed from three point bending test.  
 
6.4 Discussion 
The present study demonstrates that systemic EDTA chelation therapy does not 
reverse local elastin-specific medial aortic calcification in rats. We further show that 
systemic EDTA chelation therapy caused hypocalcemia (low serum calcium levels) and 
hypercalciuria (excessive urinary calcium excretion) but did not cause bone loss. These 
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results indicated that systemic EDTA chelation therapy might not have therapeutic effects 
in aspects of reversal of elastin-specific medial calcification that is found in patients with 
CKD and chronic diabetes. 
One of the proposed mechanisms for EDTA chelation therapy to reverse 
calcification suggests that EDTA could directly remove calcium deposits from calcified 
arteries [134]. We recently have demonstrated that EDTA could effectively remove Ca 
from hydroxyapatite and calcified elastin and human aorta tissue In vitro [28]. Animal 
studies with EDTA treatment have shown mixed results. For example,  Kaman et al and 
Cavallotti et al. showed that systemic infusion of EDTA significantly reduces calcium in 
aortas in atherosclerotic rabbit model [11, 13]. But O'Brien et al showed that EDTA 
chelation therapy (40 mg/kg, daily intravenous injection, 4 weeks) showed a 74% 
increase in triglyceride levels but no benefit on arterial lesions in an atherosclerotic, 
obese, diabetic rat model [165].   
Many clinical studies have investigated the therapeutic effects of EDTA chelation 
therapy with mixed results [15, 16, 142, 167]. Most of them were focused on other 
aspects such as improvement in clinical symptoms such as cardiac output but not on 
specifically reversal of calcification.  Olszewer et al. in 1990 [137] did a pilot double 
blinded study with EDTA chelation therapy (1.5 g/ EDTA per patient, 20 intravenous 
infusion) with 10 patients (all male, aged 41 to 53 years) diagnosed with peripheral 
vascular disease. Results showed that EDTA chelation therapy had substantial 
improvements for the walking test and master exercise test. In 2005, Shoskes et al. [170] 
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reported a case study involving 16 male patients with recalcitrant chronic 
prostatitis/chronic pelvic pain syndrome (CPPS) showing significant improvement of 
symptoms of recalcitrant CPPS in the majority of the men after ComET therapy, which 
was a combined EDTA chelation therapy with other drugs. One recent randomized trial 
done by Lamas et al. in 2013 [17] with 1708 patients with myocardial infraction showed 
that EDTA chelation therapy (50 mg/kg EDTA,  intravenous infusion , one time a week, 
40 weeks) would modestly reduce the risk of adverse cardiovascular outcomes but the 
results did not lead to statistical significance. Further, this study did not highlight calcium 
score data.  
None of the previous studies, either in animals or in a clinical study, looked at 
whether EDTA can remove calcium from medial elastin specific medial crterial 
calcification (MAC). This condition can cause significant increase in arterial stiffness and 
hypertension in patients. Thus, we tested EDTA chelation in an animal model where 
elastin specific medical calcification is observed [27]. Local periadventitial treatment of 
infrarenal aorta allowed us to induce elastin specific arterial calcification independent of 
atherosclerosis similar to what is found in CKD patients.  We chose EDTA doses similar 
to dose used previously in other animal studies and in chelation therapy in patients [11-
17].  However, the  two week treatment period of our study was shorter than others who 
investigated 4 week [12] to 9 week [14] treatment periods. We chose shorter period due 
to less severe calcification seen in our model at seven days. Our results indicated EDTA 
chelation therapy by systemic infusion might not be effective to reverse elastin-specific 
medial calcification possibly due to site of calcification, which is in the medial layer of 
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the artery and may not accessible to systemically delivered EDTA under high blood flow 
conditions in the aorta. The half-life of EDTA in human beings was 20 to 60 minutes and 
that EDTA was excreted primarily by the kidneys with about 50% excreted in one hour 
and over 95% with 24 hours [245]. Similar data for rats is not available at this time but 
half-life could be even less than humans. Thus, intravenously delivered EDTA may not 
be as effective.  
Many side effects are associated with systemic EDTA chelation therapy due to 
high dosage. The side effects include are but not limited to: hypocalcemia [14, 24, 25], 
bone loss [14, 26]  and renal toxicity [18-23]. Our current results in rats also showed side 
effects of hypocalcemia (low serum calcium levels) and hypercalciuria (excessive urinary 
calcium excretion) (Figure 6.3). However, our results did not show any bone loss either 
by morphology using Micro-CT or functional test using three points bending mechanical 
test (Figure 6.4). Rudolph et al.  in 1988 [26] conducted a case study with 61 patients and 
showed that EDTA chelation therapy (3 g EDTA, 20 intravenous infusion, 5-9 weeks) 
had no effect on bone density and may even enhance bone growth in patients with 
osteoporosis. One proposed mechanism for EDTA’s effect on bone integrity is that 
EDTA chelation therapy will lower serum calcium, and this would stimulate the 
parathyroid to release parathormone thus pulling Ca out of the bones. However, because 
the release of parathormone is pulsatile, an increase, rather than decrease, of new bone 
formation would occur [172]. Whether this theory was correct or not is still unclear. 
However, our present results indicated that bone loss was not a major adverse event for 
EDTA chelation therapy。 In fact we did find slight increase in maximum load for bone 
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fracture in EDTA group suggesting increase in bone density. However, the major 
possible side effects for EDTA chelation therapy were hypocalcemia, and hypercalciuria 
in our study. However, we did not see EDTA treatment induced renal toxicity (Shown in 
supplementary data, H&E staining of rats’ kidney) such as renal tubular vacuolization 
and pinocytosis by the chelate as shown by others  [18-23]. This might because our 2 
weeks’ EDTA treatment is too short to induce renal toxicity. 
Since systemic EDTA chelation therapy has so many possible side effects, it 
would be important to further investigate how to avoid such side effects. One possible 
way is using targeted EDTA chelation therapy. In fact, we previously showed that local 
placement of EDTA loaded nanoparticles close to calcified aorta in calcium chloride 
mediated injury model could reverse aortic calcification without causing side effects like 
hypocalcemia [28]. Of course, such surgical approach is too invasive and would not be 
feasible clinically. Our lab is currently working on targeted delivery of EDTA loaded 
nanoparticles, which may provide a promising therapy to reverse elastin-specific arterial 
calcification at much lower doses thus preventing systemic side effects.  
Limitations of Current Study 
There are some limitations to our studies. Firstly, our EDTA chelation therapy 
was performed for a period of only two weeks. We do not know if long-term EDTA 
treatment will have therapeutic effects to reverse vascular medial calcification. Secondly, 
we did not investigate possible side effects besides serum calcium, urine calcium, and 
bone loss. More kidney functional evaluation might be necessary such as serum 
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creatinine level. Finally, we only evaluated EDTA chelation therapy in rat CaCl2 injury 
model, which induces local medial calcification at the site of injury. Patients have 
calcification dispersed throughout arterial tree thus calcification animal models such as 
warfarin [96]or vitamin D [99] application where calcification is seen at various places 
such as aortic arch and renal and femoral bifurcation might be necessary in order to 
investigate EDTA chelation therapy’s therapeutic effects. 
6.5 Conclusions 
Our results demonstrated that systemic EDTA chelation therapy for 2 week period 
did not reverse local elastin specific aortic calcification in rats. We also showed that such 
therapy caused side effects of hypocalcemia and hypercalciuria but it did not cause bone 
loss. Thus, reversal of medial elastin calcification may not be achieved by short-term 
systemic EDTA therapy. As such calcification is seen patients with CKD who already 















Figure 6.5. H&E staining for rats’ kidneys. No treatment induced histological change 
































CHAPTER 7: TARGETED EDTA CHELATION THERAPY TO REVERSE 
CALCIFICATION   
7.1 Introduction 
Medial arterial calcification (MAC), termed as Monckeberg’s sclerosis, is a type 
of vascular calcification disease that mostly occurs as linear deposits along elastic 
lamellae [3]. Vascular calcification, including MAC, is a strong predictor of 
cardiovascular morbidity and mortality [98]. Almost no research except one recent study 
from our laboratory has been directed at reversing of elastin specific MAC [6, 28]. Our 
previous studies showed EDTA  might be a promising chelating agent to reverse elastin 
calcification both in vitro [28]. One recent clinical trial in the US from 2008 to 2013, 
named Trial to Assess Chelation Therapy (TACT), aimed to determine the safety and 
effectiveness of EDTA chelation therapy by systemic infusion in individuals with 
coronary artery disease [240]. Published results of TACT showed that intravenous 
chelation regimen with EDTA modestly reduced the risk of adverse cardiovascular 
outcomes but did not specifically highlight EDTA chelation therapy whether or not could 
reverse vascular calcification [246].  
Systemic chelation therapy using chelating agents such as EDTA or sodium 
thiosulfate to reverse calcification requires a high dosage and has side effects such as 
hypocalcemia, bone loss and renal toxicity [14, 18, 119]. Due to these reasons and short 
half-life of EDTA in circulation, no conclusive evidence is available about reversing 
arterial calcification by chelation therapy. Our results in previous chapter with systemic 
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EDTA therapy did not show reversal of MAC when delivered systemically as intravenous 
injection. It also caused loss of blood calcium and increase in urine calcium. We 
hypothesize that nanoparticle-based targeted chelating agent delivery could lower the 
dosage required and have many other advantages such as improved bioavailability and 
sustained release of drugs [29]. We have recently shown that the elastin antibody coated 
nanoparticles can be targeted to vascular calcification sites [30].  
Albumin based nanoparticles (NPs) have been shown as a promising nontoxic, 
non-immunogenic drug carrier [183]. Nanoparticle protein engineering therapy using 
albumin NPs offers potential solutions to many of the problems like toxicities associated 
with the solvent-based formulations [247].  
Thus, in this study we tested if albumin NPs may be a good EDTA carrier to 
deliver EDTA to the calcification sites. By surface coating with anti-elastin antibody, we 
show reversal of elastin specific MAC in vitro or in vivo without side effects associated 
with systemic EDTA chelation therapy.  
7.2 Materials and Methods 
Preparation of EDTA loaded albumin NPs 
Albumin NPs were prepared by ethanol desolvation methods [183, 186, 248]. 
Briefly, 200 mg bovine serum albumin was dissolved in 4 mL of distilled and deionized 
water (DD water) and then the pH was adjusted to 8.5 with 6N NaOH. EDTA was added 
to this solution at various concentrations (25, 50, 100 or 200 mg) for loading optimization 
experiments. The aqueous solution was added drop-wise to 16 mL ethanol under probe 
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sonication (20 Watts, Omni Ruptor 400 Ultrasonic Homogenizer, Omni International Inc, 
Kennesaw, GA) to prepare NPs. The particles were stabilized by fixation with 4% 
glutaraldehyde (100 μL) for 1 hour and washed 3 times with DD water. The prepared 
NPs were then lyophilized and stored at 4 ℃ for further use. For NP tracking 
experiments, NPs were loaded with a fluorescent dye (2.5 mg, DiR, 1, 1-dioctadecyl-3, 3, 
3, 3-tetramethylindotricarbocyanine iodide, Biotium, Inc., Hayward, CA) instead of 
EDTA. 
Characterization of EDTA loaded albumin NPs 
Particle size and Zeta potential in suspension was determined using 90Plus 
Particle Size Analyzer (Brookhaven Instruments Co, Holtsville, NY). 10 µl of 
nanoparticle suspension was diluted in 3 ml of HPLC-grade water in a disposable plastic 
cuvette. Particle size was also measured by transmission electron microscope (TEM, 
H7600, Japan). Briefly, 20 µl of nanoparticle suspension (0.1 mg/ml) was added on a 
formvar-coated copper grid and allowed to be dried overnight under reduced vacuum, 
and then copper grid was loaded into the sample chamber of the TEM. 
EDTA loading efficiency: 
The drug loading efficiency was calculated using the formula: 
Loading efficiency (%) = (
                        
                               
)                                              ⑴ 
The amount of entrapped EDTA was back calculated by subtracting the amount of 
non-entrapped EDTA in NPs mixture after separation of synthesized EDTA loaded 
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albumin NPs. The supernatant wash solution mentioned above during NPs preparation 
was collected for calculation of non-entrapped EDTA amount. EDTA was analyzed 
based on a standard curve using EDTA-FeCl3 complex by Ultraviolet–visible(UV-Vis) 
spectroscopy with peak absorption at 257 nm[249].  
In vitro EDTA release 
In vitro release studies were performed by incubating 2 mg EDTA loaded albumin 
NPs nanoparticles in 1ml of 0.1M Phosphate buffered saline (PBS) at pH 7.4. The NP 
suspension was shaken continuously at 37 ℃. At pre-selected times (2, 4, 8, 24, 48, 72, 
96 and 120 hours), the supernatant was collected for EDTA quantification.  
Determination of cell toxicity and uptake of NPs 
For cellular cytotoxicity concentrations of 100, 1000 µg EDTA loaded albumin 
NPs /ml cell culture media were used to evaluate possible toxicity to rat aortic smooth 
muscle cells (RAMSCs, passage 6). Briefly, RAMSCs were seeded at 10,000 cells/cm
2
. 
When reached at 70% confluency, RAMSCs were incubated with nanoparticles for 4 
hours. Then cell viability was determined using a LIVE/DEAD Cell Viability assay 
(Molecular Probes, Grand Island, NY). The live controls are cells cultured on normal 
media while dead controls are cells treated by 70% ethanol. Cells that have green 
fluorescence are considered alive while cells that have red fluorescence are considered 
dead in this stain. 
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Cellular cytotoxicity was also evaluated using MTT (3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay. Briefly, 5 mg of MTT (Sigma 
Aldrich, St.Louis, MO) was dissolved in 10 ml of PBS and then were added to RAMSCs. 
After 4 hours, PBS was carefully aspirated and the insoluble formazan dye was collected 
with dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, MO). Absorbance was read 
at 560 nm and normalized to control (normal media) readings.  
To visualize cellular uptake of NPs (After antibody coating, described later), NPs 
with same concentrations of 100 µg NPs/ml media and 1000 µg NPs /ml media were 
tested. DiR dye (Biotium, Inc., Hayward, CA) was used to label the NPs. 24 hours after 
DiR-labeled NPs’ incubation, the cells were thoroughly washed with PBS three times to 
remove unbound nanoparticles, fixed with 4 % formaldehyde, labeled with the lipophilic 
membrane stain DiI (or 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine 
Perchlorate, Invitrogen, Carlsbad, CA). Imaging of cells was performed using fluorescent 
microscopy (EVOS fl. Microscope, Advanced Microscopy Group, Bothell, WA).    
Demineralization of calcified tissue in vitro  
Calcified porcine aortic elastin (160~180 µg Ca/mg tissue) was prepared by 
subdermal implantation of pure porcine aortic elastin in rats as described in earlier 
publication [200].  
Calcified human aortas (100~300 µg Ca/mg tissue) from cadavers (age 49-75, 
both male and female with moderate or severe atherosclerosis) were received from the 
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Greenville Hospital System (Greenville, SC) following standard dissection technique. All 
samples were from the abdominal aorta, just below the renal arteries.  
To determine EDTA loaded albumin NPs’ efficacy to remove calcium from 
calcified tissue, calcified porcine aortic elastin and separately calcified human aorta (10 
mg each) were soaked in 10 ml EDTA loaded albumin NPs dispersion (10 mg/ml in PBS, 
n=3) with constant shaking at 37 ℃. The control groups were soaked in 10 ml blank 
albumin NPs without EDTA loading (10mg/ml in PBS, n=3). 3 days after treatments all 
tissue samples were embedded in paraffin blocks, sectioned, and stained for qualitative 
analysis of calcium with Dahl’s alizarin red stain. 
Antibody coated EDTA loaded albumin NPs – preparation and optimization for antibody 
binding 
  The antibody surface coating strategy for albumin NPs is illustrated in Figure 
7.1A. Antibody thiolation: 10 µg of antibodies were thiolated using 34 µg of freshly 
prepared Traut’s reagent (G-Biosciences, Saint Louis, MO) in 0.1 ml of PBS for 1 hour. 
Antibodies used include Alexa-Fluor 555 goat anti-mouse IgG (Molecular Probes, 
Carlsbad, CA), rabbit anti-rat IgG antibody (Thermo Scientific, Rockford, IL) and rabbit 
anti-rat elastin antibody (United States Biological, Swampscott, MA). Thiolated 
antibodies were washed three times with PBS and dialyzed through 10 kDa MWCO 
filters to remove Traut’s reagent.  
Albumin NPs conjugate to Maleimide-PEG- NHS ester: EDTA loaded albumin 
NPs were prepared as described earlier. Albumin NPs were activated with 
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heterobifunctional crosslinker α-maleimide-ω-N-hydroxysuccinimide ester poly (ethylene 
glycol) (Maleimide-PEG- NHS ester, MW 2000 Da, Nanocs Inc.,NY, USA) in order to 
achieve a sulfhydryl-reactive particle system.  2.5 mg of Maleimide-PEG- NHS ester 
solution was added into 10 mg albumin NPs dispersion. Then the mixture was left under 
shaking for 1 hour at room temperature.  
Albumin NPs conjugate to antibodies: purified and thiolated antibodies were then 
added to the activated albumin NPs and incubated overnight at room temperature for 
conjugation. Samples were centrifuged and the supernatant was analyzed using 
fluorescent spectrometry (n=3). A calibration curve was plotted from standard solutions 
(0.1-25µg of Alexa-Fluor 555 goat anti-mouse IgG in 1 ml of PBS). The bound dye was 







Figure 7.1. A: Schematic representation of antibody surface coating strategy for albumin 
NPs.  1) Antibody thiolation using traut’s reagent to produce a terminal sulfhydryl group 
on antibody. 2) Albumin NPs conjugated to NHS ester-PEG-Maleimide with amide bond. 
3) Antibody conjugated to albumin NPs with maleimide – sulfhydryl reaction. B: 
Experimental protocol for CaCl2 injury model and treatments of rats. CaCl2 injury model 
(represented as a symbol of arrows) was created at starting time point of experiment (Day 
0, week 0). There were total five treatment groups with following treatments by tail vein 
injection (two times a week, two weeks): 1) saline as control group (n=5, 5 rats); 2) High 
dose (HD) EDTA group (n=5, 5 rats, 50 mg/kg EDTA); 3) Low dose(LD) EDTA group 
(n=3, 3 rats, 2.5 mg/kg EDTA); 4) IgG-NPs/EDTA group (n=5, 5 rats, 5 mg of NPs for 
each rat at each injection); 5) EL-NPS/EDTA group (n=5, 5 rats, 5 mg of NPs for each rat 
at each injection). Rats were placed in metabolic cages for urine collection for 24 hours 
(Day 21); then all rats were given another injection on Day 22  (depending on individual 
treatment groups) and then urine samples were taken at time points of 1, 2, 3 and 4 hours 
post injection; right after that rats were euthanized and organs were harvested 
(represented as a symbol of six-point stars).  
 
Immunostaining to visualize antibody coating on NPs 
Rabbit anti-rat IgG antibody coated albumin NPs (IgG-NPs) were prepared as 
described earlier. 0.1 ml of NPs (1 mg/ml) without antibody coating and IgG-NPs (2 µg 
IgG/mg NPs,  1 mg/ml) were incubated with 0.1 ml of 10 nm gold stained goat-anti-
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rabbit IgG (Sigma Aldrich, St.Louis, MO) overnight in 0.01M tris buffered saline (TBS), 
with 0.05% bovine serum albumin and 15% glycerol and 7.5 mM sodium azide. NPs 
were washed twice with TBS to remove unbound antibodies at 14,000 × g for 15 minutes 
after incubation. Then 20 µl of NPs’ suspension (1 mg/ml) was added on a formvar-
coated copper grid and allowed to be dried overnight under reduced vacuum. Antibody 
surface conjugation was then analyzed by TEM. 
Ex-vivo nanoparticle targeting studies using elastase damaged aorta  
Aortas from Sprague-Dawley rats (Pel-Freez Biologicals, Rogers, AR) were used 
in these studies (n=2, 2 samples in each group, total 8 groups). High purity porcine 
pancreatic elastase (Elastin products company, Owensville, Missouri) was prepared 
(5U/ml) in 100mM Tris Buffer, 1mM calcium chloride, 0.02% sodium azide, pH 7.8. 
Elastase damaged aortas were prepared by injecting elastase intra-luminally for 1 hour to 
mimic a damaged aorta in medical calcification [30]. Intra-luminal injection was done by 
clamping both ends of the aorta during injection.  
Rabbit anti-rat elastin antibody coated albumin NPs (EL-NPs) or rabbit anti-rat 
IgG antibody coated albumin NPs (IgG-NPs) loaded with DiR dye were prepared by 
following the same method as described earlier, Antibody coated NPs were injected 
either in control fresh healthy aortas (without elastase treatment) or with elastase 
damaged aortas. Following injection, the aortas were thoroughly washed 3 times with 
PBS to minimize non-specific adherence of nanoparticles. The bound NPs (DiR dye 
fluorescence) in aortas were quantified by Caliper IVIS Lumina XR image system 
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(Hopkinton, MA) with Ex/Em of 745/810 nm. The dry weights of the aortas were 
recorded for fluorescent density normalization.  
In vivo nanoparticle targeting studies based on local periadventitial CaCl2 injury model 
CaCl2 injury model was used to mimic local aortic calcification at the abdominal 
aortic region following previous protocol [27, 28]. Briefly, 6 male Sprague-Dawley (SD) 
rats (6 to 8 weeks old) were anesthetized by 2-3% isoflurane.  A ventral laparotomy 
exposed the peritoneal cavity. A 15 mm section of the infrarenal abdominal aorta was 
exposed and injury was created by placing 0.5 M CaCl2 soaked sterile cotton gauze on 
top of the aorta for 15 minutes. After CaCl2 application, the gauze was removed and the 
area was briefly flushed with warm saline. Incisions were then closed with continuous 
sutures (Abdominal and subcutaneous) and surgical staples. Then rats were allowed to 
recover and maintained in standard chow conditions for one week.  
After one week (when calcification in injured site is seen), rats were anesthetized 
and EL-NPs/IgG-NPs were injected through the tail vein (10 mg of NPs/kg body weight 
in 0.1 ml saline). Rats were euthanized 24 hours after the injection.  
Only organs that showed fluorescent signal were lyophilized and used to calculate 
bio-distribution, which include aorta, heart, lung, liver, kidney, spleen. All other organs 
and tissue such as brain, muscle, skin, and blood did not have detectable fluorescent 
signal.  
Percentage of targeting for each organ was calculated as follows: 
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%targeting   
                       
                                 
  ) / (dry weight of organ))*100 
In vivo nanoparticle therapeutic efficacy studies based on local periadventitial CaCl2 
injury model 
An illustration of experimental design for this animal study was shown in Figure 
7.1B. Firstly at starting time point (Day 0) CaCl2 injury was created same as mentioned 
above. CaCl2 injury model mimics local elastin specific MAC.  One week later rats were 
divided into five groups for the following treatments by tail vein injection (two times a 
week, two weeks): 1) saline as control group (n=5); 2) High dose (HD) EDTA group 
(n=5, 50 mg/kg EDTA); 3) Low dose (LD) EDTA group (n=3, 2.5 mg/kg EDTA); 4) 
IgG-NPs/EDTA group (n=5, 5 mg of NPs for each rat at each injection); 5) EL-
NPS/EDTA group (n=5, 5 mg of NPs for each rat at each injection). Rats were placed in 
metabolic cages for urine collection for 24 hours at the end of the treatment day (Day 21). 
Then all rats were given another injection on Day 22 (depending on individual treatment 
groups) and then urine samples were taken at time points of 1, 2, 3 and 4 hours post 
injection and were kept in – 80 ℃ for further analysis. Right after that rats were 
euthanized by CO2 asphyxiation and organs were harvested including the aorta (from the 
heart to the iliac bifurcation), blood, femoral bone, kidney, heart, liver and spleen. 
Heparin (10 units/ml blood) was used as anti-coagulant for blood samples and serum was 
removed and stored at – 80 ℃ for further assay. Aorta, kidney, heart, liver and spleen 
were fixed in 10% buffered formalin for further analysis. 
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Aortic calcifications were evaluated by stereomicroscope (Leica M80 stereo 
microscope, Leica Microsystems Inc. Buffalo Grove, IL), micro-computed tomography 
(micro-CT) scanner (Siemens Inveon microPET/CT preclinical scanner, Siemens 
Healthcare Molecular Imaging, USA), histology and atomic absorption spectrometry 
(AAS). Aortas from all rats were cleaned of all adherent tissues by blunt forceps after 
formalin fixation. Plastic tube (PE, 1 mm outside diameter) was inserted into the cleaned 
aortas for easier handling during imaging. Whole aortas were imaged by 
stereomicroscope (Leica M80 stereo microscope, Leica Microsystems Inc. Buffalo Grove, 
IL) both before and after alizarin red staining [96, 243, 244]. Briefly, whole aortas were 
soaked in freshly made 2% alizarin red solution (pH 4.1-4.3, pH) for 10 minutes and 
washed by distilled and deionized water for another 5 minutes. Then aortas were imaged 
by stereomicroscope. Micro-CT for harvested aortas in vitro was based on modified 
protocol [237, 239]. Briefly, a 360-degree axial scan was collected at a peak tube 
potential of 80kVp and tube current of 500uA. Data were reconstructed to 100 μm pixel 
size using a Feldkamp cone beam algorithm. Virtual 2D cross-sections and 3D maximum 
intensity projection views were created using MeVisLab software (MeVisLab, Mevis, 
Bremen, Germany, http://www.mevislab.de). Exported movies from MeVisLab were 
further edited by video-editing software- Corel VideoStudio Pro X7(Corel Inc, Mountain 
View, CA) (Available as online video supplement 4). 
Following the non-invasive imaging by stereomicroscope and micro-CT scanner 
mentioned above, aortas were processed for histology with alizarin red staining for 
visualization of calcium. Remaining parts of abdominal aortas were then used for Ca 
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quantification by atomic absorption spectroscopy, AAS [28, 232]. Briefly, 2 ~ 10 mg of 
abdominal aortas ware hydrolyzed in 1ml of 6N Ultrex HCl (Baker Company, 
Phillipsburg, NJ) and then re-suspended in 0.01N Ultrex HCl. Hydrolyzed samples were 
diluted and analyzed  with AAS. Serum and urine samples were thawed and diluted 
before Ca quantification by AAS.  
Rats’ femoral bones were dissected and fixed in 10% buffered formalin. The 
integrity of femoral bone was evaluated by Micro-CT and by functional mechanical test. 
Stiffness and maximum load were tested based on three points bending test. Micro-CT 
for rats’ femoral bones was done by same protocol as aortas mentioned earlier (One 
representative scanning data for the whole 2D view slices from each group is available as 
online supplement video 5). Three points bending test was done using Bose test machine 
(Electroforce 3200, Bose, MN, USA) equipped with a 450N load cell. First, stiffness was 
tested by measuring bone displacement (in Millimeter, mm) at a given force (in Newton, 
N). Second, bones were exposed to higher force until fracture occurred and the maximum 
enduring load (N) was determined.  
Statistical analysis 
Results are expressed as means ± standard deviation (SD). Statistical analyses of 
the data were performed using single-factor analysis of variance. Differences between 
means were determined using the least significant difference with an α value of 0.05. 





Characterization for EDTA loaded albumin NPs – optimization and function  
The size of NPs was dependent on sonication time; 10, 45 and 60 minutes of 
sonication resulted in 1207.9 ± 177.3, 144.1±10.6 and 121.9 ± 13.5 nm size NPs 
respectively (Figure 7.2A, 7.2B). Studies have shown that particle size with ~200 nm 
could get sufficient retention of nanoparticles in the extracellular matrix and also 
minimum cellular uptake by VSMCs [182, 250, 251]. So all NPs used later were prepared 
by 45 minutes of probe sonication to get particles with ~200 nm size.  Zeta potential of 
NPs after antibody modification is shown in Table 7.1. As we wanted to target 
extracellular matrix elastin and reduce cellular uptake, all NPs used in the animal study 
were negatively charged (due to the inherent negative charge on the mammalian cell 
membrane, negatively charged particles are repelled) (Table 7.1).  EDTA loading 
increased with initial EDTA concentration used but plateaued to ~ 22 % with no further 
increase in loading with additional starting EDTA concentration (Figure 7.2 C). Release 
profile for EDTA loaded albumin NPs showed initial burst and then continuous release 
for up to 5 days (Figure 7.2 D) both before and after antibody modification. The amount 
of total EDTA was slightly lower after antibody modification because of loss during 
washing steps in antibody coating.  
EDTA loaded albumin NPs did not cause cytotoxicity to RASCMs based on 
Live/Dead assay and MTT assay in the range of 100 µg NPs/media to 1000 µg 
NPs/media (Figure 7.2 E and 7.2 F). EDTA loaded albumin NPs did not show cellular 
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uptake in the concentration range between 100 µg NPs/media to 1000 µg NPs/media 
(Figure 7.2 G). EDTA loaded albumin NPs could remove calcified mineral efficiently 
both from calcified elastin and calcified human aorta samples as shown by Alizarin red 
stain (Figure 7.2 H). The blank albumin NPs without EDTA loading were unable to 
regress calcification (Figure 7.2 H).  
Table 7.1. Characterization of nanoparticles. 
Type of 
nanoparticle 




ζ- potential ±  SD 
(mV) 
IgG-NPs/DiR 177.9 ± 21.6 0.795 - 22.89 ± 5.28 







Figure 7.2. Characterization for albumin NPs – optimization and function. A: Particle 
size measured by 90Plus Particle Size Analyzer with sonication times of 10, 45, and 60 
minutes. B:  Images showed particle size measured by TEM with corresponding 
sonication times. C: Loading efficiency with serials of EDTA and albumin ratios. D: 
Release profile for EDTA loaded albumin NPs before and after antibody modification. 
Ab: antibody. E: LIVE/DEAD cell viability assay. Live control - normal media; Dead 
control - treated by 70% ethanol; 100 µg NPs/ml media and 1000 µg NPs /ml media are 
two studies groups. Magnification: 100X. Scale bar: 400µm. F: Cell viability determined 
by MTT assay. G: Cellular uptake study with two NPs’ concentrations of 100 µg NPs/ml 
media and 1000 µg NPs /ml media. Red fluorescence: cell membrane stained by 
lipophilic membrane stain DiI (Excitation/Emission: 549/565nm). Purple fluorescence: 
albumin NPs stained by DiR near-infrared dye (Excitation/Emission: 745/810 nm). 
Magnification: 100X. Scale bar: 400µm. H: Demineralization of calcified elastin and 
calcified human aorta. Blank albumins NPs without EDTA were control groups. EDTA 
loaded albumin NPs were study groups. Alizarin red stains calcium as red and 
counterstained by light green. Magnification: 100X. Scale bar: 100 µm. 
 
Antibody coated EDTA loaded Albumin NPs – antibody binding and targeting efficacy 
in vitro  
Antibody binding yield was assessed by Alexa-flour 555 labeled IgG based on 
standard curve (data not shown) of Alexa-fluor 555 conjugated IgG with 
excitation/emission: 555/595 nm. The amount of IgG bound to albumin NPs increased 
with more starting amount of antibody added but the bound percentage peaked around 5 
µg IgG / mg albumin NPs (Figure 7.3 A and 7.3 B). Successful antibody coating was 
also verified by gold immune-staining under TEM showing 10 nm gold particles on the 
surface in the IgG-NPs (2 µg/mg IgG-NPs) while no gold particles presented in the 
control NPs without antibody coating (Figure 7.3 C).  
Control healthy aortas without NPs treatment showed no auto-fluorescence 
(Figure 7.3 D); Control healthy aortas without elastase damage showed little 
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fluorescence. This indicated that either IgG-NPs or EL-NPs would not bind to healthy 
aortas. Only damaged aortas (with antibody concentration of 1, 2.5, 5 and 10 µg/mg EL-
NPs) had strong fluorescence. The relative percentages of EL-NPs bound to damaged 
aortas were normalized to control samples (1 µg/mg IgG-NPs). Fluorescent density was 
quantified based on IVIS fluorescent counts (Figure 7.3E) and showed that antibody 
concentration in range of 1 to 5 µg/mg EL-NPs could increase NPs binding to 159.8 % (1 
µg/mg EL-NPs) or 176.1% (5 µg/mg EL-NPs). 2.5 µg/mg EL-NPs had good targeting 
efficacy (Figure 7.3E) and higher ratio of antibody to NPs did not significantly increase 
targeting efficacy so this ratio was chosen for later animal studies.  
 
Figure 7.3. Antibody binding and targeting efficacy in vitro. A: Amount of IgG antibody 
bound in 1 mg of albumin NPs with serials of starting ratio of antibody and albumin NPs 
(1, 5, 10, 25 µg IgG/mg NPs). B: Percentage of IgG antibody bound with albumin NPs 
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with serials of starting ratio of antibody and albumin NPs (1, 5, 10, 25 µg IgG/mg NPs). 
C: Gold immune-stained albumin NPs by TEM. Left: NPs without antibody coating 
serviced as negative control. Right: NPs with IgG antibody coating, antibody 
concentration used: 2 µg/mg IgG-NPs. Small black dots on NPs’ surface (right) represent 
10 nm gold stained IgG. D: Fluorescent image for aortas by IVIS image system. Aortas 
of numbers 1 to 8 are controls. Aortas of numbers 9 to 16 are study groups. Samples 7 to 
16 in red rectangle area were used for DiR quantification. E: Quantification of EL-NPs 
bound percentage by fluorescent density from IVIS images. C in horizontal axle: control 
groups of sample 7 and 8(Damaged aortas and treated with 1 µg/mg IgG-NPs). 
Fluorescent density of study groups (aortas numbers 9 to 16) were normalized to control 
groups of sample 7 and 8.  
 
Efficacy of EL-NPs targeting to damaged aorta in vivo 
Most of the DiR dye was entrapped permanently in albumin NPs (data not shown), 
thus NP tracking with fluorescence was possible for bio-distribution in animal studies. 
Photography, fluorescence and X-ray image for all six aortas has been shown in Figure 
7.4A.  Red rectangle areas show where injury caused elastin damage and calcification in 
the abdominal aortas.  Those areas showed considerably more fluorescent signal in the 
study groups (treated with EL-NPs/DiR) and no fluorescence for IgG-NPs/DiR. 
Representative histological sections from damaged aortas both from EL-NPs/DiR and 
EL-NPs/DiR treated groups showed that EL-NPs had better targeting efficacy and could 
infiltrate from lumen to adventitia in damaged blood vessel (More purple fluorescence 
from DiR dye labeled as red arrows in Figure 7.4B). Green fluorescence was auto-
fluorescence from aortic tissue section. EL-NPs treated groups had more NPs distribution 
in aortas (15.98% in EL-NPs versus 5.75% in IgG-NPs) while less in spleen, kidney, lung 




Figure 7.4. Efficacy of EL-NPs targeting to damaged aorta in vivo. A: Photography, 
fluorescent image and X-ray image taken by IVIS image system. IgG-NPs/DiR: rabbit 
anti-rat IgG antibody modified albumin NPs entrapped with DiR dye. EL-NPs/DiR: 
rabbit anti-rat elastin antibody modified albumin NPs entrapped with DiR dye. The red 
rectangle areas were calcified and damaged region detected by X-ray. B: Fluorescent 
microscopy of abdominal aorta from representative histological section. Purple 
fluorescence: albumin NPs stained by DiR near-infrared dye (Excitation/Emission: 
745/810 nm). Green fluorescence: auto-fluorescence from aortic tissue section. Red 
arrows indicated area with more purple fluorescence. Left: aortic section from IgG-
NPs/DiR groups as control. Right: aortic section from EL-NPs/DiR groups which 
indicated that EL-NPs had better targeting efficacy and could infiltrate from lumen to 




Table 7.2. Organ distribution of fluorescent nanoparticles.  
Organ % total fluorescence/g dry weight  
(IgG-NP/DiR) 
% total fluorescence/g dry weight  
(EL-NP/DiR) 
Aorta  5.75 ±  0.54 15.9 8 ±  0.87 
Liver 32. 47 ±  0.83 36.60 ±  8.44 
Spleen 35.55 ± 3.55 30.84 ±  5.48  
Kidne
y 14.38 ± 1.81 11.59 ±  2.77 
Lung 6.76 ±  0.23 3.37 ± 0.49 
Heart 5.10 ±  3.18 1.61 ±  0.30 
 
Therapeutic effects of targeted EDTA chelation therapy to reverse calcification  
Aortic calcification for both systemic EDTA chelation therapy and targeted 
EDTA chelation therapy is shown in Figure 7.5. Aortic calcification evaluated by 
stereomicroscope before and after whole aorta’s alizarin red stain, Micro CT, and 
histological stain by alizarin red showed that EL-NPs/EDTA groups showed best 
therapeutic effects to reverse aortic calcification (Figure 7.5A). Four out of five aortas 
showed complete reversal of calcification. No other groups including IgG NPs, low and 
high EDTA systemic injections showed any significant reduction in calcification of the 
aorta (Figure 7.5 A). These staining results corroborated calcium quantification in aorta 
by AAS. Quantitative calcium results also showed that EL-NPs/EDTA groups had best 
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therapeutic effect to reverse aortic calcification and had lowest Ca amount in the aorta 







Figure 7.5. Evaluation of aortic calcification for both systemic EDTA chelation therapy 
and targeted EDTA chelation therapy. A: Aortic calcification evaluated by 
stereomicroscope before and after whole aorta’s alizarin red stain, Micro CT and 
histological stain by alizarin red. Here showed results of IgG-NPs/EDTA and EL-
NPs/EDTA groups. B: Ca quantification in aorta by AAS for all five treatment groups 
(For IgG-NPS/EDTA and EL-NPs/EDTA groups, P = 2.63E-06, n =5).  
 
Targeted EDTA chelation therapy did not have side effects associated with systemic 
EDTA chelation therapy 
Possible side effects with both systemic EDTA chelation therapy and targeted 
EDTA chelation therapy are shown in Figure 7.6. Results showed no side effects to 
serum and urine Ca as seen in high dose EDTA treated groups in EL-NPs/EDTA groups, 
or targeted EDTA chelation therapy groups, (Figure 7.6A, P = 0.0045, n = 5; Figure 
7.6B, P = 0.0001, n = 5; Figure 7.6C). Similarly, there were no bone losses seen in all 
treated groups both from morphology and from functional test of stiffness and fracture 







Figure 7.6. Possible side effects with systemic EDTA chelation therapy and targeted 
EDTA chelation therapy. A: Serum Ca quantification for all five treatment groups (For 
Saline and HD EDTA groups, P = 0.0045, n = 5). B: Urine Ca quantification for all five 
treatment groups (For Saline and HD EDTA groups, P = 0.0001, n = 5). C: Urine kinetic 
Ca quantification after tail vein injection of all five different reagents up to four hours. D: 
Bone morphology analyzed by Micro CT showing 15 mm below the trochanter major of 
femoral bone for all five treatment groups. E: Stiffness of femoral bone for all five 
treatment groups. F: Maximum load of femoral bone for all five treatment groups (For 
Saline and HD EDTA groups, P = 0.027, n =3). 
 
7.4 Discussion 
To our knowledge this is the first time anyone has shown that targeted 
nanoparticles when injected systemically can bind to calcified artery and regress 
calcification in vivo. Vascular calcification occurs at two different sites- intima and media. 
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Intimal calcification is generally associated with atherosclerotic plaques and 
inflammation and can occlude the lumen while medial calcification occurs in the elastin 
lamina of medium and large arteries in patients with chronic kidney disease (CKD) or 
diabetes causing increase in arterial stiffness. Surgical methods like directional 
atherectomy and stent grafts are used to treat atherosclerosis and intimal calcification and 
to open occluded arteries [4, 5]. However, there are no treatments available for medial 
elastin-specific calcification.  
Chelation therapy has been touted to remove calcification of arteries, mostly for 
intimal atherosclerotic calcification; however, very few animal studies have been 
performed and none of the clinical studies have proven its effectiveness in improving 
cardiovascular function [174, 176].  We wanted to test if elastin-specific medial 
calcification can be removed by targeted chelation therapy. We chose EDTA as our 
previous comparative study of three chelating agents: EDTA, sodium thiosulfate and 
DTPA (diethylene triamine pentaacetic acid) showed that EDTA worked best to remove 
calcium from hydroxyapatite and calcified tissue [28].  In the same study, we have also 
shown that local placement of EDTA loaded poly(lactic-co-glycolic) acid (PLGA), 
nanoparticles on top of calcified aorta after exposing calcified abdominal aorta by ventral 
laparotomy, could effectively reverse elastin-specifically medical calcification in a rat 
calcification model [28]. However, such invasive procedure cannot be translated for 
human use. In an attempt to target drugs to diseased arteries, we recently discovered that 
specifically designed NPs with elastin-targeting antibodies on the surface were able to 
deliver agents to the site of elastic-lamina damage [30]. Elastin fibers in elastic lamina in 
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healthy artery are covered with microfibrillar glycoproteins and thus not accessible to 
elastin antibody targeted to elastin. In most vascular diseases, elastic lamina gets 
damaged and elastic fibers get exposed. We used this knowledge to create NPs that 
specifically targeted to diseased site in artery [30]. These previous studies paved the way 
to design an elastin antibody coated and EDTA loaded albumin NPs to reverse elastin-
specific MAC and to avoid side effects associated with systemic EDTA chelation therapy. 
We choose albumin nanoparticles instead of polymeric nanoparticles like PLGA or PLA 
(Polylactic acid) because albumin NPs are less toxic as no organic solvents are used in 
preparation and used frequently in clinical applications [183, 247]. We could also load 
significant amount of EDTA in albumin NPs rather than PLGA NPs. 
We optimized surface charge and size of albumin NPs so that they are not taken 
up by cells and remain in the extracellular matrix.  Others have shown that small particle 
size less than 100 nm would have more uptake in vascular smooth muscle cells [250] 
while big particles larger than 500 nm could not effectively penetrate endothelium and 
basement membrane in blood vessels. Previous results in our lab indicated that 
nanoparticles of ~200 nm size were able to penetrate both the endothelium and the 
basement membrane and also limited cellular uptake [30]. The size of EDTA loaded 
albumin NPs was quite dependent on the duration of sonication time and we found that 
45 minutes of probe sonication resulted in 150~200 nm size. Since mammalian cell 
membrane has negative charge, negatively charged particles show less cellular uptake 
[252]. Our result showed that our negatively charged albumin NPs with size of 150~200 
nm have limited cellular uptake. We could load up to 20 % EDTA (wt/wt) and NPs 
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sustained release of EDTA for up to 5 days. We found EDTA loaded albumin NPs did 
not cause significant cell death or uptake. Next we checked if such NPs can remove 
calcium from calcified elastin and human aorta in vitro. Indeed, EDTA releasing NPs 
when incubated with calcified tissues removed calcium both from calcified elastin and 
calcified human aorta in vitro. Once the charge, size, and targeting and therapeutic 
efficiency was tested in vitro , we next designed in vivo experiments to test if such NPs 
can deliver EDTA to the calcified aorta under high shear and blood flow present in the 
aorta. We injected NPs through rat tail vein and allowed them to circulate and target to 
the site. We clearly found that NPs (with DiR dye) with elastin antibody on the surface 
(EL-NPs/DiR) did accumulate at the inured aortic site while IgG-NPs with DiR did not. 
We then injected NPs containing chelating agent EDTA with either elastin antibody on 
the surface (EL-NPs/EDTA) or irrelevant IgG antibody (IgG-NPs/EDTA). We decided to 
inject NPs 2 times a week based on in vitro release profile for EDTA. Within 2 weeks of 
injections (total 4 injections) we could observe complete removal of calcium from 4 out 
of 5 arteries in EL-NPs EDTA group as confirmed by alizarin red staining, microCT, and 
quantitative calcium scores. Not only calcium was removed but the elastic lamina seemed 
to be less damaged after removal of calcium. On the other hand EDTA loaded IgG NPs 
did not target to the site and did not remove any calcium. We also injected EDTA 
systemically in the same manner NPs were delivered (2 times a week), either in high dose 
(similar to what is used clinical studies) or low dose (based on how much total EDTA 
was delivered through NPs). In both of these direct injection cases, EDTA failed to 
remove calcium from the arteries as there was no change in calcification seen by alizarin 
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red staining, quantitative calcium results, and microCT experiments. Moreover, we found 
that EDTA dose similar to what used clinically (50 mg/kg) caused significant adverse 
events for serum and urine calcium, specifically hypocalcemia and hypercalciuria. Our 
NPs contained 20 times lower EDTA (which was protected) and it was released slowly 
over a period of five days. Thus, we did not find any systemic toxicity for nanoparticle 
groups. Thus, elastin antibody coated and EDTA loaded albumin NPs might be a 
promising nanoparticle protein engineering therapy to reverse elastin-specific medial 
calcification. This targeted nanoparticle delivery method will lower the dosage required 
for chelating agent - EDTA so as to avoid side effects associated with systemic 
intravenous infusion such as hypocalcemia and bone loss [14, 18, 119]. It is a safe and 
non-invasive method to reverse calcification compared to surgical methods. Antibody-
mediated tissue targeting of albumin NPs for clinical practice has been approved by the 
FDA for other drugs [253, 254] so our antibody coated albumin NPs have great potential 
clinical relevance.  
Limitations of Our Study: There are some limitations to our studies. First, our 
EDTA chelation therapy was performed for a period of only two weeks. We do not know 
if calcification will return after halting the therapy and also we do not know long the NPs 
will stay at the of calcification after intravenous injection. Secondly, we did not 
investigate possible side effects besides serum calcium, urine calcium, and bone loss. 
More kidney functional evaluation might be necessary such as serum creatinine level. 
Finally, we only evaluated EDTA chelation therapy in rat CaCl2 injury model, which 
induces local medial calcification at the site of injury. Patients have calcification 
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dispersed throughout arterial tree thus  calcification  animal models such as warfarin 
[96]or vitamin D [99] application where calcification is seen at various places such as 
aortic arch and renal and femoral bifurcation might be necessary in order to investigate 
EDTA chelation therapy’s therapeutic effects. Careful risk-benefit analysis needs to done 
before use in individual human patients.  
7.5 Conclusions 
We prepared EDTA loaded albumin NPs with optimized size of 150~200 nm, 
zeta potential of – 22.89 ~ - 31.72 mV, loading efficiency of 15~ 20 %, and a sustained 
release of EDTA for up to 5 days. Both ex-vivo study and in vivo study using aortic 
calcification model showed that elastin antibody coated and EDTA loaded albumin NPs 
could have good targeting efficacy and also therapeutic effects to reverse elastin-specific 
medial calcification. EDTA loaded albumin NPs did not cause side effects of serum and 
urine Ca, as seen in high dose EDTA treated groups. There was no bone loss in all treated 
groups. Elastin antibody coated and EDTA loaded albumin NPs might be a promising 
nanoparticle protein engineering therapy to reverse calcification in elastin-specific medial 
calcification and to avoid side effects associated with traditional EDTA chelation therapy 











Figure 7.7. H&E staining for rats’ kidneys (All five groups). No treatment induced 








Figure 7.9. Graphical abstract to show nanoparticle structure and targeting and chelation. 
A: nanoparticle schematic. EDTA (yellow) was encapsulated into albumin nanoparticles 
(NPs, green). EDTA was chelating agent to chelate calcium complex deposition along 
elastic lamina fibers. NHS ester-PEG-Maleimide was bifunctional spacer. NHS ester 
formed a stable amide bond through amine group on albumin. Reaction of a sulfhydryl on 
antibody (blue) to the maleimide group results in formation of a stable thioether linkage.  
B: NPs targeting and chelation schematic. Elastic fibers are formed by 90% mature cross-
linked elastin core and 10% microfibrils (arrows) components. In disease state 
mircofibrils degrade and calcium complex depositions occur along elastic lamina fibers. 
Exposed elastin allows elastin antibody coated albumin NPs (EL-NPs) targeting and 
released EDTA chelates calcium complex depositions (purple) eventually reverse elastin-





Figure 7.10. DiR standard curve and release profile in vitro.  
 
Methods for figure 7.9: Characterization of antibody coated EDTA loaded albumin 
NPs - DiR release profile in vitro  
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A DiR standard curve was plotted using a serial of standard solution (0, 0.05, 0.10, 0.15, 
0.25 mg DiR/ml in DD water) by fluorescent spectrometry (Excitation/Emission of 
745/810 nm). 5 mg of NPs (n =3, prepared as described earlier, after antibody coating) 
were soaked in 1ml of PBS at pH 7.4. The NPs suspension was continuously shaken at 
37 ℃. At pre-selected times (2, 4, 6, 8, and 24 hour), The supernatant was collected for 
DiR quantification.  After 24 hours the NPs were homogenized by Powered 125 
homogenizer (Fisher Scientific, MA) and Omni Ruptor 400 Ultrasonic Homogenizer 
(Omni International Inc, Kennesaw, GA) to extract non-released DiR in PBS. The 
supernatant was collected to detect entrapped DiR after 24 hours. Our data showed that 
DiR release was less than 30% (data not shown) within in 24 hours. Most of the DiR dye 
would still be entrapped in albumin NPs after 24 hours. So the near-infrared fluorescent 
signal from DiR dye could be used to track the albumin NPs bio-distribution in animal 





Figure 7.11. NPs bio-distribution present by organs. A summary of all 6 rats’ NPs 
distribution based on near-infrared fluorescent signal based on DiR dye (Ex: 745 nm, Em: 





Figure 7.12. NPs bio-distribution present by individual rats. A summary of all 6 rats’ 
NPs distribution based on near-infrared fluorescent signal based on DiR dye (Ex: 745 nm, 










CHAPTER 8: CONCLUSIONS AND RECOMMENDATIONS   
8.1 Conclusions  
The broad goal of this project was to understand mechanisms of elastin specific 
MAC, to evaluate efficacy of chelating agents to reverse elastin specific MAC, to 
evaluate therapeutic effects of systemic disodium ethylene diaminetetraacetic acid 
(EDTA) chelation therapy in the aspect of reversal of calcification and possible side 
effects, and to develop a targeted delivery system to reverse elastin specific MAC and to 
avoid side effects.  
We show the following: 
1) In aim 1, we demonstrate that RASMCs lose their smooth muscle lineage markers 
like alpha smooth muscle actin (SMA) and myosin heavy chain (MHC) and undergo 
chondrogenic/osteogenic transformation in presence of mineral deposits. This is 
indicated by an increase in the expression of typical chondrogenic proteins such as 
aggrecan, collagen type II alpha-1 (Col2a1) and bone proteins such as runt-related 
transcription factor 2 (RUNX2), alkaline phosphatase (ALP) and osteocalcin (OCN). 
Furthermore, when calcified conditions are removed, cells return to their original 
phenotype. Our data supports the hypothesis that elastin degradation and calcification 
precedes VSMCs’ osteoblast-like differentiation. 
2) In aim 2, we show that both EDTA and diethylene triamine pentaacetic acid (DTPA) 
could effectively remove calcium from HA and calcified tissues, while sodium 
thiosulfate (STS) was not effective. The tissue architecture was not altered during 
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chelation. In the animal model of aortic elastin-specific calcification, we further 
show that local periadventitial delivery of EDTA loaded in to poly (lactic-co-glycolic 
acid) (PLGA) nanoparticles regressed elastin specific calcification in the aorta. 
Collectively, the data indicate that elastin-specific medial vascular calcification could 
be reversed by chelating agents. 
3) In aim 3, we demonstrated that systemic EDTA chelation therapy did not reverse 
local aortic calcification. Systemic EDTA chelation therapy caused adverse events 
for serum and urine calcium, specifically hypocalcemia and hypercalciuria, but did 
not cause bone loss or affect kidney function may be due to short treatment times of 
two weeks. These results indicated that systemic EDTA chelation therapy might not 
have therapeutic effects in the aspect of reversal of calcification and a strict protocol 
is required for safety dosage.   
4) In aim 4, we developed EDTA loaded albumin Nanoparticles (NPs) that could 
release EDTA slowly. We prepared EDTA loaded albumin NPs with optimized size 
of 150~200 nm, zeta potential of – 22.89 ~ - 31.72 mV, loading efficiency of 15~ 20 
%, and a sustained release up to 5 days. We further show that when such NPs were 
decorated on the surface with elastin antibody, they could be targeted to degraded 
elastic lamina efficiently when administrated by intravenous injection. Both ex-vivo 
study and in-vivo study using local aortic calcification model showed that elastin 
antibody coated and EDTA loaded albumin NPs have good targeting efficacy and 
also therapeutic effects to reverse elastin-specific medial calcification. Such NPs 
delivery did not cause systemic side effects that were seen for direct injection of 
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EDTA. Elastin antibody coated and EDTA loaded albumin NPs might be a 
promising nanoparticle protein engineering therapy to reverse calcification in elastin-
specific medial calcification and avoid side effects associated with traditional EDTA 
chelation therapy by systemic intravenous infusion. 
8.2 Limitations of this project and recommendation for future work  
1) Mechanisms of  how calcified matrix trigger osteogenic  response in VSMCs 
It is unclear as to how calcified matrix triggers VSMCs transformation to 
osteoblast like cells and further cellular pathway studies are needed to test this. Calcium 
and phosphorus levels in the media were similar in controls and calcified matrix groups 
(data not shown), thus osteoblast-like transformation seen on our studies was not due to 
higher amounts of free ions as shown by others[71, 208, 215]. We speculate that VSMCs 
synthesize small quantities of bone proteins (they come from same mesenchymal origin 
of osteoblasts). These proteins in healthy state do not accumulate in the vessel media; 
however, calcified elastin matrix can bind to these synthesized proteins[224, 225] and 
increase local concentration causing VSMCs to turn to osteoblast-like cells. We further 
speculate that local increase in bone morphogenetic proteins (BMPs) can activate BMP 
receptor pathway in SMCs thus causing osteogenic dedifferentiation.  
2) Long term therapeutic effects and side effects of systemic EDTA chelation 
therapy 
EDTA chelation therapy in this work was performed for a period of only two 
weeks. Thus, we do not know if long-term EDTA treatment will have therapeutic effects 
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to reverse vascular calcification or more severe systemic side effects. Others have shown 
that long-term EDTA chelation therapy does cause systemic side effects. Secondly, we 
did not investigate possible side effects besides serum calcium, urine calcium, and bone 
loss. More kidney functional evaluation might be necessary such as serum creatinine 
level.  
3) Targeted EDTA chelation therapy to reverse calcification using elastin 
antibody coated and EDTA loaded albumin NPs 
We have clearly shown in chapter 7 that systemic delivery of EDTA loaded NPs 
remove calcium from arteries in rats. A lot more work needs to be done to guarantee 
limited variation for nanoparticle size, loading efficiency and release between batch-to-
batch preparations for EDTA loaded EL-NPs.  
We also do not know whether calcification would return after nanoparticles 
deliver all EDTA and resorb calcification. A long term animal study is needed to confirm 
that once calcium is removed, it does not return. We also did not test cellular 
dedifferentiation in vivo. It would be interesting to see if VSMCs surrounding calcified 
matrix show osteoblast-like behavior and whether they return to their native smooth 
muscle cell behavior after removal of calcium in vivo similar to what was observed in 
vitro in cell cultures. 
Only one animal model was used in our current study, where MAC was induced 
by chemical treatment. We need to test it different animal models of vascular 
calcification, such as animal model for systemic vascular calcification (warfarin + 
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vitamin K injections in rats) [96], and atherosclerosis (fat-fed apoE-/- mice) [255] by 
collaboration with other labs.   
In our NPs’ bio-distribution study,  we only examined it after 24 hours of 
injection of NPs, longer time points, 3 or 7 days, might be necessary to see how long the 
NPs could stay.  Also, more toxicity tests need to be done on animals such as renal 
toxicity, liver toxicity, and trace metal deficiency. Careful risk-benefit analysis needs to 
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Supplemental videos online： 
1) Micro CT for rat aortas of 2 groups (Saline and HD EDTA).  
2) Micro CT rat femoral bone of 2 groups (Saline and HD EDTA).  
3) Three points bending test.  
4) Micro CT for rat aortas of 5 groups (Saline, HD EDTA, LD EDTA, IgG-
NPs/EDTA, and EL-NPs/EDTA).  
5) Micro CT rat femoral bone of 5 groups (Saline, HD EDTA, LD EDTA, IgG-
NPs/EDTA, and EL-NPs/EDTA).  
 
